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Summary
Epilepsy affects over 450,000 people in the UK and there are over 50 epilepsy 
phenotypes; genetic generalised epilepsy (GGE) account for up to 30% of seizure types. 
It is established that GGE and other neurological disorders are, in some cases, caused by 
channelopathies within post-synaptic inhibitory neurotransmitter systems such as 
GAB A (epilepsy) and Glycine (hyperekplexia). GAB A is the primary inhibitory 
neurotransmitter in the brain and is synthesised from glutamate by GAD65 and 67, and 
is released from the pre-synaptic nerve terminal into the synaptic cleft, where it binds to 
post-synaptic GABA receptors and initiate neuroinhibition. This inhibition is removed 
by post-synaptic GABA transporters (GAT1 and GAT3) that uptake GABA back into 
the cell for re-packaging in presynaptic vesicles or breakdown by transamination. 
Abnormalities in this system have been linked to diseases including anxiety, psychosis, 
Parkinsons’s Disease and epilepsy. GABAergic animal models have demonstrated a 
tendency to seizure, including GABA transporter and enzyme models in relation to 
epilepsy.
Given the above, the aim of this study was to identify GGE causing variants in four 
GABAergic genes. GGE patient samples (n=101) were recruited from 3 global centres 
and screened for variations in GAT1, GAT3, GAD65, GAD67 using high-throughput 
LightScanner analysis and bi-directional Sanger sequencing. Control population studies 
(«=480) were carried out and analysis of online databases to determine the frequency of 
variants. Twenty novel or very rare variants were identified in 48 patient samples 
representing a detection rate of 6.8%, where a clustering of phenotypes included a 
predisposition towards absence seizures. The biological consequences of these variants 
were predicted using three online predictive programmes, multiple phylogenetic 
alignments and 3D structural modelling. Mutation expression constructs were prepared 
and expression levels were validated by immunocytochemistry. Functional 
characterisation of these variants will hopefully improve genetic diagnosis in GGE and 
determine causality of GABAergic absence seizures.
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Chapter One 
Introduction
1.1 Epilepsy
Epilepsy is a neurological disorder that affects adults and children from every major 
population in the world; over 450,000 people in the United Kingdom and 50 million 
people worldwide. The highest incidence of epilepsy occurs in young children and the 
elderly, with approximately 3% of all living people under the age of 80 receiving a 
diagnosis (Hesdorffer et al., 2011). The prevalence of epilepsy is 25% higher in the 
most socially deprived areas of the United Kingdom (Purcell et al., 2002) and the cost 
of epilepsy management and treatment in the UK is estimated as £268 million (Joint 
Epilepsy Council, 2011) per annum. The misdiagnosis of epilepsy, which can occur in 
20-30% of patients, contributes an additional cost of £130-£190 million a year (Stokes 
et al., 2004).
Epilepsy is characterised by the onset of spontaneous convulsive and non-convulsive 
seizures, which are synchronous momentary electrical discharges that occur in the brain, 
resulting in too much excitation or too little inhibition (Treiman, 2001). The official 
terms for epilepsy and seizures as agreed by the International League Against Epilepsy 
(ILAE) and International Bureau for Epilepsy (IBE) are as follows (Fisher et al., 2005):
“Epilepsy is a disorder o f the brain characterized by an enduring predisposition to 
generate epileptic seizures and by the neurobiological, cognitive, psychological and
social consequence o f the condition
“An epileptic seizure is a transient occurrence o f  signs and/or symptoms due to 
abnormal excessive or synchronous neuronal activity in the brain. ”
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1.1.1 Causes of Epilepsy
Epilepsies are divided according to their aetiology. Three main groups were recognised 
by ILAE: Idiopathic, Symptomatic and Cryptogenic (1989). However, recent 
modifications to disease classifications have occurred as recommended by ILAE (2011) 
and the current aetiology stratifiers are i) Genetic, ii) Structural/Metabolic and iii) 
Unknown (Berg and Scheffer, 2011). Epilepsies that are considered i) genetic are 
understood to be the direct result of a known or presumed genetic defect where seizures 
are the core symptoms of the disorder, ii) Structural/metabolic epilepsies occur due to a 
distinct structural or metabolic condition or disease affecting the CNS; this can include 
trauma, stroke, tumours and/or infection, iii) Unknown epilepsies are those remaining 
cases where there is no known cause. These may have an unidentified fundamental 
genetic source or they may be the consequence of an unrecognised structural or 
metabolic disorder. Epilepsy is often multifactoral and even if a major cause is 
identified, there can often be additional contributing factors (Berg and Scheffer, 2011). 
Comorbidities occur in epilepsy including cognitive problems such as learning 
difficulties, psychiatric issues such as depression and physical problems such as chronic 
fatigue.
There is a large variation in epilepsy cause depending on age groups and environment 
(Figure 1.1). For example genetic epilepsy is more common in early life whereas 
epilepsy as a consequence of structural/metabolic deficits are more common in later life. 
Epilepsy caused by infectious and post-infectious diseases such as TB and HIV is more 
common in certain parts of the world than others, although meningitis is an epilepsy- 
causing infection that is common worldwide (Marks et al., 1992). Several single-gene 
disorders that cause epilepsy are associated with variable and complex syndromic 
phenotypes. These include disorders such as tuberous sclerosis, neuronal migration 
disorders such as double cortex syndrome, Rett syndrome and the spectrum of epileptic 
encephalopathies (Dravet Syndrome, Lennox Gastou, Otahara syndrome). With 
improved patient classification and phenotyping combined with the rapid development 
of genetic analysis technologies, more single-gene disorder epilepsies will be identified 
(Merwick et al., 2012).
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Approximate frequencies of epilepsy cases
■  G enetic  ■  Vascular
B  Congenital ■  N eu r o d e g en er a t iv e
■  Hippocampal sc lerosis  03 Brain tum or
■  Trauma ■  Childhood ep ilepsy
□  Infectious and p os t- in fec t ious  B T o x ic  and m eta b o l ic  d isorders
■  Single g e n e  d isorders 9  Unknow n
Figure 1.1 Approximate frequencies of epilepsy cases. Whilst approximately 70%  of 
epilepsies fit into a  causal category, the c a u se  of up to 30% of epilepsies still rem ains unknown 
(Shorvon, 2009).
1.1.2. Epileptic syndromes and seizure types
Epileptic syndromes are categorised according to seizure type, age of onset, 
electroencephalogram (EEG) results and neuroimaging, amongst other features 
(Crompton and Berkovic, 2009). Table 1.1 shows the different categories of epilepsy 
syndromes, demonstrating their aetiology and anatomical origins according to ILAE 
criteria (1981, 1989, Berg et al., 2010). The ILAE classification scheme is based on 
clinical semiology (1981, Berg et al., 2010). According to this scheme, there are three
7
main seizure types; focal (previously called partial), generalised and unknown seizures. 
The ILAE, however, recognise that further improvements in classification, for example 
with seizures of an unknown type, can be made by means of magnetic resonance 
imaging, whilst some epilepsies of structural/metabolic category are neither truly 
structural nor metabolic. These include some epilepsies with an autoimmune, 
inflammatory, neurochemical, synaptic or degenerative pathologies (Uttam et al., 2013).
Focal seizures arise in one hemisphere of the brain’s cerebral cortex at a specific site 
termed the epileptic focus. Symptoms of focal seizures vary, dependent on the location 
of the epileptic focus, and patients may or may not experience impairment of 
consciousness or awareness (Berg et al., 2010).
Generalised seizures occur in large areas of the cerebral cortex, involve both 
hemispheres simultaneously, and do not present a focal cerebral onset (Berg and 
Scheffer, 2011). There are six recognised types of generalised seizure (Figure 1.2); 
Tonic, Clonic, Tonic-clonic, Myoclonic, Atonic and Absence seizures. Tonic seizures 
involve tonic muscle contractions and changes in consciousness. These contractions 
cause movement of the neck, arms and legs, with pronation of the forearm and flexing 
of the wrists and feet; the patient may also cry out. Tonic seizures occur in all ages and 
may last less than 20 seconds (Lance, 1963). Clonic seizures are most frequently seen in 
children and neonates. This seizure is characterised by violent flexor movement and 
rhythmic spasms (Rosso et al., 2003). Tonic-clonic seizures are characterised initially 
by massive violent tonic muscle contractions, followed by a second clonic phase of 
jerking movements (Hsieh et al., 2008). Myoclonic seizures are sudden and brief 
involuntary movements caused by muscle contractions or inhibitions due to cortical 
discharges. These can occur as a single episode or they can be repetitive, with changes 
in the severity of the attack. The seizures tend to occur during the first few hours of 
awakening or whilst falling asleep; the patient will recover immediately from the 
seizure (Fahn et al., 1986). Seizures are very brief, lasting only a few seconds. Although 
they may involve the whole body, there is much less movement in comparison with 
other generalised seizures (Leppik, 2003). Atonic seizures involve a sudden loss of 
postural tone which can range from a slight loss (such as a jaw drop), to more severe 
loss of posture (whereby the whole body would drop to the ground), causing the seizure 
to adopt the name ‘drop attack’. If there is loss of consciousness,
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it is very brief (Hsieh et al., 2008, Pazzaglia et al., 1985)
Absence seizures occur in numerous syndromes such as childhood absence epilepsy 
(CAE) and juvenile myoclonic epilepsy (JME), and are one of the most common types 
of seizures identified in patients with genetic generalised epilepsy (GGE) (Helbig et al., 
2008). My work is concerned with the genetic aetiology of absence seizures. I will 
therefore consider these in more detail along with the syndromes they occur in.
There are three subtypes of absence seizure: typical, atypical and absences with special 
features (Figure 1.2). Typical absence seizures are the only neurological absences to 
occur almost exclusively in GGE. Absence seizures are characterised by recurrent non- 
convulsive episodes with brief loss of awareness and responsiveness (Jones et al., 
2011). This can include brief staring episodes, behavioural arrest, and can sometimes 
result in facial myoclonus, blinking and automatisms (Sullivan and Dlugos, 2004). 
Patients are often unaware that an attack has occurred as it ends as abruptly as it started, 
with most seizures lasting less than 10 seconds. However, the seizures can take place 
hundreds of times in one day and they can often occur in clusters, especially when the 
individual is tired or drifting in and out of sleep. Seizures can also be brought on by 
fatigue, relaxation, photic stimulation and hyperventilation (Shorvon, 2009); the latter is 
used to provoke seizures to aid diagnosis and treatment (Panayiotopoulos, 1999).
Typical absence seizures occur due to abnormal electrical activity in the thalamo­
cortical network, with little or no involvement of other brain regions. Many seizure 
types that occur in the thalamus have a genetic cause (Slaght et al., 2002). EEG results 
of a patient suffering with absence seizures would consist of a symmetrical 2.5-4 Hz 
‘spike and slow’ wave complexes that occur without lateralising or localising features. 
The background EEG rhythm would ordinarily be normal for those cases presenting 
with absence seizures (Holmes et al., 2004, Cordelli et al., 2013).
Atypical absence seizures are far less common than typical absences, but have a more 
severe phenotype, they can occur at any age, and are associated with severe 
neurological impairment (Farwell et al., 1985). It is believed that, as with typical 
absence seizures, the thalamo-cortical network plays a key role in atypical absence
10
seizure generation but may also involve other brain regions. Velazquez et al (2007) 
suggest that the spread of a seizure from the thalamo-cortical network to other regions 
could be due to weakened inhibition leading to seizure recruitment in originally 
unaffected brain areas (Velazquez et al., 2007). EEG results show activation in the 
thalamus and deactivation in the medial frontal and posterior cingulate cortices as well 
as significant thalamic connections during generalised spike and wave discharges. 
(Camey et al., 2010, Zhang et al., 2014).
Absence seizures with special features such as absences with eyelid myoclonia involve 
typical childhood absences with jerking of the eyelid immediately after closing, rolling 
of the eyes and, on occasion, subtle loss of awareness (Jeavons, 1977). Seizures can be 
triggered by hyperventilation, photic stimulation and almost invariably by eye closure in 
the presence of light. Absence seizures with eyelid myoclonus are often missed by the 
medical practitioner and can be misdiagnosed as autonomic tics (Covanis, 2005). The 
average age of onset of absence seizures with eyelid myoclonia is 6 years and there is a 
female preponderance. Joshi and Patrick (2007) identified that 77% of patients with 
absence seizures and eyelid myoclonia had low IQ and were four times more likely to 
experience difficulties with school compared to their peers (Joshi and Patrick, 2007).
As previously mentioned absence seizures are the most predominant seizure type in 
GGE patients. As GGE accounts for a large percentage of all epilepsies the phenotype 
and subgroups will be discussed in more detail.
1.2 Genetic generalised epilepsy (GGE)
There are over 50 epilepsy phenotypes, and GGEs account for up to 30% of all 
epilepsies (Jallon et al., 2001). These genetic epilepsies are characterised by generalised 
spike waves on EEG that typically arise from normal background activity. Patients 
suffering with GGE may experience seizures including absences, myoclonic jerks and 
tonic-clonic seizures that arise in both hemispheres of the brain and show no
11
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identifiable macroscopic or microscopic structural brain abnormality (1989) 
(Woermann et al., 1998).
Two of the more common GGEs are childhood absence epilepsy (CAE) and juvenile 
myoclonic epilepsy (JME), followed by juvenile absence epilepsy (JAE) and myoclonic 
absence epilepsy (MAE).
1.2.1 Childhood Absence Epilepsy (CAE)
CAE affects otherwise neurologically normal children between the ages of 4 and 10 
years, with incidence peaking between 5 and 7 years of age. CAE involves brief 
absence seizures that occur numerous times a day, end abruptly and are more common 
in females (Pal et al., 2006). Early onset CAE is uncommon, occurs in children under 
the age of four and affects more males than females (Asadi-Pooya et al., 2012). Early 
onset childhood epilepsy is believed to share some common biological and possibly 
genetic determinants as typical CAE, however they may have additional seizure types, 
movement disorders and neurodevelopmental delay. For example, generalised tonic- 
clonic seizures (GTCS) have been reported in 30-60% of patients with CAE: A study by 
Asadi-Pooya and colleagues, (2012) found that 56% of early onset CAE patients had 
GTCS, whilst febrile convulsions are reported in 25% of early onset CAE compared to 
10% of CAE. There is an almost equal occurrence of myoclonic seizures in both typical 
and early-onset CAE (Asadi-Pooya et al., 2012).
1.2.2 Juvenile Myoclonic Epilepsy (JME)
JME is characterised by teenage onset of myoclonic jerks. There are differences 
amongst myoclonic jerks experienced by those diagnosed with JME; some experience 
only upper limb jerking and others experience leg and head movement. GTCS and 
absences are also common in JME. Seizures usually occur after waking and are related 
to sleep deprivation, stress and illness (Genton and Gelisse, 2001; Clement and Wallace, 
1988). This is taken into account when treating patients with JME as they are advised to 
avoid precipitants such as sleep deprivation and excessive alcohol. The age of onset of
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JME depends on the individual and can present itself between the ages of 8 and 36 
years; peaking between the ages of 12 and 18 (Sullivan and Dlugos, 2004). Many 
individuals experience childhood absence epilepsy or juvenile absence epilepsy before 
evolving to JME, though some experience absence seizures following their first 
myoclonic episode at puberty (Thomas et al., 2013, Delgado-Escueta and Enrile-Bacsal, 
1984).
1.2.3 Juvenile absence epilepsy (JAE)
Juvenile absence epilepsy (JAE) is a GGE that occurs between the ages of 8 and 16 and 
peaks at puberty (1989). Patients have severe absence seizures albeit at a lower 
frequency than that of typical CAE patients, but with a higher frequency of tonic-clonic 
seizures (Wolf and Inoue, 1984). Seizures tend to occur in clusters in the hour following 
waking, or as one daily seizure lasting 4-20 seconds. The normal trigger for a seizure in 
a patient with JAE is, as with CAE, sleep deprivation as well as hyperventilation 
(Trinka et al., 2004). Patients with JAE can demonstrate normal neurodevelopmental 
and physical characteristics, and is predominantly identified in females (Christensen et 
al., 2005).
1.2.4 Myoclonic absence epilepsy (MAE)
MAE is a rare epilepsy syndrome with male predominance, occurring between the ages 
of 5 months and 13 years. MAE is characterised by absence seizures that can manifest 
with rhythmic bilateral myoclonic jerks with varied consciousness impairment. The 
seizures tend to last between 10 and 60 seconds and occur numerous times throughout 
the day. Two-thirds of patients with MAE also experience tonic-clonic seizures (Engel, 
2001).
Developing childhood absence epilepsy can be life changing. Diagnosis and prognosis 
with the aid of genetic testing can significantly improve epilepsy management and 
quality of life.
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Table 1.2 Genes identified in generalised epilepsy
Generalized epilepsies; febrile seizures, absence seizures
Gene sym bol Gene name Score
A L D H 7 A 1 A ldehyde dehydrogenase  7 family, m em ber  A l 2
C AC N A 1A Voltage dependant ca lc ium  channel, alpha 1A subunit 3
C A C N A J H Voltage dependant ca lc ium  channel,  alpha 1H subunit 3
C A C N B 4 Voltage dependant ca lc ium  channel, beta 4 subunit 3
C ASR C alc ium  sensing receptor 2
C H R N A 2 Cholinergic  receptor, alpha 2 (Nicotinic) 3
C H R N A 4 Cholinergic  receptor, alpha 4  (Nicotinic) 3
C H R N B 2 Cholinergic  receptor, beta 2 (Nicotinic) 3
C LCN 2 C hloride channel 2 2
EFH C 1 E-F  hand dom ain  (C-terminal)  contain ing 1 3
EL P4 E longator  acety ltransferase com plex  subunit 4 1
G ABRA1 G A B A  A receptor, alpha 1 3
G A B R B 3 G A B A  A receptor, beta  3 3
G A B R D G A B A  A receptor, delta 3
G A B R G 2 G A B A  A receptor, gam m a 2 3
GRIN2A Glutam ate  receptor. N -m ethyl;  D  aspartate 3
G RIN 2B Glutam ate receptor, ionotropic, N -methyl D-asparta te  2B 3
K CNA1 Voltage gated po tassium  channel, shaker-related subfamily, m em ber 1 3
K CN M A 1
Potassium  large conductance  ca lc ium-activated  channel, subfamily  M. 
alpha m em ber 1 3
K C N Q 2 Voltage-gated  po tassium  channel, K QT-like  subfamily, m em ber 2 3
K C N Q 3
Voltage-gated  po tass ium  voltage-gated channel. K QT-like  subfamily, 
m em ber 3 3
K C N T I Potassium channel subfam ily  T. m em ber 1 3
M B D 5 M ethyl-C pG -bind ing  dom ain  protein 5 2
M E 2 M alic  enzym e 2. NAD( + )-dependent. mitochondrial 1
P C D H 19 P rotocadherin  19 2
PRRT2 Prolein rich repeat protein  type 2 2
SC N1A Voltage-gated  sodium channel,  voltage-gated, type I. alpha subunit 4
SC N 1 B Voltage-gated  sodium channel,  type I. beta subunit 3
SC N2A Voltage-gated sodium channel ,  type II, alpha subunit 4
SC N9A Voltage-gated  sodium channel,  type IX. alpha subunit 3
SLC2A1 Solute carr ier  family 2 (facilitated glucose transporter), m em ber 1 4
TB C 1D 24 TBC1 dom ain  family, m em ber  24 3
Table 1.2 Genes identified in generalised epilepsy. The most relevant g e n e s  identified in 
generalised  se izures  have been  scored  from 1 to 4 b ased  on the level and depth of evidence: 1 
rep resen ts  g e n e s  that were identified from linkage studies, however no mutation have been 
identified in the gen e  nor h a s  any functional work been  carried out; 2 would su g g es t  that 
mutations in the g en e  have been  identified, however, no validation had been  carried out by 
m ean s  of function or population studies; 3 if mutations had been  identified which had supporting 
functional results; and 4 for g e n e s  with extensive supporting functional work for the causality of 
mutations and the g en e  assoc ia ted  with large unrelated cohorts and robust population study 
results.
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1.3 Epilepsy associated genes
The identification of causal epilepsy genes has impact on diagnosis & prognosis, assist 
with treatment & management, and is informative in the risk of the epilepsy occurring 
in offspring. Numerous genes and mutations have been identified in relation to 
generalised epilepsies (Table 1.2) (Lemke et al., 2012, Garofalo et al., 2012), however, 
the number of cases with a definitive disease-associated genetic signature are only a 
very small proportion of the epilepsy population. Although the genes listed in table 1.2 
are the primary genes associated with generalised epilepsy, there are additional genes, 
identified in syndromic disorders, where epilepsy plays a substantial role in the patient 
phenotype (Lemke et al., 2012, Garofalo et al., 2012).
Mutations in ion channel genes and neurotransmitter receptors have been discovered in 
genetic epilepsies, although mutations where epilepsy is the primary morbidity feature 
may also be linked to genes important for cortical development, cell metabolism and 
mitochondrial function (Deng et al., 2013). Linkage analysis in multiplex families, 
candidate gene analysis in cohorts and findings in animal models of epilepsy have 
confirmed that channelopathies are an important cause of GGE. Channelopathies have 
been instrumental in providing the molecular insights into epileptogenesis.
1.3.1 Sodium Channels
Sodium channel dysfunction is recognised as being extremely important in the aetiology 
of GGEs and have long been a target for anti-epileptic drugs. The sodium channel is 
made up of a pore-forming a-subunit and regulatory P-subunits; nine genes are known 
to encode a-subunits and four genes encode p-subunits (Scheffer and Berkovic, 2003). 
Numerous epilepsy syndromes have been associated with mutations in the sodium 
channel SCN1A; the majority of mutations (over 100) interestingly occur in patients 
suffering with Dravet syndrome. Sodium channelopathies due to mutations in SCN1B 
and SCN2A have also been linked to generalised epilepsy with febrile seizures-plus 
(GEFS+) and benign familial neonatal infantile spasm (Mulley et al., 2005).
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1.3.2 Potassium Channels
There are three structural families of approximately 100 potassium channel genes 
identified in the human genome that are primarily expressed in the brain. Potassium 
channels are required for stabilising the resting membrane potential of cells and 
regulating neuronal excitability by repolarising action potentials or producing M 
currents to mediate hyperpolarisation; therefore a loss of voltage-gated potassium 
channel function can result in increased excitation (Jentsch, 2000, D’Adamo et al., 
2013).
1.3.3 Chloride Ion Channels
Chloride channel mutations had been shown to cause impairment of chloride efflux 
resulting in an increase in intracellular chloride. This in turn lowers the transmembrane 
gradient for chloride and causes a decrease in GABA mediated inhibition. Mutations in 
the chloride channel gene CLCN1 are identified in association with GGE and mutations 
in CLCN2 are associated with four GGEs: CAE, JAE, JME and epilepsy with grand mal 
seizures on awakening (Haug et al., 2003; Chen et al., 2013).
1.3.4 Calcium channels
Mutations in voltage gated calcium channels in HEK293 cells cause a slowing of 
inactivation, causing a shift of inactivation potential toward depolarisation, which are 
electrophysiological features characteristic of absence seizures (Khosravani et al., 
2004). Numerous animal models show that the consequences of calcium channel 
mutations can include symptoms of idiopathic generalised epilepsy; especially absences 
with ataxia, which is a rare phenotype (Escayg et al., 2000).
1.3.5 Neurotransmitter receptors and transporters
Ligand-gated ion channels have been widely researched and mutations have been 
identified in GABA receptors and neuronal nicotinic acetylcholine receptors in relation
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to epilepsy. Mutations in both GAB A a and GAB Ab receptors have been associated with 
the childhood epilepsies JME and CAE. Studies of the R43Q mutation, identified in 
GABRG2, demonstrates the slowing of receptor deactivation and an increase in the rate 
of desensitisation, resulting in CAE. This resulted in a build up of desensitised 
receptors, and therefore excessive excitation occurs (Bowser et al., 2002). Mutations in 
the major CAE causal gene of GLUT1 (SLC2A1) were identified by Suls et al. (2009) in 
12% of early onset CAE cases, which is now a gene used to aid in CAE diagnosis and 
allow genetic counselling (Suls et al., 2009).
Nicotinic acetylcholine receptors in neurons are expressed in abundance at synapses. 
They are involved in numerous neurotransmitter systems and in both excitatory and 
inhibitory systems; it is therefore unsurprising that mutations have been identified in 
both CHRNA4 and CHRNB2 having functional affects on the alpha and beta subunits of 
this protein respectively (Scheffer and Berkovic, 2003).
The identification of these ion channel genes has significantly improved successful 
epilepsy magangement and treatment as well as other diseases. Numerous epilepsy 
drugs are available and patient symptoms along with genetic testing has allowed for 
accurate drug selection and protein targetting.
1.4 Epilepsy treatments
Over the past 30 years, there has been rapid development in anti-epileptic drugs 
(AEDs). However, 30% of epilepsy patients do not achieve successful seizure control 
from current seizure treatment including AEDs, surgery or vagus nerve stimulation 
(Perucca et al., 2007). The main AEDs dispensed are presented in table 1.3, along with 
their primary mechanism of action and the type of epilepsy treated.
1.4.1 Antiepileptic drugs and genetic generalised epilepsy
Most genetic generalised epilepsies respond well to AEDs, but treatment is often 
lifelong. Valproate, lamotrigine, ethosuximide, topiramate and levetiracetam are the 
most common AEDs for children used today (Beydoun and D'Souza, 2012). Valproate
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has been the medication of choice for JME patients for decades and is considered the 
first-line of treatment for these patients (Nicolson and Marson, 2010). Absence seizures 
and GTCS are the primary GGE seizure type treated by valproate, but if valproate is 
ineffective or poorly tolerated, then lamotrigine may be offered. Valproate is not 
generally recommended for women as it can lead to the development of polycystic 
ovary syndrome, but how valproate may be causal is unclear. Lamotrigine blocks the 
conductance of sodium channels to prevent excitation and therefore seizure; the actions 
of valproate are not fully understood at this time although it is known that it has an 
effect on GABA and glutamine activity as well as calcium and potassium conductance 
(Sullivan and Dlugos, 2004).
JME can also be treated with the synaptic vesicle protein binding AED levetiracetam, 
which acts to prevent myoclonic seizures as well as generalised tonic-clonic seizures. 
This drug is beneficial for epilepsy patients as it does not cause the usual sedative 
affects that other AEDs can, however, it can cause irritability and weight gain (Sullivan 
and Dlugos, 2004). The AED topiramate works in numerous ways including enhancing 
GABA activity, blocking sodium channel conductance and blocking glutamate 
receptors. The drug is used in the treatment of generalised tonic-clonic seizures and can 
be used as a monotherapy or as an adjunctive therapy with lamotrigine. As with JME, 
CAE is also treatable with valproate and is again a first line treatment along with the 
calcium channel inhibitor ethosuximide and lamotrigine (Sullivan and Dlugos, 2004). 
Ethosuximide suppresses the spike and wave activity associated with lapses in 
consciousness (Goldenberg, 2010).
Tiagabine is generally used in conjunction with other AEDs and is used when other 
lines of treatment have failed. Tiagabine is used to treat primary generalised seizures by 
selectively inhibiting the GABA transporter, GAT1. This increases the GABA levels, 
especially in the hippocampus and thalamus. Interestingly, tiagabine also has unwanted 
proepileptic effects, which involve desensitisation of GABAa receptors and increased 
synchronisation. This was seen to occur most frequently in the thalamocortical circuit 
resulting in absence seizures and myoclonic jerks (Walker, 2002, Angehagen et al., 
2003). GABA receptors have been extensively studied in a number of epilepsies, 
implicating the wider GABAergic system to disease onset. This will be discussed and 
analysed further in the following section.
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1.5 The GABAergic system
Gamma-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter in the 
mammalian brain, whilst glutamate is the principal excitatory neurotransmitter. GABA 
is present in almost all prokaryotic and eukaryotic organisms, identified not only in the 
central nervous system where it is believed to be present in 60-70% of all synapses, but 
also in the immune system (Nagga et al., 1999). It is also present in many organs 
throughout the body such as the testes, uterus, ovaries, pancreas, pituitary, 
gastrointestinal tract and adrenal medulla (Gladkevich et al., 2006). A change in level of 
either GABA or glutamate has great affect on an organism, increased levels of 
glutamate (or decreased GABA levels) can cause seizures, increased GABA levels (or 
decreased glutamate levels) can cause drowsiness, sleep deprivation, nervousness, 
anxiety and instability amongst other symptoms (Rimmer and Richens, 1984).
1.5.1 GABA formation
The formation of GABA occurs in the central nervous system of vertebrates from 
glutamate. This process is catalysed by the enzyme glutamic acid decarboxylase (GAD) 
and involves the swift a-decarboxylation of L-glutamic acid in the brain (Figure 1.3). 
The mitochondrial aminotransferase, GABA-transaminase (GABAT), is responsible for 
the transamination of GABA, causing the removal of an amino group and adding it to a- 
ketoglutarate. This process reloads glutamate and produces succinic semialdehyde (Kim 
et al., 2009). Succinic semialdehyde dehydrogenase (SSADH) catalyses succinic 
semialdehyde oxidation into succinic acid which in turn is utilised in the Krebs cycle; 
the final aerobic oxidation pathway (Figure 1.4). It must be noted however that there is 
an absence of GAD in astrocytes, and glutamate cannot therefore be converted to 
GABA in these cells. In astrocytes, glutamate is synthesised into glutamine for transfer 
to axon terminals by transporters, where it is converted back into glutamate by 
glutaminase and the cycle is repeated (Schousboe et al., 1993). The delicate balance 
between the glutaminergic excitation and GABAergic inhibition is crucially conserved 
via this pathway (Pearl et al., 2009).
21
HiN +
G lu ta m a te
o -  o
H,N +
GABA
O
SSADH
Figure 1.3 G lutam ate m olecule conversion. GABA is formed by the a-decarboxylation of 
Glutamate by GAD. GABAT rem oves an amino group from GABA to form SSADH.
1.5.2 GABA activity
The regulated expression of G A BA receptors at the post-synaptic cell surface and the 
controlled release and re-uptake of G A BA  are vital to uphold the equilibrium between 
neural excitation and inhibition. Upon stimulation, there is a slight increase in 
membrane potential of a neuron from -70mV. If this potential reaches the threshold of 
approximately -55mV, further depolarisation occurs causing opening of voltage-gated 
sodium channels and a sodium ion influx; this triggers an all or nothing action potential. 
As the voltage o f  the cell increases to approximately 40mV, the sodium channels close 
and voltage gated potassium channels open. The opening o f  potassium channels causes 
efflux of positively charged potassium from the cell as they are repelled by the positive 
charge in the cell and a decrease in membrane potential is therefore seen which results 
in a negatively charged cell in relation to its microenvironment once more. Potassium 
channels remain open until the voltage reaches, at least, resting membrane potential. 
This is followed by a refractory period where the voltage is stabilised to approximately
GABAT
O '
H
GAD
o-
U
o-
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-70mV once more, in this time another action potential cannot be fired (Stuart et al, 
1997). This nerve impulse is propagated along axons due to sodium ions entering the 
cell and depolarising neighbouring regions of the axonal membrane as they move 
laterally along the axon. In a wave like fashion, the action potential is transmitted from 
the input source to the axons synapse (the pre-synapse) at the target dendrite (the post­
synapse) (Bean, 2007).
Neurotransmitters such as GABA are packaged into vesicles by the proteins encoded by 
the SLC17 and SLC18 genes (Chen et al., 2004). Depolarisation of the pre-synaptic cleft 
causes calcium channels to open and there is an increase in intracellular calcium. This 
allows the fusion of the GABA filled vesicles with the pre-synaptic membrane causing 
GABA to be exocytosed from the pre-synapse into the synaptic cleft, where it binds and 
activates GABAa and GABAb receptors of the post-synapse that mediate chloride 
influx across the post-synaptic membrane. GABA acts as an agonist ligand if bound to 
phase-active GABAa receptors and if bound to G-coupled GABAb receptors stimulates 
tonic inhibitory influences (Mao et al., 2010, Madsen et al., 2010). GABA is removed 
rapidly from the post-synapse and taken up by glial processes and the pre-synaptic 
nerve terminal, where it is catabolised by GABAT (Treiman, 2001). This rapid removal 
is carried out by GABA transporters (GATs) and occurs in order to regulate synaptic 
transmission and reduce GABA spill-over to neighbouring synapses (Borden, 1996, 
Velisek et al., 2011), preventing disproportionate tonic activation of synaptic and extra 
synaptic GABA receptors (Figure 1.3) (Semyanov et al., 2004).
1.5.3 GABA receptors
Speedy inhibitory neurotransmission in the brain is primarily due to GABA’s actions on 
GABA receptor type A (GABAa). A member of the Cys-loop ligand gated ion channel 
superfamily, the receptors are heteropentametric GABA-gated chloride channels, 
typically composed of two a-subunits, two p-subunits and a third subunit. Nineteen 
mammalian subtypes of GABAa have been cloned including a 1-6, p 1-3, y 1-3, 5, e, n, 
and 0 (Olsen and Sieghart, 2009). Binding of GABA ions to the GABAa receptor’s two 
GABA binding sites causes the opening of chloride channels and an influx of negatively 
charged chloride ions, decreasing the membrane potential. This causes a decrease in
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overall voltage of the cell and prevents it reaching the threshold for depolarisation and 
therefore reduces the chance of propagating the action potential in the post-synaptic 
nerve terminal (Bean, 2007).
GABAa receptors are expressed in abundance in neurons along their entire axis, hence 
any changes in their activity and expression level affect brain function immensely 
(Luscher et al., 2011). Although every neuron contains GAB A a receptors, the expressed 
subtypes change dependant on the stages of development of the different neurons. Other 
members of this superfamily include nicotinic acetylcholine receptors, glycine receptors 
and 5-HT3 receptors. All named receptors have four transmembrane domains, an 
extracellular N-terminal domain and an extended cytoplasmic loop mediating 
interactions with trafficking and signalling factors (Figure 1.4) (Luscher et al., 2011).
Gephyrin is a multifunctional protein that is involved in the clustering of GABAa 
receptors in the synaptic membrane; the two associate via the GABAa receptor- 
associated protein (GABARAP) (O'Sullivan et al., 2005). The guanine nucleotide 
exchange factor and gephyrin-associated protein, Collybistin, translocates gephyrin 
from the cytoplasm to the submembranous regions. The N-terminal domain of 
collybistin regulates collybistin as well as gephyrin cluster size (Kins et al., 2000). It is 
believed that GABAa receptors are trafficked to the cell membrane by palmitoylation 
where gephyrin controls the cell surface dynamics of the receptor (Jacob et al., 2005).
Mutations in the GABAa receptor have been identified in four subunits (al, (33, 5 and 
y2) that are associated with the childhood epilepsy syndromes, JME (Cossette et al.,
2002) and CAE (Table 1.2) (Wallace et al., 2001; Tanaka et al., 2008). Mouse models 
show that the deletion of the a l subunit gene shows no epileptic phenotype that may 
demonstrate a compensatory mechanism of additional inhibitory systems, and as with 
other diseases, the loss of a receptor could be less dangerous than a receptor with a 
mutant subunit (Noebels, 2003, Kralic et al., 2002). Mutations in the (33 subunit have 
however been linked to a susceptibility to seizure (Tanaka et al., 2008) and variants in 
the subunit are also believed to cause insomnia (Buhr et al., 2002). Patients with a 
missense mutations in the GABA receptor 8 subunit have demonstrated a susceptibility 
to generalised epilepsy with febrile seizure plus and JME (Dibbens et al., 2004). The y2
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subunit also been linked with CAE and numerous epileptic encephalopathies and 
seizures, including absences, myoclonic jerks and tonic-clonic seizures; these 
phenotypes were due to missense mutations, including one de novo mutation (Wallace 
et ah, 2001; Carvill et ah, 2003)
Unlike the GABAa receptor, GABA receptor type B (GABAb), contain only two 
subunits, GABA-Bi and GABA-B2. There is a third GABA receptor, GAB Ac, which, as 
with the GABAa receptor, forms a ligand gated chloride channel, however this channel 
is primarily expressed in the retina (Euler and Wassle, 1998) and will not be considered 
further in this thesis. Heterodimerisation of the two subunits of GABAb are required for 
optimal function and cell surface expression to occur, whereby subunits combined 
primarily by a coiled coil motif between the two carboxyl termini (Figure 1.5) (Bowery 
et al., 2002). In some brain regions such as the striatum, however, GABA-Bi is 
functionally expressed without GABA-B2, suggesting that another protein could be 
replacing GABA-B2 trafficking GABA-Bi to the cell surface. GABA-Bi is the subunit 
capable of agonist binding, whereas GABA-B2 is responsible for G-protein coupling 
(Duthey et al., 2002).
Activation of GABAb by GABA causes a decrease in L-glutamate release in the pre­
synapse by causing the release of heterotrimeric GTP-binding proteins Gpy and Gai/Gao. 
Gpy diffuses locally to open potassium channels and close calcium channels, causing 
lowered calcium conductance and increased potassium conductance; deactivating the 
molecular machinery of vesicle fusion (Malcangio and Bowery, 1996). Gaj/Gao is also 
involved in post-synaptic inhibition, by firstly inhibiting adenylyl cyclise activity, 
which, prevents the conversion of ATP into cAMP. Under normal circumstances cAMP 
would activate PKA, which, would then activate targets such as the glutamate receptor, 
NMDA.
Mouse studies of deleted neuronal GABAb show an epileptic phenotype with clonic and 
rare absence seizures, with a reduction in pre and post synaptic GABAb responses 
(Schuler et al., 2001). Disruption in GABA receptor function has been linked to 
numerous diseases including anxiety (Shekhar et al., 1990) and mood disorders 
(Brambilla et al., 2003).
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Figure 1.5 GABAa receptor. A. The m em brane  bound GABAa receptor com prises  of four 
t ran sm em b ran e  domains, with both the N and C terminals lying extracellularly. B. The GABAa 
receptor com prises  of two a-subunits  (yellow), two p-subunits (pink) and a  y-subunit (purple). 
The receptor h a s  must have two GABA molecules bound for successful activation (Dark blue 
circles).
Mutations in the glycinergic inhibitory system, which, includes the post-synaptic 
glycine receptor gene GlyR as well as the pre-synaptic membrane transporter gene 
GlyT2, have been identified as the principle cause of hyperekplexia (Rees et al., 2006). 
It is therefore possible that other members o f  the GABAergic system such as GA BA 
transporters could be involved with the GABA receptors in being the primary cause of 
disease.
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Figure 1.6 GABAb receptor heterodimer
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Figure 1.6 GABAb receptor. Heterodimerisation of two GABAb subunits occurs  via a  C-terminal 
coiled coil motif. Binding of GABA to subunit 1 c a u s e s  activation of the receptor and G protein 
coupled inhibition via subunit 2.
1.5.4 GABA Transporters
Four subtypes of GABA transporters (GATs) have been cloned in rodents; G A T 
subtype 1 (GAT1) (Guastella et al., 1990), betaine/GABA transporter subtype 1 
(Yamauchi et al., 1992), GAT subtype 2 (GAT2) and GAT subtype 3 (GAT3) (Borden 
et al., 1992). Rat brain GAT1 was the first to be cloned in 1990 from purified protein 
(Guastella et al., 1990). These four subtypes can be distinguished by their 
pharmacological properties and tissue distribution (Hirunsatit et al., 2009). GAT1 and 
GAT3 are the most extensively expressed GATs in the hum an brain. GAT1 is primarily 
localised at GABAergic axons and nerve terminals and is expressed in abundance in the
28
cerebral cortex (Conti et al., 2004), hippocampus and striatum. GAT3 is exclusively 
localised to astroglia and is abundantly expressed in the glomerular layer of the 
olfactory bulb, thalamic paraventricular nucleus and the inner nucleus of the retina (Jin 
et al., 2011).
The neurotransmitter transporter family SLC6 commands the translocation of solutes 
across cell plasma membranes by coupling solute transport with the cotransport of 
sodium and chloride down their electrochemical gradients (Chen et al., 2004). GAT1 
and GAT3 both function with the stochiometry of a GABA molecule, two sodium ions 
and one chloride ion; Chloride is required for transport but may not undergo net 
translocation (Yu et al., 1998).
The solute carrier family 6 member 1 (SLC6A1) gene, encodes for the Na+Cf GABA 
transporter GAT1, which, was initially identified by Lam et al (1993). Using in situ 
hybridisation mapping, SCL6A1 has been mapped to chromosome 3p24-p25 (Huang et 
al., 1995). Initially identified in 1993, SLC6A1 contained 15 exons and was 
approximately 25 kb in length (Lam et al., 1993). The March 2006 genome build 
however, identified that there are in fact 16 exons in SLC6A1 spanning 46.5kb; in 
addition there are two main transcripts (Hirunsatit et al., 2007). The first transcript 
comprises of all 16 exons whilst the second is coded by only 14 exons; exons 3-16 
(Hirunsatit et al., 2009). SLC6A1 encodes a protein of 599 amino acids and this single 
polypeptide has a molecular weight of 67kDa (Guastella et al., 1990).
The GABA transporter, GAT3, is encoded by solute carrier family 6, member 11 
(SLC6A11) gene. SLC6A11, mapped to chromosome 3p25.3 by Borden et al (1992), has 
been shown to have 632 amino acids and demonstrates 52% homology to GAT1 at this 
level (Minelli et al., 1996; Chen et al., 2004). Fewer studies have been carried out 
independently examining GAT3 in the brain.
The SLC6A transporter family penetrates at least one phospholipid bilayer of the 
plasma membrane and all of the peptide sequence is embedded in the membrane. It has 
been shown that approximately 50% of the protein is on the plasma membrane at basal 
state and the remainder of the protein is found intracellularly in the vesicle (Deken et 
al., 2003). SLC6A comprise of 12 putative transmembrane a-helices and due to the
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lacking of a signal peptide, it is believed that the N and C-termini both face the 
cytoplasm. As these regions contain phosphorylation sites working in conformity, it is 
thought that both, especially the N-terminal, may be responsible for the regulation of 
transportation (Bennett and Kanner, 1997). Mutagenesis studies relating to the GAT1 
N-terminus support this and suggest that intracellular transport domains regulate 
substrate transport; the mechanism however is uncertain (Bennett et al., 2000). The 
functional roles of the C- terminal tail of SLC6A1 transporters include transporter 
trafficking, stability and degradation (de Juan-Sanz et al., 2013).
As demonstrated in Figure 1.7 the large extracellular loop between transmembrane 
domains 3 and 4 contains the three preserved N-glycosylation sites Asnl76, Asnl81 
and Asnl84. It has been demonstrated that N-glycosylation is most importantly a post- 
translational modification in eukaryotic cells and can result in the manipulation of 
physicochemical and biological properties of the protein including protein folding, 
stability, targeting and ligand binding (Bismuth et al., 1997). Importantly it has been 
suggested that the transport activity and surface expression of neurotransmitter transport 
is regulated by N-glycosylation. Via site-directed mutagenesis, Bennett and Kanner 
(1997) found that the removal of either one or two of the N-glycosylation sites had little 
effect on GABA uptake activity, yet the removal of all three sites caused a reduction in 
GABA uptake activity (Bennett and Kanner, 1997).
Residues in close proximity to or in the first and sixth transmembrane domain of GAT1 
have been mapped as the ion binding sites (Hansra et al., 2004). There is a break in the 
helical structure of TM1 and TM6, which, expose main-chain carbonyl oxygen and 
nitrogen atoms, which, binds hydrogen and can therefore organize ions. Mutations have 
suggested that substrate binding occurs in the third and eighth transmembrane domain 
as well as in extracellular loops of the protein (Bismuth et al., 1997, Tamura et al.,
1995). It is believed that the V-shape created by TM4 and TM5, and TM9 and TM10, 
hold TM3 and TM8 in place like pincers. Transmembrane domains 2, 4, 5, 7, 9, 10, 11
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and 12 are believed to contain highly conserved residues, which, emphasises their 
importance (Yamashita et al., 2005).
The identification of novel naturally occurring mutations as well as the formation of 
transgenic animals has linked the SLC6A family and the GABAergic system to 
numerous diseases. There is substantial evidence associating human disorders such as 
anxiety disorders (Tasan et al., 2011), diabetes (Chattopadhyay et al., 2011), 
Huntington’s disease (Sherif and Ahmed, 1995) & epilepsy (Luscher et al., 2011) with 
altered GABAergic transmission.
GABA receptors have been extensively explored and many mutations in their genes 
have been found in epilepsy cases (Macdonald, 2001). None have yet been identified in 
GABA transporters however. Conversely, Gatl knockout mice show that an increase in 
GABA levels resulting from GAT1 deficiency, can induce post and pre-synaptic 
changes in GABAergic synapses causing epileptogenesis (Velisek et al., 2011, Conti et 
al., 2004). Gatl knockout mice have also been found to display the phenotype of 
attention deficit/hyperactivity disorder, identifying Gatl as a possible gene for drug 
therapy (Yang et al., 2013). Additional Gatl knock-out mice have also displayed signs 
of motor disorders, constant tremors, mild anxiety and nervousness (Chiu et al., 2005).
To date, no Gat3 knockout animal model studies have been published. However, in an 
animal model for depression, a significant decrease in GAT3 levels was identified 
demonstrating a link with neurological disease (Zink et al., 2009). Other transporters 
relating to GABA, such as glutamate transporters have been published due to their 
association with seizures in early infancy (Demarque et al., 2004), and mutations in 
Na+/Cf glycine transporter GlyT2 can results in human startle disease; these give reason 
to believe that mutations in the GATs could result in epilepsy (Rees et al., 2006).
One missense mutation and one duplication in GAT1 have been identified and suspected 
to be linked with disorders in humans. The missense mutation was identified by exome 
sequencing of autism spectrum disorders, and involves the conversion of alanine to 
valine at protein position 228 (Sanders et al., 2012). The duplication, which, is 21bp in 
length alters promoter activity and is believed to be useful in predicting clinical 
responses to pharmacological modulators such as tiagabine and GAT1 inhibitors; this
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variant was only identified in African-Americans and not in other populations 
(Hirunsatit et al., 2009). A missense mutation has also been identified in GAT3 at 
protein position 524 that has been linked with anti-epileptic drug pharmacoresistance, 
increasing the risk of seizure by 1.5 fold in the epileptic brain (Kim et al., 2011).
1.5.5 Glutamate Decarboxylase (GAD)
The biosynthetic enzyme for GABA, GAD, presents itself in the two isoforms GAD65 
and GAD67 which are primarily localised in the GABAergic neurons in the brain. GAD 
has been identified outside of the nervous system in tissues such as the pancreas, ovaries 
and testes (Taniguchi et al., 1977; Erdo et al., 1982; Bu et al., 1992). These isoforms are 
named after their approximate molecular mass of 65 and 67 kDa respectively 
(Battaglioli et al., 2003). Both GAD65 and GAD67 have 16 coding exons, however 
GAD67 has an additional non-coding exon (Bu and Tobin, 1994). GAD65 and GAD67 
are encoded by two genes that have been identified on separate chromosomes, GAD65 
on chromosomes 10 at 10pll.23 and GAD67 on chromosome 2 at 2q31. GAD67 cDNA 
encodes 594 amino acids and GAD65 cDNA encodes 585 amino acids (Bu et al, 1992)
The GAD monomers comprise of an N-terminus, C-terminus and pyridoxal-5’- 
phosphate (PLP) binding domain. The PLP binding site comprises of nine a-helices that 
encase nine stranded p-sheets and the C-terminal domain contains three a-helices and 
four anti-parallel p-sheets. The N-terminal’s two parallel a-helices form the functional 
dimer by packing against the N-terminal and PLP binding of a neighbouring monomer. 
N-terminus truncated crystal structures demonstrate that each of the GAD67 active sites 
are enclosed by a catalytic loop which is contributed in trans by the additional 
monomer. This however is not the case with GAD65, this region is incorrectly formed 
leaving the active sites exposed (Fenalti et al., 2007).
Derived from a common precursor, GAD65 and GAD67 demonstrate 65% homology at 
protein level, demonstrating prevalent homology in their mid-regions and C-terminus. 
However, in the N terminal regions, which, is 90-100 amino acids in length, the 
isoforms demonstrate only 22% homology (Kanaani et al., 2010, Bu et al., 1992). All 
known phosphorylation sites of GAD65 and GAD67 have been identified in the N- 
terminal domain, as have the palmitoylation sites (Bao et al., 1995). The GAD65 N-
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terminal contains three trafficking signals that are responsible for the targeting of the 
enzyme to the pre-synaptic nerve terminals, Golgi membranes and post-Golgi 
trafficking to cytosolic vesicles (Kanaani et al., 2002, Namchuk et ah, 1997).
Both GAD65 and GAD67 are synthesised as soluble and hydrophilic though GAD65 
undergoes N-terminal modifications causing hydrophobic post-translational changes; 
GAD67 however does not and remains hydrophilic. Hydrophobic GAD65 is targeted to 
the cytosilic membrane of the Endoplasmic Reticulum and Golgi, where palmitoylation 
causes its trafficking to the trans-Golgi network and cytosolic vesicles in non-neuronal 
cells. In neurons however, GAD65 is targeted selectively to axons and pre-synaptic 
clusters, which, facilitates rapid filling of synaptic vesicles for intense firing of 
GABAergic neurons (Kanaani et al., 2008). Kanaani et al. (1999) demonstrated in mice 
that GAD67 remains membrane-anchored and targets pre-synaptic clusters in the 
absence of GAD65 (Kanaani et al., 1999).
GAD activity, as with many enzymes, is altered by phosphorylation; this can be an 
increase or decrease in activity depending on whether GAD is soluble or membrane 
bound (Namchuk et al., 1997). Phosphorylation of GAD65 by protein kinase C activates 
the enzyme, but phosphorylation of GAD67 mediated by protein kinase A causes 
inhibition of activity (Buddhala et al., 2008). The majority of GAD remains inactive in 
the brain and is regulated by the co-factor PLP (Miller et al., 1977). GAD is active when 
it contains the bound PLP (holoenzyme) and only then will it convert glutamate into 
GABA. In the majority of cases the PLP will stay attached during this process but in a 
small percentage of reactions, if glutamate is decarboxylased, GAD will cause an 
additional reaction whereby SSADH and pyridoxamine-P (PMP) are produced and PLP 
will readily dissociate from GAD leaving inactive apoGAD. HaloGad can however 
reform and create a cycle of activation and inactivation by binding with free PLP (Porter 
and Martin, 1984).
Battaglioli et al (2003) found that haloGAD67 activity was 72% of GAD67 activity 
compared to 6.7% of haloGAD65. One reason could be that haloGAD65 is converted to 
apoGAD approximately 15 times faster than haloGAD67. Also the activation of 
apoGAD65 is strongly associated with and affected by inorganic phosphate and NTPs 
such as ATP, while GAD67 is fundamentally unaffected by these factors. However,
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apoGAD65 can be activated by PLP 10 times faster than GAD67 (Battaglioli et al.,
2003). This may support work by Buddhala et al (2012) that claims 90% of GABA is 
due to the expression of GAD67, whilst GAD65 is activated to reinforce GABA for 
high frequency GABAergic neurotransmission at the synapse (Buddhala et al., 2012).
Animal models demonstrate that Gad65 knockout mice appear normal at birth, there is 
no change in the GABA concentration in the brain and the changes in animal behaviour 
are anxiety phenotypes and the more severe susceptibility to fatal seizures (Asada et al.,
1996). A conflicting mouse study indicates that GAD65 caused the majority of 
increased GABA synthesis during a seizure in the cortex (Patel et al., 2006). In Gad67 
knockout mice, the mice had a severe cleft palate which resulted in neonatal death the 
morning after birth and a 90% decrease in the GABA content in the brain, though no 
structural brain defects (Asada et al., 1997).
One disease associated mutation has been identified in GAD65 and two in GAD67; as 
well as two disease causing mutations. The GAD65 regulatory mutation is believed to 
associate GAD65 and obesity whilst the two disease associated mutations in GAD67 
cause familial association between the gene and schizophrenia (Boutin et al., 2003; 
Straub et al., 2007, Du et al., 2008). Cerebral palsy and Complex I deficiency are the 
two diseases believed to be caused by mutations identified in GAD67 at protein 
positions 12 and 330 (Lynex et al., 2004; Calvo et al., 2010).
1.5.6 GABA Transaminase (GABAT)
As stated in section 1.5.1, the enzyme GABA transaminase (GABAT; 4-aminobutyrate 
transaminase) catabolises GABA into glutamic acid and succinic acid. GABAT is 
present, not only in the human brain, but throughout the body and especially in the liver. 
It is localised in the inner matrix of mitochondria and is the primary enzyme for 
eliminating GABA. The PLP dependant transamination of GABA occurs by firstly 
recruiting two ketoglutarate, formed by the GABA shunt, as nitrogen acceptors which 
regenerates glutamate by their removal from GABA; a process which also produces 
succinic semialdehyde (SSA) (Medina-Kauwe et al., 1999).
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Mouse models have demonstrated that inhibition of between 55% and 85% of GABAT 
action resulted in a 5- to 10-fold increase in GABA, which had an anticonvulsant affect 
on a variety of rodents and photosensitive baboons. This discovery has allowed for great 
advances in anticonvulsant therapy (Meldrum and Horton, 1978). Vigabatrin, is used to 
inhibit the actions of GABAT by decreasing its activity, increasing the GABA levels in 
the brain and therefore inhibiting synaptic transmission. GABA levels are increased in 
the cytoplasm but this increase is not always transferred to GABA levels in the vesicles 
or vesicular GABA release. Vigabatrin increased GABA levels was found to be not 
only due to blockage of GABAT but also due to reversal of GABA transporters, which 
occurred spontaneously and continuously (Wu et al., 2001).
Mutations in the GABAT gene (ABAT, chromosome 16pl3.3) have been discovered in 
patients that suffered with GABAT deficiency. These patients experienced severe 
psychomotor retardation, hypotonia, hyperreflexia, and seizures; patients died before the 
age of two (Jaeken et al., 1984). In socially isolated mice, reducing GABAT level 
caused a decrease in anxiety and aggression.
1.5.7 Succinic semialdehyde dehydrogenase (SSADH)
Succinic semialdehyde dehydrogenase (SSADH) is the enzyme responsible for the 
oxidation of SSA into succinic acid in the mitochondrial matrix. This carbon skeleton 
form of GABA then enters the tricarboxylic acid cycle (Krebs cycle) and eventually 
reloads glutamate in the form of a-ketoglutarate (as described in section 1.5.1) (Kim et 
al., 2009). SSADH knock-out mice initially experience a milder absence seizure, which 
in time leads to lethal tonic-clonic seizures. This is believed to be due to a rapid increase 
in GABA in the synapse but also due to a downregulation of the GABAa receptor 
subunits in the cerebral cortex of the mice (Gupta et al., 2004).
One disease that is associated with SSADH pathology is Succinic semialdehyde 
dehydrogenase deficiency (SSADHD). SSADHD is a rare inherited metabolic disorder 
with a range of mild and extremely severe phenotypes resulting from insufficient 
GABA degradation by SSADH (Akaboshi et al., 2003). Patients in one study revealed 
symptoms such as behavioral disturbances (42% of patients), and 13% experienced
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episodes of psychosis (Gibson et al., 2003). However, the most common symptoms are 
seizures (especially absences and myoclonic seizures) but patients also experience 
delays in development, hypotonia, myopathy, and ocular abnormalities. Neonatal 
problems can also occur and can cause prematurity, respiratory difficulties, and 
hypoglycaemia (Gordon, 2004).
Numerous mutations have been identified in the SSADH gene, ALDH5A1 (chromosome 
6p22) including point mutations, deletions and insertions. In one study, 36 of 37 
missense mutations identified caused a reduction in SSADH to 5% its normal level. To 
date however, treating patients with SSADHD is very difficult due to the wide variation 
in phenotypes (Akaboshi et al., 2003).
1.6 GABAergic neurons and the thalamo-cortical network
GABAergic neurons are intemeurons that are involved in regulating information 
processing and oscillations are also hugely important to normal functioning of the 
cerebrum. GABAergic neurons are bom in the medial and caudal ganglionic eminences 
of the ventral telencephalon, from where they migrate tangentially to their desired 
cortical region before then moving radially through the cortical plate to their correct 
laminar location. GABAergic neurons migrate to locations that are highly populated 
with excitatory neurons (mainly glutamatergic) that are birth-date matched (Sahara et 
al., 2012). Although GABA is the primary inhibitory neurotransmitter in mature 
neurons, GABA has an excitatory role in immature neurons. In immature neurons, 
GABA causes the efflux of chloride ions due to an increased intracellular chloride 
concentration compared to extracellularly, causing an increase in membrane potential 
and cell depolarisation (Hori and Hoshino, 2012).
The thalamus is located between the cerebral cortex and the midbrain and plays a 
pivotal role in relaying information to and from the cerebral cortex. It has many 
functions including controlling motor function, receiving auditory and visual sensory 
inputs, and controlling awake and sleep states of consciousness. The dorsal thalamus 
contains two types of neurones: relay neurons that project to areas outside the thalamus, 
which are excitatory and local circuit neurons, which do not leave the thalamus and are
37
GABAergic (Arcelli et al., 1997). The thalamus and the pyramidal cells of the cortex 
are connected by excitatory (primarily glutamatergic) connections, whilst GABAergic 
neurons are positioned throughout the thalamus and form an almost continuous layer 
along the lateral, rostral and ventral part of the thalamus (Thalamic reticular nucleus 
(TRN)) (Steriade et al., 1987).
The cerebral cortex forms the outer layer of the brain and receives and processes inputs 
from various regions of the brain. The cerebral cortex maintains general cognitive 
function such as sensation, intelligence, personality and motor function. Across most 
cortical regions in the adult forebrain one in five inter-neurons are GABAergic. 
GABAergic intemeurons function to influence the response of pyramidal cells to 
incoming signals, prevent excessive excitement, process cortical receptive fields and 
manage the timing and synchrony of population rhythms expressed as cortical 
oscillations (Rossignol, 2011).
The inter-connections between the cortex and thalamus, the thalamo-cortical network, 
not only generates normal synchronous oscillations (7 to 15Hz), which include sleep 
spindles, but also the spike-wave discharges (SWD) observed in absence seizures (2.5 
to 4Hz) (Crunelli and Leresche, 2002). More recent blood oxygenation level-dependant 
(BOLD) signal studies have reported the involvement of the frontotemporal network in 
SWD generation as well as consistently reported increments in BOLD signal in the 
thalamus (Lee et al., 2014). Cortical fMRI signal has been shown to increase many 
seconds before thalamic signal emphasising the neocortex as the site of ictogenesis. 
Animal models of absences show focal bilateral cortical changes, believed to cause 
seizures. It has also been reported that SWD are strongly related to the default mode 
network of the brain (wakeful rest state) (Bai et al., 2010).
Spindle waves are generated by bursts of action potentials in the GABAergic cells of 
the TRN and thalamo-cortical neurons. These action potentials are caused by cortical 
discharges which hyperpolarise thalamo-cortical cells by activating chloride 
conductance via GABAa receptors resulting in temporal summation of inhibitory post- 
synaptic potentials (IPSP) (Ushimaru et al., 2012). Recovery from hyperpolarisation 
causes a low-threshold calcium spike followed by bursts of action potentials. This 
induces sodium action potentials, which once again excite the TRN cells initiating the
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next cycle. The pacemaker of the rhythm of sleep spindles is the TRN, and its 
continuous firing in this way causes excitatory post-synaptic potentials (EPSP) of 
cortical pyramidal neurons forming EEG spindles. Neurons of the TRN are inhibitory 
and cause both feedback and feed forward inhibition to thalamo-cortical neurons 
(Kostopoulos, 2000, Bazhenov et al., 1999, Stroh et al., 2013).
Absence seizures usually emerge in periods of restful wake, the transition to and from 
sleep and in light non-REM sleep. An increase in burst firing of thalamo-cortical and 
TRN neurons by GABAa receptors blockade was found by Kim et al. in ferrets (1997). 
This resulted in a decrease in calcium spike duration and therefore ESPS. It has been 
identified that fast activating IPSP by GABAa receptors can be produced upon 
stimulation of TRN. In pathological circumstances, GABAb receptors are activated, 
causing slow activating IPSP and changing oscillation frequency from 7-15 Hz to 3-4Hz 
(Kim et al., 1997, Blumenfeld, 2003).
It has been suggested that an increase in cortical synaptic transmission causes increased 
firing of thalamic GABA neurons and therefore a large-scale increase in TRN GABA. 
Increased GABA release causes hyperpolarisation of most TC neurons resulting in little 
neuronal firing. Astrocytic GAT1 malfunction resulting in high GABA levels also 
causes activation of GABAa receptors, maintaining the hyperpolarisation stage, which 
is modulated by GABAb receptors, causing absence seizures (Crunelli et al., 2010, 
Pirttimaki et al., 2013).
GAT1 and GAT3 are the primary GABA transporters identified in the brain and are 
present predominantly in astrocytic cells of rat and human thalamus. Pirttimaki et al 
(2013) identified a lack of astrocytic GAT1 transporter current in the well established 
genetic animal model of absence seizures, the genetic absence epilepsy rats from 
Starsbourgh (GAERS) compared to a non-epileptic control strain (NEC) (Pirttimaki et 
al., 2013). This would suggest that mechanisms such as glial transport, would be 
affected by the dysfunctional transporter consequently interfering with astrocyte-neuron 
signalling. This was proven in the study by a slower outward current decay time as well 
as decreased amplitude. The frequency of this slow outward current in the thalamo­
cortical neurons was restored by the introduction of the GABA transaminase inhibitor 
vigabatrin, which typically exacerbates absence seizures (Pirttimaki et al., 2013). This
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could suggest that GABA uptake mechanisms from astrocytic cells may contribute to 
absence seizure generation.
GABA receptors and the GABAergic system are identified as a primary cause of 
epilepsy; however numerous neurological diseases have been associated with the 
system.
1.7 Hypothesis
GABAergic pathway genes have the mutational capacity to cause Genetic Generalised 
Epilepsy by compromising inhibitory neurotransmission.
1.8 Aims and objectives
1. Identify genetic variations in GABAergic genes, GAT1, GAT3, GAD65 and GAD67 
in 707 individuals with genetic generalised epilepsy.
2. Utilise in silico methods to predict the consequences of identified variants with 
particular focus on bioinformatics and molecular modelling.
3. Prepare the mutation expression-constructs for suspected deleterious variants to 
begin functional characterisation.
4. in vitro expression validation of the mutation constructs in preparation for functional 
validation assays.
1.9 Justification for research
1. Epilepsy affects approximately 3% of the population as an expression of lifetime 
prevalence. 40% of patients will not reach seizure-freedom upon medication.
2. Epilepsy causality is heterogeneous but 60% will have a simple or complex genetic 
basis. Gene discovery in epilepsy remains a research priority.
3. The GABAergic system is already linked to genetic generalised epilepsy with 
numerous reports of GABA receptors mutations.
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4. Knock-out animal models of GAT1 show signs of epileptogenesis. No animal 
models for GATS have been created to date but the transporter shares significant 
homology and biological synergy with GATL Mutations in other neurotransmitter 
transporters (DAT, GLUT1) cause epilepsy.
5. GAD65 and GAD67 synthesises GABA in the brain. Animal models of GAD65 
knock-outs show a susceptibility to seizure and is significantly homologous to 
GAD67.
6. Anti-epileptic drugs vigabatrin (GABAT) and tiagabine (GAT1) directly targets the 
GABAergic pathway to increase GABAergic tone in epilepsy patients. On 
occasion, drugs can mimic the effects of acquired or inherited gene mutations in the 
target system. Tiagabine can inadvertently increase the number of absence seizures 
by hyperpolarising thalamo-cortical neurones.
7. No GGE mutations have been identified in any of the four GABA synthetic and 
transporter genes investigated in this study in relation to epilepsy.
8. Glycine, the other inhibitory neurotransmitter system, works in tandem with 
GABAergic action. Mutations in the inhibitory glycine receptor (GLRA1, GLRB) 
and transporter genes (SLC6A5) cause neuromotor disorder hyperekplexia and so 
demonstrating cognate implications for GABA transporters.
9. Identifying a cause for certain epilepsies will be vital for current patients their 
families and future patients with the same mutations. The data identified could be 
used to diagnose patients and help treat patients with current drugs and future 
interventional research.
1.10 Experimental approach
To fulfil the aims and objectives of this study the following experimental approaches
were carried out. Each point will be addressed and discussed in greater in detail in
Chapter Two - Materials and Methods.
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Figure 1.9. General workflow. Proposed  research  workflow for this study ranging from 
genetic screening and variant analysis to functional analysis.
A genetic study in human disorders begins with well phenotyped and ethically 
reputable assembly of patient samples. Prior to this study, the neurology team at 
Swansea had collected over 700 GGE samples by combining cohorts from the Wales 
Epilepsy Research Network (WERN), the Epilepsy Research Centre, University of 
Melbourne (Berkovic, Scheffer), the Neurology Unit at Auckland District 
Healthboard (Bergin), and the UCL historical cohort now hosted by St. G eorge 's  
Medical College, London (Everett, Gardner).
With the samples secured, the next stage genetically analysed GAT1, GAT3, 
GAD65 and GAD67 by working out the genomic structure, exon/intron boundaries, 
the ATG initiation site, the STOP codon, SNP maps and the respective 5 ’ and 3' 
untranslated regions. To amplify and analyse the coding region and splice site 
regions of the genes, Polymerase Chain Reaction (PCR) was carried out on the GGE
42
patient samples. Optimised PCR products were tested using heteroduplex 
Lightscanner™ technology to ensure high-throughput variant detection.
Samples which deviated from normalised melt profiles were isolated and purified 
before being outsourced for bi-directional Sanger sequencing. Sequencing results 
returned to Swansea were analysed using Mutation Surveyor™ analysis software 
with comparison to wild-type sequences. Any gene variants discovered by 
sequencing were scrutinised using on-line and in silico methods including PDB 
molecular modelling. In addition, the population frequencies were assessed for 
suspected damaging non-synonymous variants in a panel of commercially sourced 
controls using the Lightscanner™ protocols.
To investigate the pathogenic potential of non-synonymous variants, expression 
constructs were be prepared from C-terminally DDK tagged wild-type vectors for 
GAT1, GAT3, GAD65, and GAD67. Mutations were introduced to wild-type vectors 
using site-directed mutagenesis (Origene, Cat.PS 100001), with successful clones 
being mini- and maxi-prepped (Qiagen) after transformation into E.coli bacteria (One 
Shot TOPIO Chemically competent E.coli, Life technologies, Cat.C404006). 
Sequence validated mutation constructs were used to investigate the expression level 
of each mutant using HEK293 cells which were visualised using confocal 
microscopy and semi-quantitative approaches.
The mutation constructs were also used in further functional analysis (for future use 
after this thesis) which will incorporate an enzymatic assay for GAD65 and GAD67, 
biotinylation of cell-surface proteins GAT1 and GAT3, splice-site assays of exon 
skipping candidate mutations, and mass spectrometry quantification of GABA 
transporter and GAD activity. Lastly, these constructs will also be used in 
collaborative project in and around the creation of model systems and in-depth 
electrophysiology.
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C h a p t e r  T w o  
M a t e r i a l s  a n d  M e t h o d s
Aseptic techniques were practised at all times and equipment sterilised prior to use by 
autoclaving. Disposable gloves and lab coats were worn in order to prevent 
contamination of  samples and for personal safety. All designated lab work surfaces, 
pipettes and equipment were cleaned and sprayed with 70% ethanol to ensure a sterile 
environment. Standard operating procedures were accessed and adopted to ensure best- 
practice and uniform approaches relative to each technique in this chapter.
2.1 Patient samples and ethical approval
Four hundred and eighty five genetic generalised epilepsy patient DNA samples were 
ascertained from Australia, New Zealand and the Wales Epilepsy Research Network 
(WERN). A further one hundred and eighty seven DNA samples from childhood 
absence seizure patients were then recruited from University College London based on 
initial preliminary data and represented a replication cohort (Table 2.1). Samples were 
not linked to known epilepsy genes and had not previously gone through screening 
projects involving SLC6A1 (GAT1), SLC6A11 (GAT3), GAD2 (GAD65) and GAD] 
(GAD67) genes.
Table 2.1 Sample Ascertainment and Origin
Origin of samples Epilepsy type Sample number
Cohort 1 Melbourne, Australia GGE 400
Cohort 2 Auckland, New Zealand GGE 59
Cohort 3 Wales (WERN) GGE 59
Cohort 4 UCL, London CAE 189
Inclusion criteria included a secure diagnosis of genetic generalised epilepsy or 
childhood absence epilepsy as declared by a neurologist with a speciality in 
epileptology and the electro-clinical signatures that reflect the diagnosis. Ethical 
approval for the sample archiving and genetic analysis was approved under the W ERN 
epilepsy Biobank IRAS framework (Wales REC study # 12/WA/0150).
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2.2 Mutation detection by candidate gene analysis
This section outlines the procedures adopted for the screening and mutation analysis of 
genomic DNA from epilepsy cases.
Polymerase chain reaction (PCR) has become one of the most widely used and integral 
techniques in molecular biology and medical genetics. In essence, PCR accumulates 
small sections of DNA by exponentially amplifying target sequence to enable 
visualisation, sequencing, cloning and further manipulation of the DNA (Higuchi and 
Ochman, 1989). The last twenty years has witnessed extensive development in the PCR 
technique concept that facilitated more advanced molecular approaches such as 
quantification of DNA and RNA levels, Sanger sequencing and the detection/cloning of 
mutations and polymorphisms. PCR is now an automated process carried out using 
high-throughput approaches enabling simultaneous analysis of hundreds or thousands of 
samples.
Mimicking the basic components of naturally occurring replication machinery from 
within the cell, short fragments of DNA are amplified in a PCR reaction mixture. This 
reaction mixture typically contains a buffer to maintain optimum pH and ionic 
concentrations, deoxynucleotides as the building blocks of DNA, primers 
complementary to target sequence that will be amplified and a DNA polymerase 
enzyme to catalyse the reaction amplification. LC green fluorescent dye was also added 
for visualisation of double stranded DNA as a result of increased temperature to enable 
light-scanner mutation analysis.
DNA is amplified exponentially with a linear phase in which DNA concentration is 
directly proportional to the cycle number. There would be a point therefore, where one 
of the constituents of the reaction is exhausted and amplification will cease. PCR is an 
extremely sensitive technique and can be very easily confounded by contamination, 
leading to false-positive results. To avoid contamination, aseptic techniques were 
adopted such as the use of designated, regularly cleaned PCR pipettes and lab work 
surfaces, sterile filter tips, and centrifuge tubes. This is also in combination with good 
laboratory practice positioning of PCR consumables, discarding tips to avoid cross 
contamination and a consistent action of methodology.
45
2.2.1 PCR Primer design
PCR primers were designed using gene sequence information from publicly available 
databases such as NCBI (http://www.ncbi.nlm.nih.gov/) and Primer 3 
(http://frodo.vvi.mit.edu/primer3). Oligonucleotide primers were typically designed 
within intronic regions of genes and flanking the desired exonic target, avoiding SNPs 
and repeat structures as outlined on dbSNP. Primers were designed to be approximately 
20 nucleotides in length with an annealing temperature of approximately 60°C. To 
prevent secondary structure formation, self-complimentary sequences and non-specific 
binding were avoided using BLAST2.2.14 (NCBI) software. Custom designed primer 
sets were manufactured by Eurofins MWG Operon. Primer sequences, their 
corresponding anneal temperatures and fragment sizes were calculated and shown in 
tables 2.2, 2.3, 2.4 and 2.5.
2.2.2 Polymerase chain reaction
Each PCR Lightscanner reactions contained a master mix of 1.5pl sterile water, 0.25pM 
forward and reverse strand primer (Eurofins MWG Operon), 5pl Type-it Multiplex PCR 
Mastermix (2x) (Qiagen, Cat. 206143) and lpl LC Green Dye (Idaho technology, 
Aquascience Cat.BCHM-ASY-0006). 8pl of master mix per sample was aliquoted into 
a sterile 96 well Lightscanner plate; lOng of DNA was then added as well as 15pl of 
mineral oil to each sample reaction to prevent sample evaporation. Negative controls 
were also carried out for all PCR reactions, by replacing the DNA with sterile water. All 
exons screened were optimised using their specific primers between 55°C and 70°C. On 
occasions where unclear or multiple bands were witnessed via gel electrophoresis, 
DMSO or MgCl2 (percentages used range from 1% to 10% DMSO/MgCh) were added 
in order to improve optimisation.
The reaction mixture was cycled 40 times through three temperature stages after an 
initial denaturation stage at 94°C for three minutes, which, denatures the DNA strands 
by breaking the hydrogen bonds between matched base pairs. The temperature cycles 
include a second denaturation stage at 94°C for 30 seconds; an annealing step for one
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minute at a temperature specific to the primer set (typically SO T - 65°C optimisation 
range) which allows primers to bind to the DNA template at a specific hom ologous 
location; and an extension stage at 72°C for one minute, the optimum temperature for 
the DNA polymerase enzyme to add nucleotides to the 3*-OH end of the newly forming 
DNA, thus producing new duplex molecules. This is the stage at which new DNA is 
synthesised (Figure 2.1) and the num ber of cycles can depend on the efficacy o f  the 
PCR reaction. Following the multiple cycle steps, a final ten minute extension stage at 
72 C is needed before samples are held at 94°C for 30 seconds and 25°C for 30 seconds 
to form heteroduplexes; samples are retained at 4 C until removed for analysis.
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Figure 2.1 Polymerase chain reaction. The exponential amplification of DNA occurs by an 
initial denaturation of DNA, an annealing s tag e  which allows the binding of specific primers and 
an extension ph ase  where the primer is extended by po lym erase to form a  new duplex 
molecule. This cycle is repea ted  39 times c rea te  large am ounts  of desired DNA product.
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Amplification of exons was not always possible, even following the use of DMSO and 
MgCl2 to create the ionic conditions or help resolve complex annealing structures. For 
example, this was the case with the GC rich exon 1 of GAT3, where alternative 
amplification approaches were needed. In this case a Q5® Hot Start High Fidelity DNA 
polymerase protocol (NEB, Cat M0493L) was used to successfully amplify the exon. A 
PCR master mix for the exon consisted of 0.2pM of both forward and reverse primer, 
200pM of each deoxynucleotide triphosphate (Promega, Cat U1330), 2pl Q5 Reaction 
Buffer (5x), 2pl Q5 High GC Enhancer (5x) (NEB, Cat B9027S, lp l LCGreen dye 
(Idaho technology, Aquascience Cat.BCHM-ASY-0006), ljul DMSO (Sigma, Cat 
D2650) and 0.1 pi Q5 hot start high-fidelity DNA polymerase; lOng of DNA was added 
to the mastermix. The reaction mix was cycled 40 times following an initial 30 second 
denaturation stage at 98°C. The cycle included a second denaturing stage of 10 seconds 
at 98°C, an annealing step at 63°C for 45 seconds, followed by an initial extension stage 
at 72°C for 20 seconds. Following the 40 cycles, a final extension stage at 72°C for 2 
minutes followed by two 30 second holding stages at 98°C and then 25°C.
2.2.3 Lightscanner™ analysis
Lightscanner analysis is a high-throughput method using high-resolution melting 
analysis of post-PCR products. Upon completion of PCR cycles the plated samples were 
centrifuged for one minute at 2500g and placed into the Lightscanner on a platform- 
stage. The Lightscanner heated the plates with PCR products causing separation of the 
double stranded DNA (dsDNA) and the release of LC Green dye, an intercalating dye 
that binds to dsDNA causing high fluorescence. Therefore, upon melting, the dye 
cannot bind as strongly and will fluoresce at a lower level (Figure 2.2). The level of 
fluorescence is detected for each well and the presence of genetic variance will generate 
differences in melt-curve properties. Sequence factors affecting melt differences include 
GC-content, product length and whether a variant genotype is homozygous or 
heterozygous. The platform is sensitive enough to detect Single-Nucleotide 
Polymorphisms (SNPs) and was used as an initial screening process where deviations in
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melt profiles would be Sanger sequenced to confirm or reject the presence of sequence 
variation.
*n
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Figure 2.2 Lightscanner melt profile. Patient DNA, which contained a  novel variant, w as 
highlighted in dark green. As the Lightscanner hea ts  the DNA of each  patient in 96 well form, 
variant DNA melts at a  different rate to the control DNA sam ples  (indicated by arrows).
2.2.4 PCR product purification
Prior to Sanger sequencing, all samples were purified using a QIAquick PCR 
purification kit (Qiagen, Cat.28106), to remove any unwanted PCR mix that may inhibit 
downstream applications. Briefly, 50pl of Buffer PB was added to each sample (5x 
volumes of Buffer PB to lx  volume of  PCR product, excluding mineral oil) and 
transferred into a QIAquick spin column and collection tube. Solutions were centrifuged 
at 17,000g for one minute allowing DNA to bind to the spin-column membrane and 
removal of flow-through eluate. 750pl o f  Buffer PE was added to wash the DNA, and 
centrifuged for one minute at 17,000g with any flow-through discarded. Samples were 
then centrifuged again at 17,000g with no added buffer in order to completely remove 
the wash solution and QIAquick spin columns were placed in clean 1.5pl collection 
tubes. Clean PCR products were eluted by adding 30pl of sterile water to the spin-
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column membrane for one minute, before a final minute centrifuge at 17,000g. The spin 
column was then discarded leaving purified DNA remaining in the collection tube.
2.2.5 Agarose gel electrophoresis
To determine the success of the PCR purification, samples were visualised on agarose 
gels. Agarose gel electrophoresis determines the size and presence of the PCR amplicon 
and can detect any generalised contamination that may compromise the reliability of 
sequencing results. If contamination was detected or the amplicon was the incorrect 
size, then the sample would be PCR repeated under re-optimised conditions. Generally, 
the percentage of agarose used in gels is dependent on the size of the amplicons, 
however the DNA fragments in this study typically ranged between 200bp and 500bp in 
length and consequently 1.5% agarose gels were used.
1.5% agarose gels were created by adding 1.5g Ultra pure agarose (Invtrogen, Cat. 
16500500) to 100ml 0.5 x TBE (Tris/borate/EDTA) buffer; TBE contains a mix of 108g 
tris-base (Sigma Cat. 154563), 55g boric acid (Fisher scientific, Cat.B3F00/60) and 
40ml EDTA (Fisher scientific, Cat. 10011123) in one litre of sterile water. The agarose 
and TBE solution was heated to boiling point in a microwave before cooling and 
stirring to approximately 60°C. A 1:10,000 dilution of Sybr safe DNA gel stain 
(Invitrogen, Cat.533102) was added and poured into a plastic mould held in a casket 
with a toothcomb inserted. The gel was left to solidify at room temperature before being 
placed in a horizontal electrophoresis tank and covered with 0.5% TBE. The comb was 
removed to reveal loading wells; 5jul PCR product and lp l of 6x loading dye (NEB, 
Cat.B70215) were mixed and loaded into the gel. One hundred base pair DNA ladder 
(NEB, Cat.N3231L) was added to the first well, which, was made up of lp l 6x loading 
dye, 0.25pl lOObp ladder and 3.75pl sterile water. Depending on the size of the gel, the 
conditions of the electrophoresis equipment were set between 80-120V, for between 35- 
60 minutes, until the dye band reached approximately three quarters of the gel. The 
recommended voltage to be used, as described by Life technologies, is 4-10V/cm 
(distance between anode and cathode) (https://www.Iifeteelinologies.com).
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Gel images were captured using the Trans UV BIO-RAD Gel Doc via Quantity One 
(version 4.6.3) analysis software. If clear DNA bands of the correct size were observed, 
then samples were quantified using a NanoDrop™ spectrophotometer 8000 (Thermo 
Scientific, version 2.2.0), so that DNA could be standardised to 5ng/pl. The DNA and 
1.5pmol/|ul of exon-specific forward primers were sent for Sanger sequencing using a 
sequencing provider centre and ABI 3730 XL sequencing machines (Eurofins).
2.2.6 Gene-variant identification, validation and analysis
Sequencing files were visualised in chromatograph form by using Chromas software 
(Technelysium Pty Ltd). SNPs and variants were identified using Mutation Surveyor 
software (version 3.10, SoftGenetics, State College, PA) on sequences obtained by 
comparison to a wild-type reference sequence obtainable in GeneBank Sequence 
Database (http://www.ncbi.nlm.nih.gov/genbank/). The detection of a variant was 
further checked using NCBI dbSNP for SNP status i.e. common, rare and novel; 
synonymous or non-synonymous.
For the purpose of this study rare SNPs were defined by the ‘Common-disease 
common-variant’ hypothesis as polymorphisms with a frequency >1% (Gorlov et al., 
2008). Any variants identified that were in the public domain with a frequency greater 
than 1% were excluded from the study but noted along with any synonymous SNPs for 
further scrutiny for expression effects or splicing abnormalities. If a novel or rare 
variant was identified using a forward primer this was validated by sequencing in the 
antisense direction from stock samples to control for positional errors using 96-well 
plates. Following bi-directional sequencing confirmation, a population study would be 
used to further assess the presence or absence of the rare/novel variation in the 
unaffected population (section 2.2.8).
2.2.7 Bioinformatic Predictions
All variants underwent bioinformatic predictive analysis to assess putative pathological 
effects. This was carried out using three prediction webtools; ‘Sorting Tolerant From
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Intolerant’ (SIFT) (http://sift.icvi.org/). Polymorphism phenotyping (PolyPhen) 
(http://genetics.bwh.harvard.edu/pph2/) and Align GVGD
(http://agvgd.iare.fr/agvgd input.php); all three tools predicted whether an amino acid 
substitution affects normal protein function.
SIFT calculated the degree of amino acid conservation in sequence alignments with 
closely related sequences using a PSI-BLAST algorithm (Ng and Henikoff, 2001). In a 
study by Kumar et al. (2009), SIFT was proven to be 69% accurate in correctly 
identifying pathogenic mutations (Kumar et al., 2009). A SIFT score ranges between 0 
and 1 with position specific scoring matrices and if predicted to be less than 0.05 then a 
variant would be considered deleterious and probably pathogenic. A SIFT score of more 
than or equal to 0.05 would suggest that the effect of the amino acid change was 
tolerated by the protein and considered benign. However, no one-prediction tool is 
accurate and is prone to type-2 false negative outcomes.
PolyPhen predicts whether any structural changes have occurred to the protein as a 
result of an amino acid change. This prediction was based on multiple phylogenic and 
structural information regarding the new amino acid substitution (Ramensky et al., 
2002). PolyPhen gave a result by calculating the probability of false-positive and true- 
positive rates (Bergman et al., 2012).
Align GVGD, which was an extension on the Grantham Difference (the assessment of 
alignment with the physicochemical characteristics of the amino acid) and used 
conservation and alignment scores to calculate amino acid effects on protein, taking into 
account composition, polarity and volume of amino acid substitutions. Align GVGD 
scores that placed variants in group CO are considered probably benign, groups C l5, 
C25 and C35 are possibly pathogenic and C45, C55 and C65 are probably pathogenic. 
(McGee et al,. 2010)
2.2.8 Population studies
Population studies involved 480 commercially available control DNA samples with no 
previous disease history (Sigma-Aldrich, Dorset, UK). Lightscanner PCR was carried
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out with the patient DNA sample carrying the suspected novel variant in the 96th well 
of the Lightscanner plate as a positive melt-curve control, and control DNA in the 
remaining 95 wells. Post-PCR samples were centrifuged for one minute at 2500g and 
placed in the Lightscanner. From the melt-curve profiles it is apparent if the control 
population DNA has some samples that follow the positivecontrol profile or remain 
typically wild-type. Some population control samples created novel melt-curves due to 
the presence of common SNPs. Typically, all melt-curve samples that did not have 
wild-type melt-profiles were Sanger sequenced. In the event where a control sample 
contains the target variant, but at a low proportion (<1%) of the population, it remained 
a pathogenic candidate since rare SNPs can be epileptogenic. One further interpretation 
consideration is that we are dealing with childhood epilepsies with subtle features and 
consenting adults providing DNA for control status may have forgotten their childhood 
illness and not declared a history.
2.2.8 Structural homology modelling
To date, homology modelling involving the recognition and comparison of known 3D 
structure homologs is the most successful in silico method for predicting protein 
structure. There are limited protein folds in nature and homologous sequences adopt 
similar protein structures along biophysical rules and possibilities. Each variant and 
wild-type sequence was uploaded on to Phyre2 server (sbg.bio.ic.ac.uk/phyre2) which 
uses a library of known protein structures from the ‘Structural Classification of Proteins 
Database’ to create a variant sequence model which is enhanced with current data from 
the ‘Protein Data Bank’ (PDB). This server compared the sequences uploaded with 
numerous proteins that had previously determined experimental structures. On 
identification of a homolog, the two sequences were aligned and the 3D protein models 
were created (Kelley and Sternberg, 2009).
The visualisation and analysis of the molecular structure of variants identified in this 
study were carried out using the UCSF Chimera package. Chimera is developed by the 
Resource for Biocomputing, Visualization, and Informatics at the University of 
California, San Francisco (supported by NIGMS P41-GM103311). The software 
enabled the direct comparison of wild-type structure with variant structure by aligning
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them to each other. Any changes in structure due to sequence variants were visible for 
analysis at an amino acid side chain level and at a protein structure level (Pettersen et 
ah, 2004).
2.3 Preparation of Gene-Specific Mutation Constructs
All gene-variants that were linked with putative pathogenic properties were introduced 
into gene-specific construct to enable cellular function experiments. Figure 2.3 
illustrates the workflow pipeline to achieve mutagenesis on a relatively large scale.
Mutagenesis
Digestion
Transformation
Transformation Plating onto Agar Bacterial colony picking
Plasmid DNA extraction
Miniprep Sequence validation Maxiprep
Figure 2.3 Flow diagram of construct preparation process. Creating constructs  for 
functional analysis follows the system atic  approach of m utagenesis , transformation and plasmid 
DNA extraction. T h e se  s teps  can be sub-divided and M utagenesis  involves PCR and digestion 
s teps, the transformation s tage  following the incorporation of the bacterial cells by the plasmid 
DNA also involves plating the constructs onto agar  and bacterial colony picking. Plasmid DNA 
extraction is sub-divided into Miniprep, and larger sca le  Maxiprep s ta g e s  with s e q u e n c e  
validation at each  step.
2.3.1 Mutagenesis
The wild-type constructs were externally-sourced for all four GABAergic genes and 
were C-terminal Myc and DDK-tagged pCM V6-Entry destination vectors that had been
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genetically-engineered to contain the open reading frame (ORF) of the corresponding 
gene with an expression tag (Origene, Cat.PS 100001). The 4.9kb Kanamycin resistant 
vector contained the human cytomegalovirus (CM V) promoter, which, enhances the 
expression of the cloned inserts, a Kosak sequence (G CC G C CG C G A TCG C) situated 
prior to the insert to encourage translation o f  the gene and a C-terminal DDK tag 
sequence (G A T TA C A A G G A TG A C G A C G A T A A G ) (Figure 2.4). A DDK antibody 
was used for visualisation (as described in section 2.4). The wild-type vectors were 
modified and the novel gene-variants and rare SNPs were inserted individually and 
amplified by mutagenesis.
Figure 2.4 Vector map of pCMV6-Entry Vector (C-term inal Myc and DDK tagged). The
pCMV6-entry vector contains a  Cytomegalovirus (CMV) promoter, a  Kosak seq u en ce ,  the 
desired open reading frame se q u e n c e  (red triangle), Myc/DDK flag and a  Kanamycin res is tance  
sequence .
2.3.2 Primer design
Mutagenic oligonucleotide primers were designed individually as outlined by 
Stratagene Site directed mutagenesis protocol, with forward and reverse primers 
containing the desired variant nucleotide. To ensure successful annealing, primers were 
optimally designed to be between 25 and 45 base pairs in length, have a melting
Kanamycin
resistance
pCMV6-Entry 
Vector 
4.9 kb
CMV Prom oter
Kosak
Sequence
Desired
ORF
sequence
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temperature (Tm) o f  >78°C, and %GC content o f  >40%. The following formula was 
used to calculate the Tm of the primers for which %GC was a whole number:
Tm: 81.5 + 0.41(%GC) - 675/N -% mismatch
So that no secondary structures were formed, primers were screened using 
OligoCalc: Oligonucleotide Properties Calculator,
( \v\vw.basic.northwesiern.edu/biotools/01igoCalc.htfflr).The mutagenesis primers 
designed to introduce the missense and nonsense variants of this study are shown in 
Tables 2.6 and 2.7.
A different approach was adopted for the deletion variant identified in this study. 
This deletion occurs in the final exon of GAT1 causing a frameshift and addition of 
16 amino acids running into the 5 'U T R  owing to the elimination of the obligatory 
stop codon. A mutagenesis primer had to initially be created (megaprimer) which 
would span the desired region of the gene from the deletion and to include the 
additional amino acids created by the frameshift; this primer ended with a sequence 
that would bind to that of the vector. The forward primer caused the deletion of the 
desired nucleotide from control DNA which resulted in a frameshift and 
consequently the removal of the stop codon. The reverse primer bound to the 
previously intronic sequence that was now a part of the protein due to the frameshift 
(as shown in table 2.8).
GAT1
d e l e t i o n
v a r i a n t
P r i m e r  S e q u e n c e
Am pl i con
Length
(bp)
A nn e a l i n g
t e m p e r a t u r e
(°C)
F o r w a r d
p r i m e r
CGGGCAGCTCCACCGCAAGGAGGCCTACATC
103 70
R e v e r s e
p r i m e r
TGCTCGAGCGGCCGCGTACGCGTGCCAGGTCGG
GGGGTGAGAGT
Table 2.8 Primer sequences of the GAT1 deletion to create m egaprimer. The forward 
and reverse  primer se q u e n c e s  for the identified deletion in GAT1 include the  ch an g es  
n eed ed  to mutate GAT1 wild type se q u e n c e  into the desired  variant by PCR. Highlighted in 
red in the reverse  primer is the s e q u e n c e  that binds to the DNA and in blue is the seq u e n c e  
corresponding to the vector seq u en ce .  The primers c rea ted  a  fragment (megaprimer) at the 
optimal annealing tem perature  of 70°C, which w as  103 b a se  pairs in length.
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2.3.3 Mutagenesis PCR in Gene Constructs
In 0.2ml tubes on ice, 2pl of the Wild-type expression construct template (at 
25ng/pl) was added to 25pl Pfu Ultra Hotstart DNA Polymerase (Stratagene), 1.25pl 
(at lOOng/pl) of both sense and antisense primer, and 20.5pl of sterile water. These 
were briefly centrifuged before being placed on the thermocycler (MJ Research). On 
the thermocycler the samples were held at 95°C for one minute before 18 cycles of 
denaturation at 95°C for one minute, annealing stage at 55°C for one minute and an 
extension stage at 68°C for two minutes/kb. Incubation periods were approximately 
4-6 hours depending on the size of the plasmid. In this study the vectors were on 
average 4.9 kb in length, and therefore the extension stage was 10 minutes long.
To degrade the parental wild-type DNA, lpl of the restriction enzyme Dpnl (NEB, 
Cat.R01765) was added to each sample upon completion of the PCR programme and 
incubated for one hour at 37°C, leaving only the desired mutant copy remaining. 
Following the incubation period, samples were visualised on a 1% agarose gel at 
85Mv for an hour. As the parental wild-type would have been degraded by the 
enzyme, the presence of a clear band at the correct size would indicate successful 
amplification of a variant construct.
For the deletion variant an initial PCR was carried out before mutagenesis using lpl 
of forward and reverse primer in a 0.2 pi PCR tube along with 0.5pl sterile water, 
25pl of Type-it™ Multiplex PCR Mastermix 2x (Qiagen Cat:206343) and lOOng of 
control genomic DNA. The genomic DNA used was previously sequenced to ensure 
that there were no exonic or intronic SNPs in the sequence for amplification. The 
PCR programme carried out on this sample involved an initial denaturing period of 
95°C for five minutes followed by 34 cycles of a denaturing step at 95°C for 30 
seconds, annealing stage at 70°C for 90 seconds, and an extension stage at 72°C for 
45 seconds. The programme ended with a final extension phase of 68°C for 15 
minutes.
Following PCR, samples underwent electrophoresis on a 3% agarose gel for 60 
minutes at 80v with a lOObp ladder (3% gels were suitable for fragments from lObp 
to 200bp in length). The megaprimer was then extracted from the gel by being placed
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on a UV plate in a dark room, which illuminated the DNA product for removal by 
cutting out with a scalpel. Using a QIA Quick gel extraction kit (Qiagen, Cat.28704) 
the DNA was extracted and purified from the agarose gel. Samples were weighed 
and a buffer was added to dissolve the gel. The sample and buffer solution was 
incubated for 10 minutes at 50°C. Isopropanol was added for precipitation and the 
mix transferred to a filter, which, was washed with two separate buffers. DNA was 
then eluted in 50 pi of water.
300-500ng of megaprimer was used in mutagenesis PCR. The PCR programme 
carried out involved an initial denaturing stage of 95°C for one minute followed by 
only five cycles of denaturation at 95°C for one minute, annealing for one minute at 
52°C and an extension stage at 68°C for two minutes per kb. This was followed by 13 
cycles of an ordinary mutagenesis programme as described above. The number of 
cycles are kept low to ensure that no unwanted variants appear and the initial five 
cycles are used to increase the yield of product as the megaprimer has trouble 
priming to the template (Datta, 1995).
2.3.4 Transformation of Wild Type and Mutant Vectors
Throughout the preparation stages of ampicillin-resistant constructs, a 1:1,000 
dilution of ampicillin (Sigma, Cat.A5354) was required in LB Broth/LB Agar. 
However, Kanamycin-resistant constructs required a 1:2,000 dilution of kanamycin 
(Invitrogen, Cat. 15240062). Before beginning transformation the LB Broth and LB 
Agar were prepared. In a glass bottle 20g of LB Broth (Sigma, Cat.L2897) was 
added to one litre of deionised water and sterilised in a bench top autoclave for 
approximately 45 minutes. To prepare LB Agar (Sigma, Cat.L3022), a magnetic flea 
and 35g of LB Agar was added to one litre of water and sterilised in a bench top 
autoclave for approximately 45 minutes. Following this the LB Agar was allowed to 
cool to approximately 50°C before adding the required antibiotic. Once the antibiotic 
was added the LB agar was mixed with a magnetic stirrer. In a bacterial hood 20- 
30ml of LB Agar was added to petri dishes by pouring and allowed to cool until 
solidified. Dishes were then sealed with parafilm and stored at 4°C until needed.
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One vial of E.coli bacteria (One Shot TOP 10 Chemically competent E.coli, Life 
technologies, Cat.C404006) per construct was placed on crushed ice. Once thawed, 
50pg of plasmid DNA was added to each of the vials, mixed by gentle tapping and 
placed on ice for 20 minutes. The vials were then transferred to a heat-block preset at 
42°C for exactly 30 seconds before returning to ice for two minutes, causing 
incorporation of the bacterial cells into the plasmid DNA. After two minutes, 250pl 
of pre-warmed LB Broth was added to the bacteria and incubated for one hour at 
37°C, whilst shaking at 750rpm. After 30 minutes, LB Agar plates were pre-warmed 
to 37°C. Following the incubation period, lOOpl of the bacteria-containing broth was 
transferred to the pre-warmed plates in three dilutions respectively with broth; 1:0, 
1:1 and 1:3. These dilutions differ for wild-type to 1:10 and 1:100. Plates were 
incubated for 16-18 hours at 37°C to allow the growth of bacterial colonies prior to 
selection.
Following the incubation period, plates were sealed with parafilm and stored at 4°C 
for approximately six hours. Six labelled falcon tubes per construct were prepared in 
a bacterial hood and into each tube 3ml of pre-warmed LB Broth and the 
corresponding antibiotic was added. Bacterial colonies were picked (using a pipette 
tip) and dropped directly into the LB Broth/antibiotic mix. Six bacterial colonies per 
construct, were incubated at 37°C for 16 hours, rotating at 225rpm to allow bacterial 
growth.
A derivation in the protocol was adopted for the deletion variation and ten colonies 
were selected and visualised on a 1.5% Agarose gel and five samples were selected 
for Miniprep dependant on the size of the bands. If the sample had been successfully 
transformed the product would have been 50bp larger than the wild type/not 
transformed and is a cost effective way to select for the variant sequence before 
investing in large Maxiprep cultivations.
2.3.5 Plasmid DNA extraction
To extract the plasmid DNA from the Miniprep bacteria, 
a QuickLyse Miniprep Kit (Qiagen, Cat.27406) was used to purify a small volume of
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plasmid for validation by Sanger sequencing (Eurofins). Upon sequence verification 
of successful mutagenesis and colony selection, the remaining Miniprep was used to 
seed larger volumes of LB Broth with antibiotics and purified using a HiSpeed 
Plasmid Maxi Kit (Qiagen, Cat. 12663). Both these processes involved the selective 
denaturation of chromosomal bacterial DNA without affecting the covalent links of 
the plasmid DNA; this could only occur at a pH of 12.0-12.5 (Bimboim and Doly, 
1979). Cell walls were weakened by a lysozyme and completely lysed by a 
combination of sodium dodecyl sulphate (SDS) and sodium hydroxide (NaOH) 
(Kado and Liu, 1981). NaOH along with glucose maintained the desired alkaline pH 
value (Bimboim and Doly, 1979).
To extract plasmids from the post incubation Miniprep, 2ml of starter culture was 
centrifuged for one minute at 17,000g to pellet the bacteria (all centrifuge steps were 
one minute at 17,000g). Ice-cold complete lysis solution was added to the pelleted 
bacterial cells and mixed using a pipette to re-suspend before a three minute 
incubation at room temperature. After the incubation period, the lysate was 
transferred by decanting to a spin column and centrifuged. The spin column was 
washed with buffer QLW and centrifuged with the flow-through discarded. An 
additional centrifuge step was carried out to dry the QuickLyse spin column. The 
QuickLyse spin column was transferred into a clean 1.5ml collection tube. DNA was 
eluted by pipetting 50pl of warmed water directly onto the centre of the QuickLyse 
spin column to solubilise the vector plasmids and pulled through with centrifugation 
generating an eluate suspension.
Samples were then quantified using a NanoDrop™ and sent for Sanger sequencing at 
concentrations ranging from 5-10ng/ul to ensure clean products, the presence of the 
desired variant and make sure no additional nucleotide variants had emerged into the 
plasmid sequence. One sample from the Sanger sequencing results of the six 
bacterial colonies was selected for Maxiprep cultivation.
Maxipreps were established by adding 200ml of autoclaved LB Broth with antibiotic 
(see previous dilutions) to autoclaved conical flasks. Five hundred micro litres of the 
successful Miniprep colony was then added with the tops of the flasks loosely- 
covered using foil and secured with tape before incubation at 37°C in an Innova 4230
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refrigerated incubator shaker (New Brunswick, USA) at 225 rpm, for approximately 
16 hours. Following the incubation period, the bacterial cells were then harvested by 
being centrifuged at 6000g for 15 minutes at 4°C.
Bacterial cell-pellets were re-suspended using 10ml Buffer PI. 10ml Buffer P2 was 
then added, mixed and incubated at room temperature for five minutes. A chilled 
10ml Buffer P3 was added, mixed and incubated at room temperature for 10 minutes 
in the barrel of QIAfilter cartridge. Using a plunger, the cell lysate was filtered into a 
HiSpeed tip and the lysate was allowed to enter the resin by gravity flow. Following 
a wash with 60ml Buffer QC, DNA was eluted with Buffer 15ml QF and precipitated 
with 10.5ml isopropanol at room temperature for five minutes. The 
DNA/isopropanol mix was then filtered and 2ml of 70% ethanol was added before 
the solution filtered. Air was forced through the filter twice to ensure no ethanol 
remained. DNA was re-suspended in 750pl of sterile water and the DNA quantified 
using the NanoDrop™ system. Sanger sequencing was used to ensure a successful 
Maxiprep cultivation, which, included sequence coverage for both the vector and 
ORF insert.
2.4 Immunocytochemistry
Once the wild-type and mutagenesis constructs were created and sequence verified 
there was a requirement to ensure all constructs in cell-lines were functioning and 
expressing. Immunocytochemistry in HEK293 was carried out on all mutation and 
wild-type constructs followed by visualisation of expression via high-resolution 
confocal microscopy. All cell culture work was carried out in laminar flow hoods 
under sterile conditions.
Immunocytochemistry is a popular technique that visualises the expression and 
localisation of proteins within a cell. Consequently, this was used to check the 
expression validity of the GABAergic mutations and wild-type constructs but also 
may show large variations in expression and or localisation when compared. A 
primary antibody is added to the cells which recognises and binds to a specific 
antigen, a secondary antibody raised in the same species is then introduced (Figure
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2.5). The secondary antibody will typically be labelled with a fluorescent probe, 
which, once bound, will allow detection of the target epitope by high-resolution 
confocal microscopy.
Cell exterior
Fluorophore
Secondary
antibody
Primary
antibody
Intracellular region
Figure 2.5 Antibody binding to target antigen. The primary antibody, a s  shown in green, 
recognises antigen A and binds. The secondary  antibody (highlighted in red) recognises  the 
primary antibody. O nce bound, antigen A can be detec ted  due  to the fluorescent probe 
contained in the secondary  antibody (yellow circle).
2.4.1 Culturing the HEK293 Cell Line
HEK293 cells are human embryonic kidney cell-line that are characteristically used 
as an expression or targeting validation platform for recombinant proteins. HEK293 
cell-lines were created by transformation of normal HEK cells with human 
adenovirus type-5 to form the permanently transformed cell-line HEK293 (Graham 
et al., 1977). In comparison to native neuronal cell-lines, HEK293 had dissimilar 
architecture and the sub-cellular organisation differed but they are widely used due to 
its dependable reconstitution of numerous neuronal proteins and they also 
demonstrated similar complexities topographically and biochemically as could be 
observed in the central nervous system (Thomas and Smart, 2005).
The culture of HEK293 cells is the first process of immunocytochemistry and
9  • ^
occurred in 75cm “ culture flasks with 15 ml o f  Dulbecco 's Modified Eagle Medium
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(DMEM) (Life technologies, Cat.41966-029) (supplemented with 10% Fetal Calf 
Serum (FBS) and 1% Penicillin/Streptomycin (PenStrep)). In a sterile incubator at 
37°C and 5% CO2, healthy, viable cells adhered to the base of the flask to form a cell 
lawn. To sustain the health of cells, when they reached 80% confluencey they were 
passaged which involved firstly removing the old media by aspiration. The cell lawn 
was then rinsed with 5ml pre-warmed Dulbecco’s Phosphate Buffer Saline (DPBS) 
(Life technologies, Catl0010-015) before being treated with 1.5ml 0.25% pre­
warmed Trypsin-EDTA (Life technologies, Cat.25300-054) causing detachment of 
cells from the flask base. Following removal of any excess Trypsin-EDTA, the flask 
was placed back in the incubator in the same conditions as previously stated for two 
minutes.
10ml of pre-warmed media was added to the flask following the incubation to 
terminate the actions of Trypsin-EDTA. This solution was placed over the cell lawn 
and repeatedly mixed to ensure the efficient dispersing of any clumps of cells to form 
a single-cell suspension. Sub-culturing requires a 1:10 dilution of cells and so 1ml of 
cells were removed and added to a new flask with 15ml of pre-warmed fresh media. 
The remaining 9ml of cells were discarded and added to bleach unless proceeding to 
section 2.4.2, where cells were placed in a falcon tube. The new flask was then 
incubated at the optimal conditions until ready for its next passage as indicated by 
close daily observations.
2.4.2 Coating cells onto coverslips
Cells were seeded onto pre-treated glass coverslips when being imaged using 
Confocal Microscopy. Coverslips were autoclaved and thoroughly dried before being 
transferred to a 12-well plate, rinsed with sterile tissue culture-grade water three 
times and treated with 10pg/ml poly-L-Lysine (PLL) (Sigma, Cat.P4707) which 
enabled cell adherence; coverslips were incubated at room temperature for one hour. 
After the incubation period, the PLL was removed from the coverslips by pipetting 
and they were allowed to air dry for approximately 30 minutes. Once dry, coverslips 
were rinsed three times with sterile tissue culture-grade water and again allowed to 
air dry at room temperature; coverslips were now ready for seeding.
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lml of pre-warmed media was added to each well with a PLL treated coverslip. Cells 
previously placed in a falcon tube (section 2.4.1) were quantified using Scepter™ 
cell counter (Millipore) and a standardised 8 x 104 cells/ml was added to each well. 
The plate was then covered and incubated at 37°C with 5% CO2 for 24 hours to allow 
cells to adhere to the glass coverslips.
2.4.3 Transfection of gene constructs into cultured cells
Constructs previously created were transfected into cultured cells via 
Magnetofection™. Magnetofection™ involves combining magnetic nanoparticles to 
the gene vectors by salt-induced colloidal aggregation and electrostatic interaction, 
causing a remarkable increase in the uptake of the vector and high transfection 
efficiency. The biodegradable iron oxide magnetic nanoparticles were coated with 
cationic molecules, which were drawn to and endocyted by cells via magnetic fields 
(Mykhaylyk et al., 2007, Buerli et al., 2007).
To carry out this stage of the study on a 12-well plate with glass coverslips, two 
separate transfection mixtures were made. The first contained 15pl Opti-MEM 
reduced serum medium (Life technologies, Cat.31985-062) and 0.5pg of DNA 
construct; the second contained 15pl Opti-MEM and lpl Lipofectamine™ 2000 
reagent (Invitrogen, Cat. 11668). Mixtures were incubated at room temperature for 5 
minutes before being combined and lpl of CombiMag (OzBiosciences, 
Cat.CM20200) 1:10 solution added. The mixture was again incubated at room 
temperature for 15 minutes. 30pl of transfection mixture was added to the media of 
the HEK293 cells coverslips and circulated around the well by swirling. The 12 well 
plate was placed on a magnetic plate and incubated at 37°C with 5% CO2 for 25 
minutes. After the incubation period, the media was removed and replaced with fresh 
pre-warmed media for 24 hours to allow in vitro expression of the constructs before 
any further analysis.
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2.4.4 Intracellular staining
Coverslips that had undergone transfection were removed from the incubator and 
media was removed before they were rinsed twice with lx PBS solution (Sigma: P- 
4417). Cells were fixed using 4% paraformaldehyde (Sigma, Cat.P-6148) and 
incubated at room temperature for 10 minutes. Paraformaldehyde was removed by 
aspiration and cells were rinsed with PBS solution to remove any excess before being 
quenched twice with 50mM NH4C1 (Sigma, Cat.254134) for 10 minutes at room 
temperature to stop any chemical or enzymatic reactions. Following removal of 
NH4C1 by aspiration and rinsing with PBS solution, the cells were permeabilised at 
room temperature in Fetal Bovine Serum (FBS) (Sigma, Cat.F6178) / Bovine Serum 
Albumin (BSA)(Sigma, Cat.A9647-50G)/Triton X-100 solution (Sigma, Cat.T8787) 
(10ml of FBS/BSA (as stated below) + lOpil Triton X-100 (0.1% v/v) for 15 minutes. 
The solution was then removed, the cells rinsed twice in PBS solution and washed in 
FBS/BSA solution for one minute.
The mouse monoclonal (IgG2a) primary antibody Anti-DDK tag (Origene, 
Cat:TA50011) was diluted at 1:1000 dilution in FBS/BSA solution (45ml PBS, 5ml 
FBS (10% v/v), 0.25g BSA (0.5% w/v)). The antibody recognises the overexpression 
of the D epitope tag (DYKDDDDK), which would be fused to the amino or caboxyl 
terminal of the transfected target protein in the HEK293 cells. The antibody solution 
was added by pipetting into a humidifying chamber and the coverslips were inverted 
on to the solution to be incubated at room temperature with a mild rotation (25rpm) 
for two hours. Following the incubation period, cells were removed from the 
humidifying chamber and washed for five minutes with mild rotation once with 
FBS/BSA and twice with PBS.
Alexa488 goat anti-mouse IgG (H+L) (Invitrogen) was the secondary antibody used 
in this study for all missense and deletion variants. The secondary antibody came 
labelled with photostable green-fluorescence Alexa488 dye that reacts with IgG 
heavy chains and immunoglobulin light chains from mouse; the antibody had been 
adsorbed against human IgG and serum to minimise any cross reactivity. Diluted at 
1:200 in FBS/BSA solution, 30pl of antibody/FBS/BSA solution was transferred by
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pipetting into the humidifying chamber with the coverslips placed on top. The cells 
were incubated at room temperature for 30 minutes with mild rotation and were 
protected from light due to its light sensitivity, before the final five minute wash with 
FBS/BSA and two five minute washes with PBS. Coverslips were left to dry at room 
temperature and then mounted using Prolong gold onto clean glass slides.
2.4.5 Confocal Microscopy and analysis of transfected 
HEK293 cell lines
High-resolution images of transfected HEK293 cells were created using the Carl 
Zeiss LSM 710 confocal microscope. Cells were initially imaged at 20x 
magnification to demonstrate and ensure cell confluence, even distribution and 
transfection efficiency. Following this, cells of interest were selected and imaged at 
the higher magnification, 63x. To ensure consistency, reliability and fair testing, the 
following criteria were outlined and adhered to throughout analysis:
1. Wild-type images of transfected proteins were firstly captured to determine 
normal expression levels and select the optimal parameters.
2. Variant images were created and analysed, blind to the gene-variants, using 
the parameters as set out by the wild-type standardisation.
3. Only HEK293 cells showing high expression of the transfected DDK-tagged 
GABAergic gene variants were selected for analysis.
72
Chapter Three
Mutation analysis of GAT1 and GAT3 in 
relation to Epilepsy
We know from previous work that there are genetic, pharmacological, 
neuroanatomical and animal studies that implicate the GABAergic system with 
epileptogenesis and seizure predisposition. Prior to this study no causative mutations 
had been identified in the GAB A transporter genes SLC6A1 and SLC6A11 (known 
from this point as proteins GAT1 and GAT3) in relation to epilepsy. This was 
intriguing as other neurological disorders were linked to cognate receptor/transporter 
systems, which seemed plausible for genetic forms of epilepsy.
A targeted, hypothesis-led candidate gene approach was adopted to allow efficient 
and systematic screening in 485 patient samples with clinically confirmed genetic 
generalised epilepsy (GGE; Melbourne). To validate and replicate the relevance of 
the data obtained from the preliminary GGE results, an additional 187 childhood 
absence seizure (CAE; UCL) and 35 juvenile myoclonic epilepsy (JME; WERN) 
patient samples were recruited and screened. Control population studies were carried 
out on 480 commercially available samples (Sigma) to assess population frequencies 
of potentially pathogenic gene variants.
The outcome of this chapter demonstrates the discovery of synonymous, novel non- 
synonymous missense/nonsense, splice site and intragenic variants identified in the 
GAT1 and GAT3 transporters. From the catalogue of variants with a mean allelic 
frequency (MAF) of less than 0.01 (1%), the result of in silico analysis is presented 
and considered to assess causative potential.
3.1 Mutation analysis of GAT1
Thirty-three variants were identified in GAT1 coding sequence and flanking intronic 
regions in 107 patient samples (Table 3.1), which, consisted of 3 non-synonymous, 1 
splice site, 1 base pair frameshift deletion, 11 synonymous, and 17 intronic variants.
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E xon N u c le o t id e
c h a n g e
T y p e  o f  M utation
A m in o
a c id
c h a n g e
S a m p le
fr e q u e n c y
(n = 7 0 7 )
R e fe r e n c e MAF
1
5 ’UTR -57 G>A Intronic 1 N ovel
c .6  G>A S y n o n y m o u s p.A2A 1 rs6343 0 .0 0 1 8
2
c .2 4 6  C>T S y n o n y m o u s P .F82F 1 N ovel
IVS1-81 C>A Intronic 1 N ovel
IV S1-26 G>A Intronic 1 rs413 0 8 2 3 2 0 .0 0 0 9
c .3 1 2  G>A S y n o n y m o u s P.L104L 2 N ovel
3
IV S3+46 G>C Intronic 4 N ovel
IVS3+1 G>A D onor S p lice  S ite 1 N ovel
4
IV S4+54 C>T Intronic 18 N ovel
c .5 3 5  A>G N on -sy n o n y m o u s P.M 179V 2 rs3 4 2 9 9 8 7 4 0 .0 1 1 9
5 c.651 G>T S y n o n y m o u s P.T217T 25 rs6 3 4 4 0 .0 4 9 6
6
c.801  C>T S y n o n y m o u s P .G 267G 2 rs15 0 5 1 9 6 5 9 0
c .7 8 0  G>A S y n o n y m o u s p.T 260T 1 rs6344 0 .0 4 9 6
IV S6+72 G>A Intronic 1 N ovel
IV S5-3 C>T Intronic 1 N ovel
7 IVS7+21 G>T Intronic 1 r s3 5 7 3 6 0 5 8 0 .0 1 1 5
8
IVS7-41 G>A Intronic 1 N ovel
c .1 0 0 2  A>G S y n o n y m o u s P.A334A 1 rs3 5 5 1 3 4 2 3 0 .0 0 6
IV S7-90 C>T Intronic 1 N ovel
c .9 6 0  C>T S y n o n y m o u s P .S 3 2 0 S 1 r s3 5 9 7 2 6 4 7 0 .0 0 9 6
9
IVS8-51 G>A Intronic 1 N ovel
IV S8-64 G>A Intronic 1 N ovel
10
c .1 2 4 3  C>A N o n -sy n o n y m o u s P.L415I 7 rs 1 1 2 0 9 5 3 3 3 0 .0 0 1 4
IV S9-23 G>T Intronic 5 rs15 0 8 8 9 2 7 0 0 .0 0 3 2
IV S9-36 G>A Intronic 1 N ovel
IV S10+ 43 G>T Intronic 2 N ovel
11 c .1 3 3 5  T>C S y n o n y m o u s P.Y445Y 2 N ovel
12
IV S12+ 23 C>T Intronic 4 rs2 0 0 9 2 2 4 6 8 0 .0 0 0 9
c .1 5 2 7  G>A S y n o n y m o u s P.A509A 2 r s3 4 9 6 9 6 5 6 0 .0 0 0 9
13
c .1 6 6 3  A>G N o n -sy n o n y m o u s P.M 555V 1 rs13 9 8 4 6 3 2 6 0
IV S13+ 16 C>G Intronic 13 rs35957531 0 .0 7 0 7
14
c .1 7 1 3  C>T S y n o n y m o u s P.V571V 1 N ovel
c .1 7 8 0  Deletion  
A D eletion
P .S 594A  
FS 22X 1 N ovel
Table 3.1 The GAT1 a//-variants table. Variant table of all variants identified via G A T 1  
screening of genetic genera lised  epilepsy patients. The frequency the variant occurs 
am ongst sam ples  is highlighted a s  well a s  the m ean  allelic frequency of any variants 
previously identified.
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These variants are mapped onto genomic positions and their novelty status indicated 
(Figure 3.1). From this compendium of gene-variations, the most likely pathogenic 
variants were selected for further analysis which included the splice variant, deletion 
variant and three non-synonymous variants (Table 3.2).
O f the five variants identified as potentially pathogenic in GAT1 3 were 
heterozygous missense variants; 1) p.M 179V (c.535A>G), 2) p.L415I (c. 1243C>A) 
and 3) p.M555V (c. 1663A>G); 1 was a heterozygous frameshift variant 4) p.S594A- 
fs22X; and there was 1 heterozygous splice site variant 5) IVS3 +1 G>A (Table 3.2, 
Figure 3.1 and Figure 3.2). The damaging status case for each variant is presented in 
table 3.2, taking into account bioinformatics databases and control frequency 
datasets; Structure/function data is presented in Chapter Five.
3.1.1 Missense Variant p.M179V
The missense variant p .M l79V , is an amino acid change from methionine to valine 
at residue 179 with a single nucleotide change from adenine to guanine at position 
535 in exon 4 of GAT1 (Figure 3.2). G A T lpMI79V was not identified in the 480 
unaffected control population study (Figure 3.3) but was identified twice from 691 
patient samples. This missense variant is listed as a polymorphism on dbSN P in a 
control sample of n=2,393 with a mean allelic frequency o f  0.024 but this frequency 
was not supported by our data and analysis.
a  <c t  a  c  a  g  c
G A T l pM179VGAT1 W T
Figure 3.2 Sequence chrom atogram  of variant GAT1pM179V identified in epilepsy patient 
samples and the corresponding wild type sequence. The variant is identified by an  arrow 
in the right hand column of the figure and the corresponding wild-type seq u e n c e  in the left 
hand column. The double peak indicates the heterozygous c.535 A>G nucleotide ch an g e  in 
the coding sequence .
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Figure 3.3 Control population study results for GAT1pM179V by Lightscanner 
technology. p.M179V (positive control) melts at a  rate that is different to the other 95 control 
sam ples .  A further 12 sam ples  (shown in red) also melt at a  different rate to the other 
controls, but they do not contain the variant M179V, and  instead contain a  com m on SNP.
LightScanner Data Analysis
tu n  Param eters
Melt Tem perature Range: 68.4 -  98.4 E xposure: 28 i Auto) 
: xpert S cann ing  Analysis Param eters
Tem perature R ange: Lower 89.0 -  89.5 Upper 94.2 -  94.7 
BackgroundC orrection: Linear 
C urve Shift: 0.050
S tan d ard s: Auto Group Sensitivity: Normal
Scanning  Visual Sum m ary
| Negative 89 90 91 92 93 94
Temperature C
[3  Unknown
89 90 91 92 93 94
Temperature C
G A T lpM179v
GATIp M179V
GAT1 variant F S N Y S  W N T T
H.sapien F S N Y S M V N T T
P.troglodytes F S N Y S M V N T T
M. mulatto F S N Y S M V N T T
B.taurus F S N Y S A L N T T
C.lupus F S N Y S I V N T T
G.gallus F S N Y T L A N T T
R.norvegicus F S N Y S L V N T T
M.musculus F S N Y S L V N T T
Figure 3.4 Multiple phylogenetic alignm ents of the GAT7pM179V. G A T 1  variants were 
aligned against their respective wild-type s e q u e n c e  alignments and their spec ies  homologs. 
The mutated amino acid valine in this instance, was highlighted in red and its corresponding 
residue highlighted in green for different spec ies  and wild-type to indicate the level of 
evolutionary conservation.
Multiple species alignments show that the amino acid substitution is highly- 
conserved residue in primates but diverges in mammalian lines indicating a degree of 
tolerance (Figure 3.4). This is supported by the mutation prediction software using
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conservation analysis (Table 3.2) that predicts G A T1P'MI79V would be benign
(PolyPhen and Grantham) and would be tolerated by the protein (SIFT). Therefore,
G A T l pMI47V is regarded as a rare SNP that in theory is tolerated and benign, 
however, the functional properties and consequences of this SNP require 
investigation due to conflicting population and in silico evidence.
3.1.2 Missense Variant p.L415l
p.L415I, is a heterozygous c.1243 C>A gene variant in exon 10 of SLC6A1 causing 
a non-synonymous amino acid change from leucine to isoleucine at residue 415 of 
GAT1 (Figure 3.1, Figure 3.5). Seven of 631 patient samples were confirmed to 
present G A T lpL4151 as were three samples of the directly analysed 480 control 
population (Table 3.2; Figure 3.6). In dbSNP, this variant has a mean allelic
frequency of 0.003 from 2.752 control samples.
GAT1 W T
I.L415IFigure 3.5 Sequencing trace of the G A T 1 P com pared to the G A T 1  wild-type. The
heterozygous c.1243 C>A nucleotide change  c a u s e s  an amino acid ch ange  from leucine to 
isoleucine. The double peak  of the variant is indicated by an arrow and differs in comparison 
to the wild-type.
The G A T lpL4151 amino acid change has no effect on protein conservation, structure 
and composition according to all three predictive software tools, SIFT, Grantham and 
PolyPhen (Table 3.2). However, multiple species alignment analysis (Figure 3.8) 
demonstrates that the Leucine at position 415 of GAT1 is highly conserved across 
m ammalian species, which highlights the importance of  the residue and the equally 
preserved flanking amino acids.
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UghtScanner Data Analysis
12'
P.L415IG AT11
D -
P.L415I variant population study. Of the 96Figure 3.6 Lightscanner profile of the GAT1
sam ples  that underwent Lightscanner HRM analysis, the variant can be clearly identified a s  
having a  deviated melt profile from the 95 healthy control sam ples .
G A T 1 p -L4151
GAT1 variant D E Y P R I L R N R R
H.sapien D E Y P R L L R N R R
P.troqlodytes D E Y P R L L R N R R
M. mulatto D E Y P R L L R N R R
B.taurus D E Y P R L L R N R R
C.lupus D E Y P R L L R N R R
G.qallus D E F P K L L R N R R
R.norveqicus D E Y P R L L R N R R
M.musculus D E Y P R L L R N R R
Figure 3.7 p.L415l multiple species phylogenetic alignm ents. p.L415l w as  aligned 
against the GAT1 wild-type s e q u e n c e  and its putative mammalian homologs. Isoleucine w as 
highlighted in red, and its corresponding residue highlighted in green  for different spec ies  
and wild-type to specify the level of evolutionary conservation.
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Collectively G A T1P L4IM is a rare population SNP in a highly conserved region of  the 
protein and has a higher allele frequency in epilepsy cases. It therefore warrants 
further investigation on the effect of GAT1 patho-biology.
3.1.3 Missense Variant GAT1 p.M555V
The final missense variant identified in GAT1 was p.M555V, a heterozygous c.1663 
A>G nucleotide change in exon 13 causing a methionine to valine substitution 
(Figure 3.1 and Figure 3.8). G A T lp M555V was identified in one patient sample of 679, 
but was not identified in the 480 unaffected control population study and has a mean 
allelic frequency of zero in 2,276 control samples in dbSNP. (Table 3.2 and Figure 
3.9).
Figure 3.8 GAT1pM55bV sequence chrom atogram  com pared to wild-type. The
heterozygous variant can be identified by the double peak  beneath  the arrow and reflects a  
c .1663 A>G nucleotide change  com pared  to wild-type.
The predicted consequences of G A T lpM555V is identical to G A T l p MI79V where 
tolerated effects were predicted with SIFT, benign structural changes were predicted 
by PolyPhen and a possibly damaging result was predicted by the Grantham score 
when considering the effect of the amino acid on composition and polarity (Table 
3.1). Phylogenetic alignment demonstrates that methionine at position 555 of GAT1 
is a highly conserved residue in a region of highly conserved amino acids, indicating 
a selective evolutionary pressure to not mutate this site and region (Figure 3.10).
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Triage of G A T lpM555V into functional studies was decided via the novelty o f  the 
genotype, some indication of damaging effects by in silico methods and the highly 
conserved nature o f  the amino acid substitution.
Lightscanner Data Analysts
Run Param eters 
Melt Tem perature Range: 68.4 -  98.4 Exposure: 23 (Auto)
Expert Scanning  Analysis Param eters 
Tem perature Range: Lower 88.2 -  88.7 Upper 93.4 -  93.9 
B ackgroundCorrection: Linear 
Curve Snift: 0.050
Standards: Auto Group Sensitivity: High
Scanning Visual Summary
GAT1P.M555V
□ a On
■  Negative
a  Unknown
90 91 92
'em perature C
$9 90 91 92 93
Temperature C
Figure 3.9 Lightscanner data analysis profiles of a control population study.
GAT1pM555V w as identified in one  patient. As shown above p.M555V has  a different melt 
profile to the 95 control sam ples  and has  been  highlighted in blue. The results of all 5 
lightscanner population studies (n=475) indicates that M555V is not presen t in the healthy 
control population.
G A T I p  M555v
G A T 1  v a r i a n t GYMAY V F L T L K
H . s a p i e n G Y M A Y M F L T L K
P . t r o g l o d y t e s G Y M A Y M F L T L K
M . m u l a t t a G Y M A Y M F L T L K
B . t a u r u s G Y M A Y M F L T L K
C . l u p u s G Y M A Y M F L T L K
G . g a l l u s G Y M A Y M F L T L K
R . n o r v e g i c u s G Y M A Y M F L T L K
M . m u s c u l u s G Y M A Y M F L T L K
Figure 3.10 Multiple species phylogenetic alignm ents of g a t 1pM555V Wild-type GAT1 
and QAT1pM555V were aligned with homologous spec ies  with position 555 highlighted in 
green and the g a t 1 pM555V variant s e q u e n c e  in red.
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3.1.4 A 1 bp deletion causing a frameshift c.1760de!A / 
p.S594Afs22X
This frameshift variant occurs in the final exon (exon 14) of the GAT1 gene and is a 
heterozygous one base-pair deletion o f  adenine at the first position of the serine 
amino acid at position 594 of the polypeptide (Figure 3.1 and figure 3.11). 
G A T l ,)S594Afs22x causes a change in the open reading frame starting with a 
substitution of serine to alanine and a 22 amino acid nonsense message thereafter. In 
wild-type GAT1 the serine is six amino acids away from the constitutional stop 
codon, however, the deletion abolishes this stop codon but reaches a new stop codon 
22 amino acids from the deletion. This action results in an additional 17 amino acids 
being added to g a T 1 p'S594A,s22x \n the C-terminus of the polypeptide creating a 
potentially pathogenic outcome and a possible dominant-negative effect in GAT1 
dimerisation (Figure 3.12). The additional amino acid stretch does not correspond to 
any known functional domain or known proteins sequences.
GC T C C A C C A  G C A A G G AG
GAT 1p'GAT1 WT
Figure 3.11 Sequence chrom atogram  for G A T 1  wild-type and G A T lpS594Afs22x. C om pared  
to wild-type it can be se e n  that a  1 bp deletion at nucleotide position 1780 (as indicated by 
arrows) c a u s e s  a  nucleotide frameshift immediately after the deletion.
G A T lp,S594Afs22x was identified in one patient sample out o f  701 and not found in the 
480 unaffected control population study nor on online databases (Figure 3.13). 
Predictive analysis could not be carried out for such a variant, however, the very 
nature of the frameshift does indicate a likely pathogenic outcome and triage through 
to functional studies
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Wild- type  protein sequence D-S-T- S-K-E-A-Y-I-  ST OP
G A T  1pls94Afs22X D-S-T- A-R-R-P -T-S -R-V-G-A-T-H-R-P-D-T-L-T-P -R-P -G-  S T O P
Figure 3.12 GAT1 wild-type protein sequence aligned with g a t - |P -S 594A ,s22X . Following 
Serine at amino acid position 594, the wild-type s e q u e n c e  has  five amino acids before the 
stop codon. C.1760delA c a u s e s  a  protein ch ange  from serine to alanine a s  well a s  a  frame 
shift resulting in 21 amino acids before the next stop codon.
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Lightscanner Data Analysis
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Figure 3.13 Profiles of lightscanner population study results for GA7Tc.1780delA . The
patient DNA w as placed in the 96th well of the PCR plate a s  a  positive control and the 
resultant melt profile has  been  highlighted in red. Control DNA sam ples  failed to replicate the 
mutation melt profile and excluding G A T l pS594Afs22x from the control population.
3.1.5 A Donor Splice site Variant: GAT1 IVS3+1 G>A
One novel heterozygous donor-splice site variant was identified in the beginning of 
intron 3 of the GAT1 gene (Figure 3.1 and 3.14). G A T 1 ,VS3+IG>A was present in one 
patient sample from 693 (0.001) and was absent from 480 population controls and 
online databases such as dbSNP (Table 3.1 and Figure 3.15).
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G (p  ~X>G A G T  G
GAT1GAT I WT
Figure 3.14 Sanger Sequencing profiles of GAT1 w ild-type and GAT1IVS3+1g>a. The
arrows indicate the he terozygous G>A donor splice site (GT) in GAT1 exon 3. T he exon GT 
boundary site has  been  circled in red.
Lightscanner Data Analysis
Run Param eters 
Melt Tem perature Range: 6 8 .3 -9 8 .4  Exposure: 34 (Auto)
Expert Scanning  Analysis Param eters 
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BackgroundCorrection: Linear 
Curve Shift: 0.050
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Scanning Visual Summary
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GAT1 IVS3+1G>A
Figure 3.15 Lightscanner data analysis profiles of a population study for the
GAT1IVS3+1g>a variant. The melt profiles of 95 control sam ples  and the GAT1IVS +1G>A c a se  
are shown. The trace clearly indicates that there  is a  difference in melt profiles betw een  the 
variant and the control sam ples . This would sugges t  that the control sam ples  do not have  the 
variant s e q u e n c e  and the variant is, therefore, novel and not in the healthy population.
G A T 1IVS3+ig>a is not in the coding region so predictive analysis and phylogenetic 
alignment is not possible. However, the substitution o f  the +1 donor splice site is 
found in hundreds of genetic disorders and is very likely to cause exon skipping or 
intron retention with cryptic stop codons (Figure 3.16).
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5' Exon 3 3' Exon 4
ACG
Intronic region 
ATGAGT - • GCAG ACA
Figure 3.16 Splicing dynam ics of GAT1 exon 3 and exon 4. The splice variant is shown in 
red resulting in elimination of the c o n se n su s  ‘G T’ site. This could possibly result in exon 
skipping or intron retention.
3.2 Mutation analysis of GAT3
Twenty-nine variants were identified in GAT3 coding sequence and flanking intronic 
regions in 202 patient samples: ten intronic variants, 13 synonymous and six non- 
synonymous variants were identified in total. These variants are mapped onto their 
gene positions and their novelty status is indicated (Table 3.3). Six heterozygous 
missense variants (3 novel, 3 rare) were identified in the GAT3 gene that are most 
promising as pathogenic (Table 3.4).
3.2.1 Missense Variant GAT3 p.H142Y
The first variant identified in the SLC6A11 (GAT3) sequence was a cytosine to 
thymine nucleotide substitution at position 426 (c.426C>T) of exon three. This 
causes the amino acid conversion of histidine to tyrosine at residue 142 of GAT3 
(p.H142Y) (Figure 3.17 and figure 3.18). G A T3n'HI42'1 was identified in one patient 
sample from 697 cases, however, it was also identified in two of 480 control samples 
(Figure 3.19). G A T3p HI42'1 is listed as a polymorphism in dbSNP in a control sample 
of n=2,276 but with an unknown frequency (Table 3.4).
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Exon Nucleotidechange
Variation
Classification
Amino
acid
change
Sample
frequency
(n=707)
Reference MAF
3 c.426 C>T
Non-
synonymous P.H142Y 1
rs 14444052 
1 No
c.498 C>T Synonymous P.L166L 6 rs61746357 0.0037
c.480 C>G
Non-
synonymous P.N160K 1
rs37489307
4 No
5 c.645 T>C Synonymous p .S215S 29 rs2304725 0.3356
c.750 A>T Synonymous P.T250T 1 Novel
6 c.883 G>A
Non-
synonymous P.D295N 1 Novel
c.766 G>T
Non-
synonymous P.V256L 1
rs13810929 
5 No
7 c.987 C>T Synonymous p.N329N 8 rs41308275 0.0083
IVS6-11 
C>CT Intronic 1 Novel
IVS7+56 C>T Intronic 1 Novel
c.912 G>A Synonymous P.T304T 1
rs37139045 
4 No
8
IVS8+30
C>CT Intronic 1 Novel
IVS8+42
G>GA Intronic 1 Novel
9 c.1170 T>C Synonymous P .P390P 33 rs2272395 No
c.1143 G>A Synonymous P.A381A 11 rs2272394 0.0445
IVS9+62
G>GA Intronic 2 Novel
10
IVS10+22
G>GA Intronic 5 rs41295968 0.0023
c.1307 G>A
Non-
synonym ous P.R436Q 1
rs20213614
7 0.0005
IVS10+16
C>T Intronic 1
rs20119699 
6 No
11 c.1461 C>T Synonymous p. I487I 3 rs78605794 0.0179
c.1464 C>T Synonymous P.G488G 1
rs14959847 
1 0.0009
IVS11+32
G>GC Intronic 1 Novel
12 IVS11-7 C>T Intronic 37 rs2272399 0.3352
c.1572 C>T Synonymous P.C524C 9 rs2272400 0.0441
13 c.1737 A>G Synonymous P.T579T 31 rs2245532 0.3531
c.1728 G>T Synonymous P.T576T 4
rs14533133 
1 0.0028
c.1692 C>T Synonym ous P.C564C 6
rs13880506 
6 No
IVS13+28
G>GA Intronic 3
rs14919534 
7 0.0023
14 c.1791 C>T
Non-
synonymous P.R597W 1
rs14271207 
9 0.0023
Table 3.3 The G A T 3  a//-variants table. Variant table of all variants identified via GAT3 
screening of genetic  generalised epilepsy patients. The frequency the variant occurs 
am ongst  sam ples  in highlighted as  well a s  the m ean  allelic frequency of any variants 
previously identified.
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Figure 3.18 Sequence chrom atogram of the GAT3pH142Y identified in epilepsy patient 
sam ples and the corresponding wild-type sequence. The heterozygous variant is 
denoted  in the right hand column of this figure by a double peak  and shown by arrows. The 
corresponding wild-type s e q u e n c e  is shown in the left hand column and the substituted 
nucleotide indicated by an arrow.
G A T 3pHI42'1 was assigned to Grantham class C65, suggesting pathogenic 
consequences to the protein by means of composition and polarity. Benign effects 
were predicted from conservational analysis, and the structural changes o f  the variant 
are believed to be tolerated (SIFT & Polyphen) (Table 3.4). Multiple species 
alignment analysis of G A T3pHI42'1 shows the variant and its surrounding amino acids 
are highly conserved residues (Figure 3.20).
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Figure 3.19 Population study results of GAT3p H142Y. The above lightscanner profile show s 
the melting tem perature  range for GAT3 exon 3. The patient sam ple  containing variant 
GAT3P H142 melts at a  different rate to the control sam ples ,  suggesting  that the variant is not 
present in the control population.
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GAT3p-h142y
GAT3 variant Q V I E A Y L N V Y Y
H.sapien Q V I E A H L N V Y Y
P.troglodytes Q V I E A H L N V Y Y
M. mulatto Q V I E A H L N V Y Y
B.taurus Q V I E A H L N V Y Y
C. lupus Q V I E A H L N V Y Y
G.g alius Q V I E A H L N V Y Y
R.norvegicus Q V I E A H L N V Y Y
M.musculus Q V I E A H L N V Y Y
Figure 3.20 Multiple phylogenetic alignments of G AT3pH142Y. GAT3pH142Y w as aligned 
against the wild-type GAT3 seq u en ce  and its putative homologs. The mutated amino acid 
w as highlighted in red and its corresponding residue highlighted in green for different spec ies  
and wild-type to indicate the level of evolutionary conservation. It can be noted that p.H142Y 
occurs in a  highly conserved  residue of the protein.
In summary, G A T3pHI4“'i is a rare SNP as observed from dbSN P and control 
population studies, however. Grantham class results and phylogenetic alignments 
suggest functional analysis is required to assess any pathogenic effects.
3.2.2 Missense Variant GAT3 p.N160K
G A T3p NI6()K, is an amino acid substitution from asparagine to lysine at residue 160 
due to a nucleotide change in exon three at nucleotide position 480 reflecting a 
cytosine to guanine change (c.480C>G) (Figure 3.17 and figure 3.21). This variant 
has been identified on online databases such as dbSNP with a mean allelic frequency 
of 0.0037, however, the variant which was identified in one patient sample out of 
697, was not found in a control study of 480 unaffected participants (Figure 3.22).
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Figure 3.21 GAT3 w ild-type and GAT3pN160K sequence chrom atogram . The nucleotide 
c h an g e  from cytosine to guanine  at position 480 of the coding se q u e n c e  creating the  variant 
GAT3pN160\  is indicated by arrows. The heterozygous variant c a u s e s  a  double peak  on the 
sequenc ing  trace  a s  indicated.
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Figure 3.22 Lightscanner data analysis of G AT3pN160K population study. The patient 
sam ple  which p o s s e s s e s  GAT3P N160K (Shown in blue), melts at a  different rate to the  control 
population. However, a s  there  are  two sam ples  that also have  melt profiles deviating from 
the av e rag e  (shown in red and  green). They were also s e q u e n c e d  to en su re  a  lack of 
p.N160K. The sequenc ing  results indicated that GAT3pN16° w as not p resen t in th e se  
sam ples .
According to SIFT conservation analysis, G A T 3P‘NI60K is tolerated by the protein, 
however, the structural, composition and polarity changes caused by the amino acid 
change is predicted to be damaging and possibly damaging by Grantham and 
PolyPhen respectively (Table 3.4). Multiple species alignment analysis showed a 
highly conserved pattern, supporting Grantham and Polyphen results.
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Collectively, G A T 3P'NI60K is a damaging and very rare SNP that is highly conserved 
in phylogenetic analysis. The decision was taken on this evidence base to proceed to 
functional analysis and preparation of mutation constructs (Chapter Five).
G A T 3 p.N160K
GAT3 variant I F Y L S  K C F T T E
H.sapien I F Y L S N C F T T E
P.troglodytes I F Y L S N C F T T E
M.mulatto I F Y L S N C F T T E
B.taurus I F Y L S N C F A T E
C.Iupus I F Y L S N C F T T E
G.gallus I F Y L F N C F T T E
R.norvegicus I F Y L S N C F T T E
M.musculus I F Y L S N C F T T E
Figure 3.23 Multiple phylogenetic alignm ents of GAT3P N160K GAT3 variants were aligned 
against the respective wild-type s e q u e n c e  and their putative homologs. The affected residue 
is highlighted in green for all spec ies  and the variant residue is in red. It can be noted that 
GAT3P 60K occurs in a highly conserved residue throughout various species .
3.2.3 Missense Variant GAT3 p.V256L
GA T3p V256L is a heterozygous guanine to thymine nucleotide change in exon 6 of 
GAT3, at position 766 of the coding sequence (c.766C>T) (Figure 3.17). It causes 
an amino acid change from valine to leucine at residue 256 (p.V256L). (Figure 3.24). 
G A T3p V256L was identified in one patient sample out o f  the 700 cases, was absent 
from the control population of 480 and was present with an unknown mean allelic 
frequency on dbSNP (Figure 3.25).
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G A T 3  W T
Figure 3.24 Sequence chrom atogram  of G AT3P V256L. The disparity in sequenc ing  traces  
be tw een  wild-type and  variant GAT3pV2s6L is clearly indicated by arrows. The peak 
representing guanine  at position 766 becom e su p p re sse d  in the variant trace and  a p p ea rs  
along with an additional thymine trace representing heterozygosity.
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Figure 3.25 Lightscanner population study of G A T3pV256L. The p re sen ce  or a b s e n c e  of 
GAT3 variants in a  control population w as a s s e s s e d  using Lightscanner technology. The 
lightscanner results show variation in melt profiles on DNA sam ples  and can therefore  be 
indicative of c h a n g e s  in DNA sequence .  It can be se e n  above that GAT3pV,"5bL h as  a 
different melt profile to the control population, which, su g g es ts  that none  of the control 
sam p le s  contain the variant sequence .
G A T 3p'V256L was predicted to have a benign effect on the protein by the Polyphen 
software, but paradoxically was predicted possibly damaging and damaging by SIFT 
and Grantham  respectfully. Alignment analysis demonstrated that the amino acid 
change is highly conserved and is placed within a conserved region reflecting an 
important functional preservation through the evolutionary process (Figure 3.26).
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Considering all the data, this conserved novel SNP is not confirmed on population 
databases and is predicted to be damaging giving us reason to investigate the 
pathological consequences.
GAT3p-V256L
GAT3 variant G K V V Y L T A T F P
H.sapien G K V V Y V T A T F P
P.troglodytes G K V V Y V T A T F P
M. mulatto G K V V Y V T A T F P
B.taurus G K V V Y V T A T F P
C.lupus G K V V Y V T A T F P
G.gallus G K V V Y V T A T F P
R.norvegicus G K V V Y V T A T F P
M.musculus G K V V Y V T A T F P
Figure 3.26 Multiple phylogenetic alignments of the GAT3pV256L. The variant s eq u en ce  
w as aligned against the GAT3 wild-type s e q u e n c e  and their putative homologs. The affected 
residue is highlighted in green  for all spec ies  and the variant residue is in red. It can  be noted 
that GAT3P 2561 occurs in a  highly conserved but a lso  in a  highly conserved  region of the 
protein.
3.2.4 Missense Variant GAT3 p.D295N
G A T3pD295N involves a heterozygous nucleotide change in GAT3 exon six from 
guanine to adenine at position 883 of the coding sequence (c.883G>A), which 
creates an amino acid change from aspartic acid to asparagine at position 295 of the 
polypedtide (p.D295N) (Figure 3.17 and figure 3.27). G A T3pD295N was identified in 
one patient sample out of 700 cases and was absent from both the 480 unaffected 
control population and online databases such as dbSNP (Figure 3.28).
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D295NG A T 3 PG AT3  W T
Figure 3.27 GAT3 wild-type sequencing chrom atogram  com pared to G AT3pD295N.
Differences in sequencing  traces  can be se e n  betw een  wild-type and variant s e q u e n c e s  at 
the variant position (see  arrows). Although almost identical in size and sh a p e  it is perceptible 
that an adenine  peak  occurs at the s a m e  position a s  the indicated guanine, suggesting a  
heterozygous variant.
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Figure 3.28 Lightscanner data analysis of G AT3pD295N population study. The
lightscanner profiles show that the variant sam ple  (shown in orange) melts at a  different rate 
to the 95 healthy control sam ples . GAT3P D295N is not presen t in the healthy population.
G A T3pD295N was predicted to have tolerated consequences by SIFT and Grantham, 
however, PolyPhen predicted damaging structural changes to the protein. Multiple 
species alignment analysis showed that G A T 3pD295N occurred in a highly conserved 
residue and region of the protein (Figure 3.29).
In summary, enough evidence was gathered from population analysis and predictive 
tools to justify further structure / function analysis of G A T3P‘D295N.
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G A T 3 p -d295n
GAT3 variant L S R L S N P Q V W V
H.sapien L S R L S D P Q V W V
P.troglodytes L S R L S D P Q V W V
M.mulatto L S R L S D P Q V W V
B.taurus L S R L S D P Q V W V
C.lupus L S R L S D P Q V W V
G.gallus L S R L S D P Q V W V
R.norvegicus L S R L S D P Q V W V
M.musculus L S R L S D P Q V W V
Figure 3.29 Phylogenetic alignments of GAT3pD295N. GAT3pD295N protein s e q u e n c e  was 
aligned against GAT3 wild-type s e q u e n c e  and their putative homologs. The affected residue 
is highlighted in green  for all spec ies  and the variant residue is in red. GAT3pD295N as  
dem onstra ted  occurs in a  highly conserved  residue and is also surrounded by conserved  
residues suggesting a highly conserved  region of the protein.
3.2.5 Missense Variant GAT3 p.R436Q
The missense variant p.R436Q is an amino acid change from arginine to glutamine at 
residue 436 as a result of heterozygous c. 1307G>A variant in GAT3 exon ten (Figure 
3.17 and figure 3.30). The variant was recognised in one patient sample of 688 cases 
but also identified in two of the 480 control samples (Figure 3.31) and on online 
databases with a low mean allelic frequency of 0.0005.
SIFT analysis predicted G A T3pR436Q as damaging which was supported by the 
PolyPhen and Grantham results which also gave a probably damaging outcome. 
Phylogenetic alignment analysis also revealed a highly conserved target 
residue/adjacent regions, suggesting consequences on the protein (Figure 3.32).
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T T A C C G G C G G G  A G  C T G C  T T A C C G G C G G G  A G C T G C
GAT3 WT GAT3P R436Q |l
Figure 3.30 GAT3 wild-type com pared to G AT3pR436Q chrom atogram . A double peak 
representing a  heterozygous variant is noted when comparing GAT3 wild-type and 
GAT3P R436 sequencing  traces. This double peak  su g g es ts  a  nucleotide c h a n g e  from 
guanine to adenine  resulting in an amino acid ch ange  from arginine to glutamine.
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Figure 3.31 Population study results for GAT3pR436Q via Lightscanner analysis. A
Lightscanner population study w as carried out for GAT3pR436Q to determ ine w hether the 
variant w as present in the healthy population. As the patient sam ple  containing the variant 
(blue trace) melts at a  different rate to the av e rag e  control sam ples  we can determ ine  that 
the variant, in this case ,  is not presen t in the population. The two red traces  show n were 
seq u en ced  and they did not contain the variant, instead they show ed ano ther  SNP. 
However, there are  5 population studies (n=480) in total and p.R436Q w as identified in 2 
control sam ples.
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GAT3pR436Q
GAT3 variant R R G Y R Q E L L I L
H.sapien R R G Y R R E L L I L
P.troglodytes R R G Y R R E L L I L
M. mulatto R R G Y R R E L L I L
B.taurus R R G Y R R E L L I L
C.lupus R R G Y R R E L L I L
G.g alius R R G Y R R E L L I L
R.norvegicus R R G Y R R E L L I L
M.musculus R R G Y R R E L L I L
Figure 3.32 Phylogenetic alignments of G AT3pR436Q. GAT3pR436Q protein s e q u e n c e  was 
aligned against GAT3 wild-type protein s e q u e n c e  a s  well a s  their putative homologs. The 
residue in question is highlighted in green for all spec ies  and the variant residue in red. 
GAT3pR436Q occurs in a  highly conserved  residue a s  well a s  highly conserved  region of the 
protein.
Consequently, G A T3pR446Q is a rare-variant SNP that is highly conserved, and 
predicted to have damaging consequences; thereby, justifying further analysis.
3.2.6 Missense Variant GAT3 p.R597W
The variant p .R597W  was an amino acid change identified in exon 14 of SLC6A11 
(Figure 3.17). G A T3pR597VV is a heterozygous c .l791C > T  nucleotide change which 
results in an arginine to tryptophan amino acid substitution at position p .597 of  the 
polypeptide. (Figure 3.33). The variant was identified in one case out of 691 patient 
samples and was also identified in dbSNP with a rare allelic frequency of 0.0023 out 
of 2,276 samples. Conflictingly, none of the 480 control population samples have the 
variant (Figure 3.34).
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Figure 3.33 Sequence chrom atogram  of the G AT3pR597W and its corresponding wild- 
type. GAT3P R597 sequencing  trace w as com pared  to wild-type and a  variant w as  identified 
at amino acid position 597 (arrows). The variant is a  nucleotide change  from cytosine to 
thymine and is visible by double peak s  a s  indicated.
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Figure 3.34 GAT3 variant p.R597W, population study result. It is clear from the 
lightscanner traces  above that the patient sam ple  containing GAT3P R59/W melts at a  different 
rate to the 95 control sam ples .  This would indicate that they do not contain the variant 
s eq u en ce  that c a u s e s  such deviation from the ave rage  melt curve.
Predictive conservation analysis by SIFT and PolyPhen suggest that G A T 3pR597VV 
has benign effects on the protein, however, a Grantham class of C65 suggests that 
there would be pathogenic consequences (Table 3.4). Phylogenetic analysis of 
multiple species reveals a highly conserved amino acid and surrounding sequence 
suggesting that G A T3pR597W is likely to have pathogenic consequences on protein 
function (Figure 3.35).
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GAT3pr597W
GAT3 variant T D L K M W G K L G V
H.sapien T D L K M R G K L G V
P.troglodytes T D L K M R G K L G V
M.mulatta T D L K M R G K L G V
B.taurus A D L K M R G M L G A
C.lupus A D L K M R G K L G A
G.gallus S D L K M R G K L G G
R.norvegicus A D L K M R G K L G A
M.musculus A D L K M R G K L G A
Figure 3.35 Multiple phylogenetic alignm ents of GAT3pR597W. The protein s e q u e n c e  of 
GAT3pRb97W was aligned against GAT3 wild-type protein s e q u e n c e  a s  well a s  its putative 
homologs. The residue in question is highlighted in green for all spec ies  and the variant 
residue in red. It ap p ea rs  that GAT3P R597 occurs in a decidedly conserved  residue.
From the convergent evidence it was decided to take G A T 3pR597vv forward to further 
structure / function studies as a result of in silico prediction, population frequency 
and phylogenetic alignments.
3.3 Summary of mutation analysis of GAT1 and GAT3 genes
The genetic screening of GAT1 and GAT3 in GGE patients saw the heterozygous 
identification of one novel missense variant, one novel splice variant and a novel 
deletion variant which had the potential to be directly pathogenic. A further eight 
rare SNPs were also identified in these samples with unknown general population 
frequencies or frequencies of less than 1% but affecting conserved regions of the 
protein and some in silico evidence for damaging effects. All 11 gene variants 
identified were heterozygous variants that corresponded to epilepsy phenotypes with 
a component of absence seizures.
Chapter five will contain further analysis of the 11 variants including protein context 
and topology, 3D structural modelling analysis and the expression validation o f  gene 
specific mutation constructs that were created for transfection and causality research. 
Chapter 6 will contain details o f  the scheduled purpose of the constructs to determin
the pathological consequences of these variants. The next chapter (4) will focus on 
the results from the screening of the GAD65 and GAD67 proteins that constitute a 
bio-synthetic component of the GABAergic system.
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Chapter Four
Mutation analysis of GAD65 and GAD67 in 
Genetic Generalised Epilepsy
Prior to this study, no mutations had been identified in the GABAergic genes GAD2 
and GAD1 (known from this point as proteins GAD65 and GAD67 respectively), in 
relation to epilepsy. The genes encode for biosynthetic GABA enzymes maintaining 
levels of GABA in pre-synaptic terminals and were selected for candidate gene 
analysis in 485 clinically-confirmed genetic generalised epilepsy (GGE; Melbourne) 
patient samples. Results obtained from this preliminary data led to the recruitment 
and analysis of an additional 187 absence seizure (CAE; UCL) and 35 juvenile 
myoclonic epilepsy patient samples (JME; WERN). Control population studies were 
carried out on 480 commercially-available samples (Sigma) to assess the population 
frequencies of gene variants in addition to accessing bioinformatics sources.
This chapter outlines the identification of genetic variants identified in the 
GABAergic enzymes GAD65 and GAD67. Synonymous, novel non-synonymous 
missense, and intragenic variants were identified in the GABAergic enzymes GAD65 
and GAD67. As described for the GABA transporters in chapter three, this analysis 
will involve the assessment of sequencing data, evaluation of unaffected control 
population data and any previously identified online data, the investigation of the 
predictive consequences of the variants including multiple species alignments, and 
the appraisal of the variant positioning within the protein at a 2D level.
4.1 Mutation analysis of GAD65
Twenty-six variants were identified in the coding region and flanking intronic 
regions of GAD65 in 149 patient samples (Table 4.1), which consisted of 8 non- 
synonymous, 6 synonymous, and 12 intronic variants. These variants are mapped 
onto genomic positions and their novelty status indicated (Figure 4.1). From these 
gene variations, six non-synonymous gene variants were selected as most likely 
pathogenic variants and targeted for further analysis (Table 4.2).
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Exon Nucleotidechange Type of Mutation
Amino
acid
change
Sample 
Frequenc 
y (n=707)
Reference MAF
1 IV S1+8 G>A Intronic 19 rs2839671 0 .2 5 3
IVS1+11 G>A Intronic 2 Novel
2 IVS2+11 A>T Intronic 1 N ovel
c .1 3 4  G>T N on -sy n o n y m o u s P .C 45F 1 rs14 2 9 8 2 0 4 1 No
IV S2+17 C>T Intronic 1 Novel
3 IV S3+79 G>A Intronic 13 rs4 1 3 0 4 6 0 9 0 .0 4 3
IV S3+ 110  
A>G Intronic 10 rs819 0 5 9 7 0 .1 9 9
IV S2-19 G>T Intronic 1 rs1 1 2 0 2 1 2 1 8 0 .0 2 8
4 c .3 0 4  G>A N on -sy n o n y m o u s P .D 102N 1 rs 1 3 9 8 8 8 0 0 3 No
c .3 5 8  C>A N on -sy n o n y m o u s P .P 1 5 3 Q 16 rs2 8 3 9 6 7 2 0 .0 0 4
IV S4+14 G>A Intronic 3 N ovel
6 c .6 9 5  G>A N on -sy n o n y m o u s P .G 232E 6 rs2 8 3 9 6 7 3 0 .0 0 6
c .7 0 5  C>T S y n o n y m o u s P .G 235G 4 rs5 5 7 8 9 9 3 6 0 .0 0 2
c .6 1 2  G>A N on -sy n o n y m o u s p.M 204l 2 r s6 1 7 3 5 9 2 2 0.001
7 c .8 0 7  G>A N on -sy n o n y m o u s P .A 269T 6 rs52834041 0.001
IV S7+50 G>A Intronic 1 Novel
c .7 8 9  G>A S y n o n y m o u s P.K263K 1 Novel
IV S7+43 A>G Intronic 1 r s2 0 2 1 3 9 9 4 8 No
8 IV S8+8 C>T Intronic 18 r s2 8 3 9 6 7 7 0 .0 5 7
9 IV S8-20 A>G Intronic 6 rs8 1 9 0 7 0 8 0 .0 0 3
10 c .1 0 1 7  C>T S y n o n y m o u s P.T339T 15 rs18 0 5 3 9 7 0 .0 1 0
c .9 7 8  G>C S y n o n y m o u s P .G 326G 17 rs2 8 3 9 6 7 8 No
11 c .1 1 0 7  G>A S y n o n y m o u s P .G 369G 1 rs8 1 9 0 7 2 9 0 .0 0 6
12 c .1 2 1 8  T>G S y n o n y m o u s P .A 406A 1 Novel
15 c .1 5 8 0  C>T N on -sy n o n y m o u s P .S 527L 1 rs14 9 7 4 2 5 6 0 0.001
16 c .1 7 2 5  T>C N on -sy n o n y m o u s P.I575T 1 rs14 5 4 1 9 7 3 1 No
Table 4.1 The GAD65 a//-variants table. Variant table of all variants identified via GAD65 in 
GGE patients via genetic  screening. The g en e  variant frequency and the m ean  allelic 
frequency are  presented .
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The six heterozygous GAD65 variants identified as potentially pathogenic were: 1) 
p .C45F (c. 134G>T), 2) p.D102N (c.304G>A), 3) p.P153Q (c.358C>A), 4) p.G232E 
(c.695G>A), 5) p.S527L (c. 1580C>T) and 6) p.I575T (c.1725T>C). The damaging 
status case for each variant is presented in table 4.2 taking into account 
bioinformatics databases and control frequency datasets; structure/function data is 
presented in Chapter Five.
Population study and predictive analysis was also carried out for the non- 
synonymous variants p.M204I and A269T. Due to the high population study 
frequencies of the variants and limited causal effects calculated by predictive tools, 
these variants were not considered any further in this thesis.
4.1.1 Missense Variant p.C45F
The first variant identified in GAD2 was G A D 65pC45F. A guanine to thymine 
nucleotide change at position 134 of the coding sequence resulted in a cysteine to 
phenylalanine amino acid substitution at position 45 of the polypeptide (Figure 4.2). 
This variant was identified in exon two of one patient sample of the 674 cases 
successfully screened. It was not found in the 485 unaffected control samples and 
was registered online with a frequency of zero out of 2176 individuals screened 
according to SNP databases (Figure 4.1 and Figure 4.3).
GAD65 WT
Figure 4.2 Sequence chrom atogram of the GAD65 variant G AD65pC45F and the 
corresponding wild type sequence. GAD65pC45F is a  he terozygous variant, a s  illustrated 
from the double peaks on the right hand column sequencing  trace. The variant w as 
dem onstra ted  by m ean s  of an arrow, a s  were the corresponding wild-type s e q u e n c e s  in the 
left hand column of the figure.
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Figure 4.3 GAD65pC45F lightscanner control population study results; The sam ple 
harbouring GAD65pC45F w as placed in well H12 and is shown in red on the trace. 
GAD65pC 5F does  not have the s a m e  melt profile a s  any of the control sam ples , suggesting 
that it is not p resent in the healthy population a s  a common non-pathogenic SNP.
Predictive tools suggested that G A D 65pC45F will have damaging effects on the 
protein. Species alignment analysis also suggested that the amino acid change would 
be damaging to the protein as the variant affects a conserved residue in a conserved 
region o f  the protein (Figure 4.4).
GAD65p-C45F
GAD65 variant I G N K L  F A L L Y G
H.sapien I G N K L C A L L Y G
P.troglodytes I G N K L C A L L Y G
M. mulatto I G N K L C A L L Y G
B.taurus I G N K L C A L L Y G
C.lupus I G N K L C A L L Y G
G.gallus F L S A L R V V A Q G
R.norvegicus I G N K L C A L L Y G
M.musculus I G N K L C A L L Y G
Figure 4.4 Phylogenetic alignm ent of the GAD65 missense variant, p.C45F. The variant 
w as  aligned against the GAD65 wild-type and  the corresponding homologs in various 
phylogenetic species. The mutated amino acid w as highlighted in red and the related wild- 
type and phylogenetic amino acids were highlighted in green.
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Predictive analysis, population study results and species alignments all give 
collective evidence to believe that G A D 65pC45F will have pathogenic effects on the 
protein. This supports the triage of this variant for in silico and functional analysis.
4.1.2 Missense Variant p.D102N
Tw o variants were identified in exon 4 of GAD2, the first being p.D102N (Figure
4.1). G A D 65p'di02n, is a guanine to adenine nucleotide change at position 304 
consequentially leading to an amino acid change from aspartic acid to asparagine at 
residue 102 of the polypeptide (Figure 4.5). The variant was identified in one patient 
sample of 664 screened and was not identified in the 480 unaffected control 
population and was registered on online databases with a frequency of zero out of 
2275 samples (Figure 4.6).
C G  G C G
GAD65WT
Figure 4.5 Sequence chrom atogram  of G AD65pD102N and the corresponding wild type 
sequence. The heterozygosity of GAD65pD102N w as identified by the double peak  as  
highlighted by an arrow in the right hand column. The sequencing  trace show s the nucleotide 
ch an g e  from guanine to adenine  at position 304.
The predicted consequences of SIFT and PolyPhen suggest that the amino acid 
change would not affect normal protein function nor would it have a damaging effect 
on the structure o f  the protein. The Grantham score predicted a possibly pathogenic 
score, suggesting damaging changes in polarity and composition. Species alignments 
show that the variant occurred in a very conserved residue and region of the protein 
(Figure 4.7).
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Figure 4.6 G AD65pD102N lightscanner population study traces. The patient sam ple  
containing GAD65pD102N w as  place in the 96th well of a  lightscanner plate, with 95 control 
patient sam p le s  occupying the remaining plate for analysis via Lightscanner technology. 
DNA melting rates were recorded and com pared. The patient sam ple  produces a unique 
melt rate profile suggesting  the variant is not presen t in the healthy control population.
GAD65p-d102N
GAD65 variant L L P A C N G E R P T
H.sapien L L P A C D G E R P T
P.troglodytes L L P A C D G E R P T
M.mulatta L L P A C D G E R P T
B.taurus L L P A C D G E R P T
C.lupus L L P A C D G E R P T
G.gallus L L P A C D G E A A T
R.norvegicus L L P A C E G E R P T
M.musculus L L P A C D G E R P T
Figure 4.7 Multiple species alignm ent of the G A D 65pD102N. The amino acid substitution 
producing the variant GAD65pD 02N w as  aligned against the GAD65 wild-type and the 
corresponding homologs in various phylogenetic spec ies .  The mutated amino acid w as 
highlighted in red and  the related wild-type and phylogenetic amino acids were highlighted in 
green.
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Multiple species analysis as well as study/online population frequency data give 
reason to further analyse G A D 65p'dio2N by means of in silico and functional analysis 
to determine its effect on GAD65 pathobiology.
4.1.3 Missense Variant GAD65p P153Q
The variant p.P153Q is a cytosine to adenine nucleotide change at position 358 
resulting in a proline to glutamine amino acid substitution at residue 153 o f  the 
polypeptide (Figure 4.8). Interestingly, this variant was identified in 16 patient 
samples of 664 at an allelic frequency of 0.012. However, the variant was also 
identified in two samples from the control population study of 480 at a lower allelic 
frequency (0.002) and on online databases at a frequency of 0.008 out of 3121 
samples (Figure 4.9).
■
GAD65 WT
Figure 4.8 Sequence chrom atogram of the GAD65 variant p.P153Q and the 
corresponding wild type sequence. GAD65P P153Q w as identified by the double peak  as  
highlighted by an arrow in the right hand column, representing heterozygosity. The 
sequencing  trace  shows the nucleotide ch an g e  from cytosine to adenine  at position 358.
Predictive variant analysis via SIFT suggested that the variant would be tolerated by 
the protein and normal protein function would be unaffected. Grantham and 
PolyPhen results, however, suggest that the structural changes caused by the variant 
would probably have damaging consequences. This was supported by the species 
alignment analysis which showed the variant to be a highly conserved residue 
(Figure 4.10).
Despite the presence of p.P153Q in the normal population, the over representation in 
epilepsy patient samples is justification for further structure/function analysis. The
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loss o f  a proline is typically highly significant for protein structures and p.P153Q 
may represent a significant risk factor variant rather than have driver mutation status.
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Figure 4.9 Lightscanner population study results for G AD65P P153Q. 480 control sam ples  
were ana lysed  using lightscanner technology for the  population study of each  variant. The 
melt profile of the patient sam ple  containing GAD65P 1530 differs from its respective 95 
control sam p le s  a s  shown. This indicates that the control sam ples  do not p o s s e s s  the 
change  in s e q u e n c e  that is causing the variant sam ple  to melt at such a  rate.
GAD65Ppl53Q
GAD65 variant E L A D Q Q 2 N L E E
H.sapien E L A D Q P Q N L E E
P.troglodytes E L A D Q P Q N L E E
M. mulatto E L A D Q P Q N L E E
B.taurus E L A D Q P Q N L E E
C.lupus E L A D Q P Q N L E E
G.gall us E L A E Q P Q T L E E
R.norvegicus E L A D Q P Q N L E E
M.musculus E L A D Q P Q N L E E
Figure 4.10 Multiple species alignm ent of the GAD65 m issense variant, p.P153Q.
GAD65 wild-type and GAD65pp 530 amino acid s e q u e n c e s  were aligned against 
corresponding homologs in various phylogenetic species . The mutated amino acid was 
highlighted in red and the related wild-type and phylogenetic amino acids were highlighted in 
green.
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4.1.4 Missense Variant GAD65pG232E
p.G232E was identified in six out of 683 patient samples. A guanine to adenine 
nucleotide change at position 695 in exon six results in an amino acid change from 
glycine to glutamic acid at residue 232 o f  the polypeptide (Figure 4.11). The variant 
was not identified in the 480 unaffected control samples and was identified on online 
databases with a frequency o f  0.014 out of 3134 participants (Figure 4.12).
GAD65P
Figure 4.11 Sequence chrom atogram of the GAD65 variant p.G232E and the 
corresponding wild type sequence. The heterozygous variant GAD65P G232E w as identified 
in the right hand  column of the figure, identified by double peaks  in sequencing  (highlighted 
by an arrow). The sequencing  trace show s the nucleotide ch ange  from guanine to aden ine  at 
position 695.
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Figure 4.12 G AD65pG232E lightscanner data analysis profile. The melt profile of the patient 
sam ple  containing the variant GAD65P G232E show s deviation from the  average , This deviation 
is not portrayed by any of the control patient sam p le s  which leads us to trust that 
GAD65P G232E is not p resen t  in the healthy control population.
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The normal function of the protein was predicted to be unchanged by SIFT and 
Polyphen. However, with a Grantham class result of 65 the variant was predicted to 
probably have damaging effects, a result supported by alignment analysis which 
showed the amino acid change occurred in a highly conserved residue (Figure 4.13).
Collectively, these results confirm that G A D 65pG232E should be taken forward for 
further analysis to determine the pathogenic effects of the amino acid change on 
protein function.
GAD65p-g232e
GAD65 variant I I G W P E G S G D G
H.sapien I I G W P G G S G D G
P.troglodytes I I G W P G G S G D G
M. mulatto I I G W P G G S G D G
B.taurus I I G W P G G S G D G
C. lupus I I G W P G G S G D G
G.gallus M V G W P G G C G D G
R.norvegicus I I G W P G G S G D G
M.musculus I I G W P G G S G D G
Figure 4.13 Phylogenetic alignment of the G AD65pG232E. p.G232E amino acid s eq u en ce  
w as aligned against its corresponding wild-type and homologs in various phylogenetic 
species . The mutated amino acid w as highlighted in red and the related wild-type and 
phylogenetic amino acids were highlighted in green. It can  be s e e n  that the variant occurs in 
a  highly conserved  amino acid residue.
4.1.5 Missense Variant GAD65pS527L
A nucleotide change from cytosine to thymine at position 1580 in exon 15 of GAD65 
results in a serine to leucine amino acid substitution at amino acid position 527 o f  the 
polypeptide (Figure 4.14). G A D 65pS527L was identified in one patient sample out of 
681 and one unaffected control sample o f  681, but at a mean allelic frequency of 
lower than 1% (frequency 0.001). (Table 4.1 and Figure 4.15). The variant was also 
identified on online databases at a frequency of 0.003 out of 2275 participants.
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c *
GAD65 WT
Figure 4.14 Sequence chrom atogram  of the G AD65p S527L and the corresponding wild
type sequence. p.S527L, a  heterozygous variant, w as identified in the right hand column of 
the figure by double peaks  in the sequencing  trace (indicated by an arrow). The sequencing  
trace show s the  nucleotide change  from cytosine to thymine at position 1580.
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Figure 4.15 Population study of GAD65 variant, p.S527L. As se e n  in the above results, 
one control sam ple  produced a  similar melt profile to GAD65pS527L; although it has  been  
highlighted by lightscanner technology in a  different colour. This sam ple  w as S an g er  
seq u e n c e d  which confirmed the control sam ple  did contain GAD65pS527L.
The effects o f  G A D 65pS527Lon the protein were predicted to be tolerated and benign 
by SIFT and Polyphen, however, a severe pathogenic effect was predicted by the 
Grantham score. The amino acid change occurs in a highly conserved residue by 
multiple species alignment analysis (Figure 4.16).
Triage of G A D 65p S527L into functional studies was approved via some indication of 
damaging effects by in silico methods and the highly conserved nature of the amino 
acid substitution and the GAD65 region.
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GAD65p-S527L
GAD65 variant R M S R L  L K V A P V
H.sapien R M S R L S K V A P V
P.troglodytes R M S R L S K V A P V
M.mulatta R M S R L S K V A P V
B.taurus R L S R L S K V A P M
C.lupus R M N R L S K V A P V
G.gallus R M S R L M K V A P V
R.norvegicus R M S R L S K V A P V
M.musculus R M S R L S K V A P V
Figure 4.15 Multiple species phylogenetic alignm ent of the GAD65 missense variant, 
p.S527L. GAD65P 5271 am ino acid s e q u e n c e  w as aligned against  its corresponding wild-type 
and homologs in various phylogenetic species . The mutated amino acid w as highlighted in 
red and the related wild-type and phylogenetic amino acids were highlighted in green. The 
variant occurs in a  highly conserved  amino acid residue.
4.1.6 Missense Variant GAD65P15751
A nucleotide change from thymine to cytosine at position 1725, causing an amino 
acid substitution from isoleucine to threonine at residue 575 of the polypeptide, was 
identified in exon 16 o f  GAD65 (Figure 4.17). This variant was identified in one 
patient sample out o f  697 but was identified on online databases at a frequency of 
0.001 out of 2937 and not identified in 480 unaffected control samples (Table 4.1 
and Figure 4.18).
GAD65 WT
Figure 4.17 Sequence chrom atogram  of G AD65p l575T and the corresponding wild type 
sequence. The hete rozygous  variant GAD65pl575T, w as identified in the right hand column of 
the figure by double p eak s  in the sequenc ing  trace (indicated by an arrow). The sequencing  
trace show s the nucleotide ch ange  from thymine to cytosine at amino acid position 1725.
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Figure 4.18 Lightscanner data analysis results for G A D 65pl575T. Melt profiles of 480 
healthy control s a m p le s  were com pared  to a  patient sample, which contained the 
GAD65P15757 The variant sam ple  melts at a  different rate to the control population indicating 
a  lack of p resence .
Predictive analysis of the variant suggested that the amino acid change would affect 
normal protein function and cause damaging affects to the protein. These results 
along with highly conserved multiple species alignment analysis supports the 
functional analysis of the p.I575T variant (Figure 4.19).
GAD65p-,575T
GAD65 variant D I D F L T E E I E R
H.sapien D I D F L I E E I E R
P.troglodytes D I D F L I E E I E R
M. mulatto D I D F L I E E I E R
B.taurus D I D F L I E E I E R
C.lupus D I D F L I E E I E R
G.gallus D I D F L I D E I E R
R.norvegicus D I D F L I E E I E R
M.musculus D I D F L I E E I E R
Figure 4.19 Multiple species phylogenetic alignm ent of the GAD65 m issense variant, 
P.I575T. The amino acid s e q u e n c e  of GAD65P 757 w as aligned against its corresponding 
homolog s e q u e n c e s  in various phylogenetic sp ec ie s  a s  well a s  its corresponding wild-type 
seq u en ce .  The m uta ted  am ino acid w as highlighted in red and the related wild-type and 
phylogenetic amino ac ids  were highlighted in green. The variant occurs in a  highly 
conserved  amino acid residues.
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4.2 Mutation analysis of GAD67
Gene sequencing of the coding region and flanking intronic regions of GAD67 
identified twenty-one variants in 111 patient samples (Table 4.3), which consisted of 
5 non-synonymous, 6 synonymous, and 10 intronic variants. These variants are 
mapped onto genomic positions and their novelty status indicated (Figure 4.20). The 
most likely pathogenic variants were selected for further analysis which, for GAD67, 
comprised of three non-synonymous gene variants (Table 4.4).
Exon Nucleotidechange Type of Mutation
Predicted
consequences
Sample
frequency Reference MAF
2 c .111  T>C S y n o n y m o u s H37H 47 rs7 6 9 4 0 4 0 .3 6 4
3 c .2 6 5  C>T N on -sy n o n y m o u s R89W 1 rs15 0 8 4 1 2 5 5 No
c .2 6 5  C>G N on -sy n o n y m o u s R 89G 1 N ovel
4 c .3 8 0  A>T N o n -syn on ym ou s Y 127F 2 rs14 1 0 0 4 9 7 8 No
6 c .8 6 2  A>C N on -sy n o n y m o u s I228L 2 r s4 5 5 6 6 9 3 3 0 .0 0 0
c .7 5 0  T>C S y n o n y m o u s P 2 5 0 P 1 r s3 6 9 5 0 5 9 7 0 No
c .6 9 3  G>A S y n o n y m o u s K231K 1 N ovel
9
IV S8-39
C>CT Intronic 33 rs7 0 1 4 9 2 0 .2 7 4
IVS9+4
T>TG Intronic 1 rs13 9 5 3 1 6 5 3 0.001
IV S9+12
G>GA Intronic 5 rs701491 0 .0 1 6
IV S8-33
T>TC Intronic 1 rs4 1 3 1 1 3 1 3 0 .0 0 3
11
IV S11+ 102
T>TC Intronic 1 N ovel
IV S11+6
G>GA Intronic 1 N ovel
13
IVS12-41
A>AT Intronic 1 N ovel
IV S13+29 Intronic 1 N ovel
14 c .1 4 7 3  T>C S y n o n y m o u s Y 491Y 1 rs14 6 1 9 9 2 8 8 no
c.1 4 5 0 C > T S y n o n y m o u s L484L 2 rs7 6 9 3 9 2
0 .0 3 7
6
15 c .1 5 9 5  G>A N on -sy n o n y m o u s R 532Q 3 rs7 6 9 4 0 2 0 .0 4 8
IV S14-49
C>CT Intronic 1 N ovel
16
IV S16+70
A>AG Intronic 4 rs7 6 9 4 0 6 0 .0 1 9
c .1 6 4 4  G>A S y n o n y m o u s E 548E 1 N ovel
Table 4.3 The GAD67 a//-variants table. Variant table of all variants identified via GAD67 in 
GGE patients via genetic screening. The frequency the variant occurs am ongst  sam ples  is 
highlighted a s  well a s  the m ean  allelic frequency of any variants previously identified.
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Three heterozygous variant were identified in the GAD67 gene, GAD]: 1) p.R89G 
(c.265C>G); 2) p.R89W  (c.265C>T) and 3) p.Y127F (c.380A>T) (Table 4.2). The 
status of  each variant in terms of the likelihood of  damaging consequences is 
presented in table 4.2 taking into account bioinformatics databases and control 
frequency datasets; Structure/function data is presented in Chapter Five.
Control population studies and predictive analysis was carried out for variants I228L 
and R532Q. High control population frequencies and benign consequences 
calculated by predictive tools prevented further analysis of the variants in this thesis.
4.2.1 Missense Variant GAD67P R89G
The novel mutation p.R89G was identified in GAD],  and represents a cytosine to 
guanine nucleotide change at amino acid position 265, causing a change from 
arginine to glycine at residue 89 (Figure 4.21). This variant was identified in exon 
three of  one patient sample out of 704 cases and was not found in the 480 unaffected 
control samples, nor recorded on online databases (Figure 4.20 and figure 4.22).
C C C G C I T C C G<3 C G C C A C C G C T T  f  i  G G C G C *  C
G A D 67 W T  j G A D 6 7 pB89G
Figure 4.21 Sequence chrom atogram  of G AD67P R89G, and the corresponding wild type  
sequence. GAD67pR89G chrom atogram s show a  nucleotide ch an g e  at position 265 which 
have been  identified a s  he terozygous ch an g es  due to the double peak  indicated by arrows. 
The s a m e  position on the wild-type s e q u e n c e  w as also dem onstra ted  by an arrow in the left 
hand column above.
G A D 67pRxgG was predicted to have tolerated and benign consequences by SIFT and 
Polyphen. However, a high Grantham score suggests the variant will have damaging 
effects on the protein (Table 4.4). Phylogenic alignments support this as the amino- 
acid substitution affects a highly conserved residue, suggesting it is critical for 
correct protein function (Figure 4.23).
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Figure 4.22 Lightscanner control population study results of GAD67pR89G. To determine 
w hether GAD67P R89G w as  presen t in the general population, lightscanner population studies 
w ere carried out on 480 control sam ples . The sam ple  containing GAD67pR89G melts at a  
different rate to the control sam ples  and its profile is not closely resem bled by any other 
sam ple; indicating that the variant is novel.
GAD67pR89g
GAD67 variant R D A R F G R T E T D
H.sapien R D A R F R R T E T D
P.troglodytes R D A R F R R T E T D
M.mulatto R D A R F R R T E T D
B.taurus K D G R F R R T E T D
C.lupus R D G R F R R T E T D
G.gallus R E A R F R R T E T D
R.norvegicus P G A R F R R T E T D
M.musculus Q G A R F R R T E T D
Figure 4.23 M ultiple species phylogenetic alignm ent of the novel GAD67 m issense  
variant, p.R89G. GAD67P R89G amino acid s e q u e n c e  w as aligned against its corresponding 
wild-type and homolog s e q u e n c e s  in various phylogenetic species . The mutated amino acid 
w as  highlighted in red and the  related wild-type and phylogenetic amino acids were 
highlighted in green.
In summary, G A D 67p R89G is a novel variant with damaging consequences according 
to population studies, species alignments and Grantham results. Functional analysis 
is required to assess any pathogenic effects.
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4.2.2 Missense Variant GAD67pR89W
G A D 67p kmw, an amino acid change from arginine to tryptophan, was also identified 
at amino acid position 89 but instead resulted from a different nucleotide change 
(cytosine to thymine) at position 265 of the coding sequence (Figure 4.24). 
G A D 67pR89'A was identified in one patient sample out of 704, was not identified in 
any samples in the unaffected control population (n=480) but was identified on 
online databases with a rare frequency of 0.001 out o f  2,914 (Table 4.2 and Figure 
4.25).
GAD67 WT GAD67P*WIW
Figure 4.24 Sequence chrom atogram  of GAD67P R89w, and the corresponding wild type 
sequence. A heterozygous nucleotide change  from cytosine to thymine can be noted by the 
double peak  indicated with an arrow. The s a m e  position on the wild-type s e q u e n c e  w as also 
dem onstra ted  with an  arrow in the left hand column above.
Lightscanner Data Analysis
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Figure 4.25 GAD67pR89w Lightscanner population study results. Population study 
analysis using lightscanner technology show s that no control sam ple  h as  a  similar melt 
profile to p.R89W . This su g g es ts  that the variant is not p resent in the healthy control 
population.
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Predictive analysis o f  this rare SNP suggested the variant would have damaging 
effects on normal protein function (Table 4.4). Independent species alignment 
supports the predictive analysis and suggests that the amino acid substitution affects 
a functionally critical residue (Figure 4.26).
In summ ary, G A D 67pR89W is a rare SNP as observed from dbSNP, however, 
predictive results and phylogenetic alignments suggest functional analysis is justified 
to assess any pathogenic effects.
GAD67pr89W
GAD 67 variant R D A R F W R T E T D
H.sapien R D A R F R R T E T D
P.troglodytes R D A R F R R T E T D
M.mulatta R D A R F R R T E T D
B.taurus K D G R F R R T E T D
C.lupus R D G R F R R T E T D
G.gallus R E A R F R R T E T D
R.norvegicus P G A R F R R T E T D
M.musculus Q G A R F R R T E T D
Figure 4.26 M ultiple species phylogenetic alignm ent of the GAD65 m issense variant, 
p.R89W. T he amino acid s e q u e n c e  of the variant p.R89W w as aligned against its homolog 
se q u e n c e s  in various phylogenetic spec ies  a s  well a s  its corresponding wild-type sequence .  
The substituted amino acid is highlighted in red and the relevant wild-type and phylogenetic 
amino acids highlighted in green. It can be noted that the variant occurs in a  highly 
conserved  residue of the protein.
4.2.3 Missense Variant GAD67P Y127F
G A D 67pYI27F, an adenine to thymine nucleotide change at position 380, resulted in a 
tyrosine to phenylalanine amino acid substitution at residue 127 in exon 4 (Figure 
4.27). The variant was identified in two patient samples out of 696 G G E samples, but 
also four control samples out of 480 at a frequency of less than 1% (0.004); the 
variant was also identified on online databases with a frequency of 0.001 out 2,276 
participants (Figure 4.20 and Figure 4.28).
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Predictive analysis calculates that normal protein function will be affected by the 
variant, with damaging and possibly damaging results predicted. Alignment analysis 
shows the amino acid substitution occurs in a highly conserved residue, highlighting 
it as a critical residue for correct protein function (Figure 4.29).
.Y127F
GAD67 WT
Figure 4.27 Sequence chrom atogram of G AD67P Y127F, and the corresponding wild type 
sequence. The double peak  of the right hand chromatogram show s the heterozygous 
nucleotide ch an g e  from adenine to thymine constituting GAD67P Y12/F. The position can also 
be identified on the  GAD67 wild-type seq u en ce .
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Figure 4.28 Exam ple of population study results of G AD67pY127F. This lightscanner 
profile show s the results of a  population study carried out for GAD67pY127F. The variant, 
patient sam ple  w as  placed in well H12 and can be seen  on the plate diagram in blue. This 
co rresponds  to the blue traces  shown and a  unique melt curve observed  for GAD67P Y127F 
indicates that it is not presen t in the control sam ples, suggesting it is not in the general 
unaffected population.
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Online databases and population study analysis suggest that the rare variant will not 
have destructive effects on protein function. However, predictive analysis and 
multiple species alignments suggest the variant needs in silico and functional 
analysis to gather for evidence for pathogenicity.
GAD67p-y127F
GAD67 variant D I L L N  F V R K T F
H.sapien D I L L N Y V R K T F
P.troglodytes D I L L N Y V R K T F
M. mulatto D I L L N Y V R K T F
B.taurus D I L L N Y V R K T F
C.lupus D I L L N Y V R K T F
G.gallus D I L L N Y V R K T F
R.norvegicus D I L L N Y V R K T F
M.musculus D I L L N Y V R K T F
Figure 4.29 Phylogenetic alignm ents of the GAD67 missense variant, Y127F. The
amino acid s e q u e n c e  containing GAD67pY127F was aligned against its corresponding 
homolog s e q u e n c e s  in various phylogenetic spec ies  and corresponding wild-type sequence .  
The variant occurs  in a highly conserved  amino acid residue.
4.3 Summary of GAD65 and GAD67
The genetic screening of GAD65 and GAD67 in 707 G G E patient samples via 
lightscanner analysis has allowed for the identification of one novel missense variant 
and eight rare missense variants (occur in less than 1% of the general population). 
All are heterozygous variants that occur in highly conserved residues of the protein.
The outcome of  this logistically challenging screening provides a rational to 
undertake in silico and in vitro functional analysis for each variant. Chapter Five will 
combine the gene variant outcomes from Chapter Three and Four and contain further 
analysis o f  G A B A  transporters and GA D65/GA D67 including protein context and 
topology, 3D structural modelling analysis and the expression validation of gene 
specific mutation constructs that were created for cellular transfection and functional 
research.
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Chapter Five
Protein analysis of GGE GABAergic 
variants
Genetic screening of 707 GGE patient samples resulted in the identification of 20 
novel or rare variants in GAT1, GAT3, GAD65 and GAD67. This included 18 
heterozygous missense variants, a heterozygous lbp deletion and a heterozygous 
splice-site variant. A rigorous process of bioinformatic analysis, population data and 
phyolgenetic alignment has lead to their selection for further analysis. The deletion 
and splice-site event have more direct pathogenic consequences discussed later and 
so we have focussed on the missense variants to determine the likelihood of 
pathogenicity of each genetic variants identified.
This chapter describes the protein context of the missense mutations including 
topology analysis, 3D molecular structure analysis and the preparation of mutation- 
expression constructs for cellular assays. This highlights that the GABAergic 
missense variants identified caused structural changes to their corresponding 
proteins. The creation of 18 mutation expression constructs proved successful and 
displayed functional intracellular expression of transgenes to validate their use in 
downstream molecular and cellular assays.
5.1 GAT1 Protein Context
Figure 5.1 A and B represents the gene variants detailed in table 3.1 and mapped onto 
the protein domains and transmembrane topology of GAT1. They show that there are 
no amino acid substitutions within the transmembrane domains (TM domains) and 
they occur mainly in intracellular and extracellular linking domains and always in 
close proximity to TM domain boundaries. This may or may not confer a functional 
trend given the restricted numbers of gene variants .
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GATlp M179v lies between two of the highly conserved N-glycosylation sites, Asnl76 
and Asnl81 located on the extracellular loop between TM 3 and 4. If this variant 
affects one or more of the glycosylation sites, it could impact on properties of the 
protein such as protein folding, stability and GABA binding, thereby rendering the 
protein ineffective.
Independent conservation analysis of GATlp L4151 shows a highly conserved amino 
acid residue is affected by this variant which resides in the intracellular loop between 
transmembrane domain eight and transmembrane domain nine (Figure 5.1). 
Transmembrane domain eight is a crucial part of the transporter as the 
transmembrane and corresponding extracellular loop contribute to successful GABA 
binding. Variants in this region could interfere with GABA binding resulting in the 
transporter being unable to activate and carry out its function.
GATlp M555V is close to the end of transmembrane domain 12 and leading into the 
final intracellular domain of GAT1 (Figure 5.1). This variant occurs in the region of 
the transporter that controls transporter trafficking, stability and degradation. 
Variants that would interfere with either of these processes could hiave detrimental 
effects on transporter activity either by preventing effective trafficking to the cell 
surface of being ineffective once reached. As with g a T 1p’M555v, GAT1p'S594A was 
identified following transmembrane twelve, in the C-terminal of the protein (Figure
5.1), this again could cause damaging effects to the transporter preventing it reaching 
its target, causing stability concerns and degradation queries.
GATlp IVS3+l occurs directly before exon three and transmembrane domain three, 
which could result in partial or complete loss of membrane domain. Transmembrane 
domain three is a crucial part of the protein and along with domains 1, 6 and 8 forms 
the inner ring of the central substrate binding site. A loss of this domain is likely to 
interfere with GABA binding possibly causing a loss of function.
5.2 GAT1 Structural Modelling
Structural models were created for wild-type and missense variants identified in this 
study from ‘pdb’ files obtained from Phyre2 and the Protein data bank, using
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M 179
M 5 5 5
S594
Figure 5.2 3D structural m odelling of GAT1. A. Novel/rare m issen se  variants identified in 
the study are  highlighted in m ag en ta  and glycosylation site residues in blue. B. An aerial 
view of GAT1 with t ra n sm e m b ra n e  dom ains highlighted a s  shown in figure 5.1, with the 
remaining se q u e n c e  coloured in tan.
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Chimera software (See section 2.2,8). Wild-type models of all four genes were 
created (Figures 5.2, 5.7, 5.15 and 5.23) with the positioning of the variants 
identified and transmembrane domains or enzymatic regions highlighted according to 
the 2D images (Figures 5.1, 5.16, 5.14 and 5.22). Aerial views showing the 
positioning o f  the transmembrane domains o f  the GABA transporters were also 
created (Figures 5.2 and 5.7).
N184
N176
N181
179
N176
V179N184 —
Figure 5.3 Homology modelling of GAT1 w ild-type and GAT1pM179V. Wild-type modelling 
(blue) dem onstra tes  the GAT1 positioning and  side chain residue of methionine at position 
179, a s  well a s  the glycosylation sites (purple) at amino acid positions 176, 181 and 184. 
The s a m e  can be se e n  on the variant s e q u e n c e  (green) which entails a  c h a n g e  to valine at 
position amino acid 179. There  is a  clear ch an g e  in positioning of the glycosylation sites 
following the variant amino acid com pared  to wild-type.
3D modelling images of G A T lpMI79V compared to wild-type show interesting results 
not only for residue 179 but also for the glycosylation sites in close proximity 
(Figure 5.3). In the conversion from methionine to valine the amino acid remains a 
nonpolar residue but the side chains differs in size and shape, which could affect 
interaction. The sequence change occurs amongst three glycosylation sites and is 
predicted to cause the deviation in positioning of the glycosylation site asparagine at 
positions 181 and 184, between wild-type and variant. Experiments involving the N- 
glycosylation sites of other neurotransmitter transporters have been carried out. 
Mutation of the glycosylation sites of GLYT2 found that the removal of  one site 
gave similar transport activity assay results to the wild-type , whilst mutations o f  two 
and three of the glycosylation sites showed 74% and 58% of wild-type transport 
activity respectively (Martinez-Maza et al., 2001). Although mutations have not 
occurred in the glycosylation sites of the GAT1 transporter, two of the glycosylation
have deviated significantly from the wild-type position, possibly causing an inability 
to interact and lack of  function.
Figure 5.4 shows the comparison of the 3D protein structure of GAT1 wild-type with 
the variant sequence of G A T lp L4151. The GAT1 wild-type structure contains leucine 
at amino acid position 415 whilst an amino acid change to isoleucine at this position 
causes the structural changes that modify the outward facing smaller nonpolar side 
chain residue to an inward facing nonpolar variant residue. 3D modelling of GAT1 
including an amino acid change at position 555 from methionine to valine shows 
limited changes to the overall structure of the protein (Figure 5.5). However, changes 
between the hydrophobic nonpolar amino acid side chains can be noted as the variant 
residue does not reach as far in towards the pore of the membrane.
Figure 5.4 3D modelling of the w ild-type GAT1 protein structure and GAT1pU151. The
GAT1 wild-type structure a s  shown in blue, contains leucine at amino acid position 415. An 
amino acid ch an g e  to isoleucine at this position c a u s e s  the structural ch an g es  shown in 
green and the c h a n g e  in am ino acid side change  shown in red com pared  to wild-type. The 
inward facing nonpolar variant residue replaced a outward facing smaller nonpolar residue.
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Figure 5.5 Structural homology modelling of GAT1 w ild-type and variant sequence
GAT1pM555V. A 3D model of the GAT1 protein s e q u e n c e  including an amino acid ch an g e  at 
position 555 from methionine to valine (green structure) w as created  and com pared  to GAT1 
wild-type (blue structure). Limited c h a n g e s  to the overall structure of the protein can be seen ,  
however c h a n g e s  be tw een  the hydrophobic nonpolar amino acid side chains can be noted 
as  the variant residue d o e s  not reach a s  far in towards the pore of the m em brane .
5.3 GAT3 Protein Context
G A T3pHI4^  was localised to transmembrane domain three of the GAT3 protein 
(Figure 5.6). Transm em brane domain three along with domain eight is responsible 
for the binding o f  G A B A  to the transporter for its activation. If the binding of GABA 
were deterred due to a variant causing an inability to bind, the transporter will be 
unable to operate successfully. This in turn could not allow the reuptake of GABA 
from the synaptic space. The side chains of amino acid residues in this 
transmembrane dom ain are also responsible for the blockage o f  extracellular matter 
into the pore and any changes in amino acid could interfere with such processes.
Closely following G A T 3 pHI42\  G A T3P'N160K was identified on the extracellular loop 
between transmem brane domains three and four of GAT3; the variant precedes the 
three N-glycosylation sites, however is not believed to affect them (Figure 5.6 and 
figure 5.9). The variant does however occur between a highly conserved 
transmembrane dom ain four and a transmembrane domain which creates the G A BA 
and sodium binding site an could therefore play a crucial role.
G A T3p'V256L was located to transmembrane domain 5 of the GAT3 (Figure 5.6). This 
domain along with transmembrane domain 4 acts as a pincer which holds in place
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transmembrane domain 3 which is vitally important to maintain the structure of the 
pore acting as the central substrate binding site. The domain also contains a large 
amount of conserved residues which highlights the importance of the area as a 
whole. GAT3pD295N was mapped following this domain in the extracellular loop 
between transmembrane domains five and six (Figure 5.6). Extracellular loops 
surrounding transmembrane domain six are highly important in the formation of the 
central substrate binding site. Side chains of the amino acids in this area are 
important to block extracellular matter from interfering with substrate binding. 
Variants in this area could therefore have negative effects on substrate binding, either 
from interference by other products or an ability for GABA and sodium binding.
GAT3pR436Q presents itself on the intracellular loop connecting transmembrane 
domains eight and nine (Figure 5.6). Transmembrane domain eight and its 
surroundings are involved in creating the GABA binding site, whilst the role of 
transmembrane domain nine is to hold transmembrane domain eight in position along 
with the aid of transmembrane domain ten. Variants in this area could therefore have 
an impact on the binding site of GABA, interfering with GABA uptake from the 
synaptic space.
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5.4 GAT3 Structural Modelling
The 3D structure of the GAT3 was modelled as in figure 5.7. The figure 
demonstrates the transmembrane domain location of the six missense variants 
identified, cross-referenced with figure 5.6. An amino acid change in GAT3 at 
position 142 from histidine to tyrosine compared to wild-type shows there is no 
significant change to the structure compared to wild-type (Figure 5.8). Both the 
positively charged wild-type residue and the larger uncharged variant residue are 
outward facing and located near the exterior of the protein.
The protein structure of the variant GAT3P'N,60K appears relatively unchanged when 
compared to its wild-type equivalent. Both the variant and wild-type side chain 
residues which are present on the outer surface of the protein extend away from the 
protein pore (Figure 5.9). The uncharged residue is converted to a positively charged 
residue, and does not seem to alter the structure of glycosylation sites as with 
Ga t ipMI7W (Figure 5.3).
GAT3 3D predictive modelling demonstrating the effects of a valine to leucine 
amino acid substitution at position 256, shows limited structural alterations compared 
to wild-type. Although similar in shape, the side chain residues of the wild-type and 
variant residues differ in residual mass and extension length (Figure 5.10). Limited 
modifications however can be seen to the protein structure and side chain features 
when considering the variant GAT3pD295N (Figure 5.11). The variant does however 
cause a change in polarity of the residue from negatively charged to uncharged.
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N160
R436
Figure 5.7 In  s i l i c o  m odelling of GAT3 wild-type. A. 3D structural model of GAT3 with 
novel/rare variants identified in the study highlighted in m agen ta .  M em brane dom ains are  
coloured according to the 2D structure (Figure 5.6) B. An aerial view of the 3D GAT3 
structure.
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Figure 5.8 Predictive 3D structural m odelling of G AT3pH142Y and its corresponding  
wild-type. The variant amino acid structure com pared  to wild-type show s no significant 
change . Both the positively charged  wild-type residue and the larger uncharged variant 
residue a re  outward facing and located near the exterior of the protein.
Figure 5.9 Homology modelling com paring the structures of GAT3 wild-type and 
GAT3P N160K. Both the variant and wild-type res idues  which are p resen t on the outer surface 
of the protein extend away from the protein pore. The ch an g e  in amino acid modifies the 
residue from uncharged to being positively charged , and d o es  not seem  to alter the structure 
of glycosylation sites a s  with GAT1p M179V (Figure 5.3).
Convincing results were obtained when analysing the structural modelling images of 
the variant GA T3P‘R436Q compared to the GAT3 wild-type. The large positively 
charged arginine molecule that extends towards the central pore of the protein is 
converted to a negatively charged molecule, facing away from the pore towards the 
inside of the cell (Figure 5.12). Similar changes in side chain direction can be noted 
when studying structural predictions of G A T 3pR597vv compared to wild-type. The
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positively charged arginine is replaced with the larger nonpolar tryptophan. Figure 
5.13 shows that whilst the wild-type variant faced toward the cell membrane, the 
variant residue sits facing extracellularly.
Figure 5.10 3D structural homology modelling com paring GAT3pV256L to GAT3 wild- 
type. Predictive modelling show s that although at position 256 the amino acid change  from 
valine to leucine d o e s  not alter the polarity of the residue (nonpolar) there is a  slight increase 
in residue m a s s  and extension length.
Figure 5.11 3D structural modelling of GAT3 w ild-type and the variant GAT3pD295N. 3D
predictive modelling of the variant w as carried out and com pared  to wild-type sequence .  
Although there  is only a  slight alteration in the  structure of the protein and its side chain, the 
variant residue is modified from negatively charged  to uncharged.
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Figure 5.12 3D homology modelling of the variant GAT3p R436Q and its corresponding  
wild-type model, GAT3. Predictive structural modelling of GAT3pR436Q com pared to the 
GAT3 wild-type show ed convincing results a s  not only does  the polarity of the residue 
ch an g e  from positive to negative but there  is also a  change  in positioning, from extending 
towards the  central pore of the protein to facing intracellularly.
W597
Figure 5.13 Structural homology modelling of GAT3 wild-type and the variant 
sequence G AT3pR597W. Predictive 3D modelling imaging show s the conversion of positively 
charged  arginine to the larger nonpolar tryptophan. The image show s that whilst the wild- 
type variant faced toward the cell m em brane , the variant residue sits facing extracellularly.
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Crystal structures have identified three primary protein domains in GAD65 as 
indicated in figure 5.14. The structure demonstrates an N-terminal region from amino 
acid residue 84 to 187, a larger PLP binding domain from amino acid residue 188 to 
465 and a C-terminal domain from residue 465 to the end of the protein at residue 
585.
On a protein level, GAD65p C45F was identified in the amino acid sequence in the N- 
terminal domain (Figure 5.14), however it resides in the region preceding the current 
crystal structure data as identified by Fenalti et al (2007). Palmytoylation is believed 
to occur in the N-terminal domain of GAD65 at amino acid positions 30 and 45 and 
primarily involves the covalent attachment of fatty acids to cysteine. The 
replacement of cysteine in this region with another amino acid could affect the level 
of palmytoylation and therefore the trafficking of the protein to the desired location 
within the terminal for the conversion of glutamate to GABA. The removal of 
cysteine could also affect the hydrophobicity of the protein and therefore its 
membrane association.
The N-terminal domain of GAD65 as well as containing palmytoylation sites, also 
contains trafficking signals which are potentially affected by the variant to prevent 
successful targeting to the nerve terminal and golgi membranes. The N-terminal 
domain is involved in the binding of two GAD65 proteins to create a functional 
dimer. If binding is affected by the amino acid change, it will be inactive. 
GAD65pD102N and GAD65pP153Q are both present in the N-terminal domain. These 
variants could affect protein trafficking, preventing successful targeting of the 
enzyme to the nerve terminal and golgi membranes. The creation of a functional 
dimer could also be affected, rendering the protein inactive (Figure 5.14).
Variant GAD65p G232E is present on the PLP binding domain of the GAD2 protein 
(Figure 5.14). Mutations in this region could affect the successful binding of PLP and 
therefore prevent the activation of the enzyme. The creation of a functional enzyme 
monomer could also be affected as the N-terminal domain would normally pack 
against the N-terminal and PLP-binding domain of another monomer.
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On a protein level, G A D 65pS527L and G A D 65pS527L have been mapped to the C- 
terminal domain (Figure 5.14). A variant at this position could affect substrate 
binding as the catalytic loop packs against the C-terminal domain, which further 
contributes to the dynamic role o f  the catalytic loop. The mobility of the enzyme 
could also be affected by the variants and is thought to occur in the C-terminal 
domain.
5.6 GAD65 Structural Modelling
GAD65 variants were identified and mapped throughout the protein as shown in 
figure 5.15. W hen comparing the variant protein G A D 65pC45F and the GAD65 wild- 
type protein via 3D structural modelling, there is a substantial change in the amino 
acid side chain structure from the uncharged cysteine to the larger nonpolar 
phenylanine (Figure 5.16). The variant however is preceding the identified truncated 
crystal structure so there is a decrease in the confidence level of the prediction, 
nevertheless there is a great difference in the protrusion and shape of the residual 
side chain.
G 2 3 2
D 102
C 45
Figure 5.15 Structural modelling of GAD65 wild-type. GAD65 predictive model showing 
N-terminal tail in blue, PLP binding domain in green, C-terminal tail in orange  and catalytic 
loop in purple. Also highlighted are  the residues where  variants have  been  identified in this 
s tudy (magenta).
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Figure 5.16 Hom ology modelling of GAD65 wild-type and variant sequence
G AD65pC45F. Predictive 3D structural modelling show s that there  is a  substantial change  in 
the amino acid side chain structure from the uncharged  cysteine to the larger nonpolar 
phenylanine. C are  m ust be taken however when a s s e s s in g  the affect of the variant on the 
structure of the protein a s  the variant occurs in the region preceding the previously identified 
truncated crystal structure.
The first variant occurring in the N-terminal domain of the protein is G A D 65pDI'LN 
which is an amino acid change from aspartic acid to asparagine at amino acid residue 
102. 3D structural modelling of the variant protein compared to the GAD65 wild- 
type shows that the amino acid change at this position from a negative to uncharged 
amino acid causes the residue side chain to turn slightly away from the centre of the 
protein, but inward toward the cell (Figure 5.17).
Figure 5.17 3D structural modelling of the variant p.D102N and its corresponding  
wild-type , GAD65. This N-terminal domain variant is the result of an amino acid change  
from aspartic  acid to asp a rag in es  at amino acid residue 102. 3D modelling show s that the 
amino acid ch an g e  at this position not only c a u s e s  the residue side chain to protrude slightly 
outward but there  is a lso  a  change  in polarity from negative to uncharged.
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3D predictive analysis demonstrates that an amino acid change from the cyclic amino 
acid proline to glutamine at amino acid position 153, causes limited changes to 
protein structure but substantial changes in residue side chain positioning can be 
observed when compared to wild-type. Under wild-type circumstances figure 5.18 
shows that the normal forced bends of proline cause sudden changes in the direction 
o f  the chain. The figure also shows that the variant amino acid change at this position 
diminishes the rapid curvature of  the side chain, changing the residue shape 
substantially. The nonpolar wild-type side chain of proline originally faced away 
from the enzyme whilst the negatively polar variant side chain extended toward the 
centre o f  the enzyme mass (Figure 5.18).
Comparison between the GAD65 wild-type and G A D 65pG232E protein structures in 
figure 5.19 shows that there is sizeable difference in the side chain makeup . The 
nonpolar wild-type residue glycine has no side chain residue opposing the negatively 
polar variant glutamic acid which has a side chain of  relative large mass projecting 
away from the protein (Figure 5.19).
Figure 5.18 3D structural modelling of GAD65 w ild-type and the variant protein  
structure GAD65pP153Q. 3D predictive analysis d em ons tra tes  that an amino acid ch ange  
from the cyclic amino acid proline to glutamine c a u s e s  a  ch ange  in residue side chain 
positioning. The normal forced bends of the proline causing abrupt c h a n g e s  in the direction 
of the chain due  is diminished by the p re sen ce  of glutamine, changing the residue sh a p e  
substantially. The nonpolar wild-type side chain faced aw ay from the enzyme, the negatively 
polar variant ex tended  toward the centre of enzym e m ass .
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Figure 5.19 3D protein structure modelling of the variant G AD65pG232E and its 
corresponding GAD65 wild-type sequence. There is a  noticeable difference between 
GAD65 wild-type and  GAD65pG 2E when considering 3D structural modelling. The nonpolar 
wild-type residue glycine has  no side chain w hereas  the negatively polar variant glutamic 
acid h a s  a  side chain of relative large m a ss  that projects away from the residue.
Figure 5.20 3D structural modelling of the predicted consequence of G AD65pS527L 
com pared to its GAD65 wild-type. Structural homology analysis su g g es ted  that there 
limited change  to the protein structure of GAD65 when an amino acid change  occurred at 
position 527 from serine to leucine. However the uncharged s ide chain of serine differs in 
m ass ,  structural formula and polarity com pared  to its corresponding nonpolar variant.
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Figure 5.21 Predictive structural modelling of the GAD65 w ild-type com pared with the 
variant G AD65pl575T. The protein structure of GAD65 w as c rea ted  (blue) using chimera 
software and  com pared  to the variant s e q u e n c e  containing an amino acid change  at position 
575 (green). 3D predictive analysis show s that the nonpolar wild-type residue extends further 
from the enzym e than the nonpolar, smaller in m a ss  variant. Little knock on change  can be 
se e n  affecting the overall protein structure.
3D Structural homology analysis suggested that there is a slight change in the protein 
structure of  GAD65 wild-type when an amino acid change occurred at position 527 
from serine to leucine (Figure 5.20). The uncharged side chain of serine differs not 
only in mass but also in structural formula and polarity compared to its 
corresponding nonpolar variant. These changes cause the variant residue to protrude 
and extend further away from the protein than in the wild-type protein. Similar 
results were obtained when examining the predictive 3D structural modelling of  the 
variant G A D 65p l575T compared to the GAD65 wild-type protein. In this case the 
nonpolar wild-type side chain advances further from the enzyme than the smaller 
nonpolar variant side chain, with limited overall effect on the protein structure 
(Figure 5.21).
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Crystal structures have also identified three primary protein domains in GAD67, the 
N-terminal, PLP binding and C-terminal domain, as indicated in figure 5.22. The 
protein regions differ slightly to those of the GAD65 protein with the N-terminal 
region spanning from amino acid residue 92 to 196, the larger PLP binding domain 
from amino acid residue 197 to 473 and a C-terminal domain from residue 474 to the 
end of the protein at residue 594.
GAD67p R89G and GAD67p R89W variants were identified in the N-terminal domain but 
in the amino acid sequence preceding the N-terminal truncated crystal structure 
described by Fenalti et al. (2007) (Figure 5.22). A variant in the N-terminal domain 
may affect the generation of a functional dimer which, in turn, could render the 
protein inactive. This is a possible outcome as the N-terminus of one monomer is 
packaged against the N-terminus and PLP binding domain of another monomer to 
create the functional dimer; a variant affecting the structure of this site could affect 
the successful binding of two monomers.
Figure 5.22 shows that the variant GAD67p Y127F occurred in an a-helix of the N- 
terminal domain of the protein. The a-helix is packaged with the N-terminal domain 
and PLP site of another monomer to create the functional domain. A variant in the a- 
helix could affect the successful binding of the two monomers leaving them inactive 
(Figure 5.22).
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5.8 GAD67 Structural Modelling
Y127
Figure 5.23 3D structural modelling of GAD67 wild-type. The 3D model shows all 
domains of the protein; N-terminus (blue), PLP binding (green), C- terminus (orange) and 
catalytic domain (purple). The variants identified in this study are  highlighted in m agenta .
Figure 5.23 highlighted that the variants identified in GAD67 in this study occurred 
in the N-terminal domain and the region preceding this. Both the variants 
GA D 67pR89G and G A D 67pR89Vv occur at the same amino acid position but 3D 
structural modelling predicts that the variants have different consequences. The 
positively charged polar arginine wild-type protrudes toward the centre of the 
enzyme, in the variant protein G A D 67pR89G this protrusion is replaced by the 
nonpolar amino acid glycine which has no side chain, possibly affecting interaction 
with other amino acids (Figure 5.24). When considering an amino acid substitution 
to tryptophan at this position, the inward facing arginine is replaced by a larger 
nonpolar heterocyclic residue which extends away from the enzyme mass. The 
amino acid side chain shows a distinct difference not only in mass but also in residue 
structure, direction and polarity to the wild-type (Figure 5.25).
150
Figure 5.24 3D homology modelling of GAD67 and the variant G A D 67pR89G. 3D
structural modelling predicts that the positively polar arginine wild-type protrudes toward the 
centre of the enzym e. In the variant seq u en ce ,  this protrusion is replaced by the nonpolar 
amino acid glycine which has  no side chain, possibly affecting interaction with other amino 
acids.
Figure 5.25 Predictive 3D structural modelling of the variant G AD67pR89W com pared to 
its GAD67 wild-type. The predicted structure of the wild-type protein s e e m s  not to largely 
differ from its corresponding variant protein, however the amino acid side chains show a 
distinct difference in residue structure, m ass ,  direction and polarity. Inward facing arginine is 
replaced by the larger nonpolar heterocyclic residue tryptophan which ex tends  aw ay from 
the enzym e m ass .
3D structural modelling of the variant G A D 67p YI27F compared to its GAD67 wild- 
type protein structure was shown in figure 5.26. Although limited changes to the 
overall protein were observed, the amino acid change from tyrosine to phenylalanine 
shows a decrease in mass due to the loss of a hydroxide molecule. Slight changes 
were also identified in relation to the positioning of the residue side chain as well as 
a change in polarity from uncharged to nonpolar.
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Figure 5.26 Structural 3D homology modelling of the variant G A D 67P Y127F compared to 
the GAD67 wild-type. The variant s e q u e n c e  com pared  to wild-type show ed slight ch anges  
in positioning of the residue side chain and m a ss  a s  well a s  a  changed  in polarity from 
uncharged to nonpolar.
5.9 Creating Gene-Expression Constructs
To assess the functional effect of each variant, a series of gene constructs were 
created from sequence validated wild-type constructs for GAT1, GAT3, GAD65, 
GAD67 as described in Chapter two (Figure 5.27). Following mutagenesis and 
further sequencing validation, 18 mutation constructs were generated through a 
miniprep and maxiprep pipeline.
The GABAergic missense variants and wild-type sequences as well as the GAT1 
deletion variant p.S594Afs22X, were all sequence validated to ensure no other 
nucleotide changes had occurred during mutagenesis and cloning steps. The 
sequences for the identified variants and their corresponding wild-type s for the four 
genes analysed can be seen in figures 5.28, 5.29, 5.30 and 5.31. Once validated, all 
the wild-type and mutation constructs were transiently transfected into ITEK cells to 
detect intracellular expression and confirm successful production of their protein.
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Figure 5.28 GAT1 m utation-construct sequencing results. Mutagenesis steps introduced 
or removed a nucleotide to create the variant sequence. Transformation into bacteria 
allowed the amplification of the variant s e q u e n c e  which w as  purified and s e q u e n c e  validated. 
The single stranded  variant s e q u e n c e  is shown with its corresponding wild-type sequence .
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Figure 5.29 GAT3 m utation-construct s e q u e n c in g  results. M utagenesis  and transformation 
s tag es  a s  dem onstra ted  in chapter  two allowed the introduction of se lec ted  variants into the 
GAT3 wild-type construct seq u en ce .  This figure show s the sequenc ing  validation results that 
dem onstra ted  successful establishm ent of the nucleotide c h a n g e s  into the s e q u e n c e  and the 
corresponding wild-type seq u e n c e s .
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Figure 5.30 GAD65 m utation-construct validation by s e q u e n c e  ana lys is .  GAD65 gen e  
constructs were s e q u e n c e  validated following insertion of desired variants into vectors  by 
m utagenesis  and transformation (as described in chapter two). This figure show s the variants 
s e q u e n c e  and its corresponding wild-type sequence .
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Figure 5.31 GAD67 g e n e  m utation-constructs . Sequencing  results of GAD67 variant 
constructs and their corresponding wild-type s. The variants identified in this study were 
inserted into vector s e q u e n c e s  by m utagenes is  before transformation into bacteria for 
amplification. S an g er  sequenc ing  allowed for validation of the variant.
5.6 Variant expression in HEK293 cells.
Mutant expression constructs were created for each missense variant identified in this 
study (as outlined in chapter two) from their genetic wild-type clones, by site-directed 
mutagenesis. The DDK tagged wild-type and variant vectors were transfected into 
cultured HEK293 cells before being fixed with paraformaldehyde and stained with 
monoclonal mouse anti-DDK primary antibody and anti-mouse 488 secondary 
antibody. The stained HEK293 cells were imaged using confocal microscopy at x63 
magnification and 2x digital zoom. Wild-type constructs for each gene were firstly 
imaged and the optimal gain level was kept constant for all the gene variants for 
comparison.
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Figure 5.32 GAT1 wild-type and variant e x p r e ss io n  in HEK293 cells .  Cultured HEK293 cells 
were transfected with C-terminal DDK tagged  GAT1 wild-type and variant expression 
constructs. The expression w as  visualised using confocal microscopy following fixation and 
staining. Bar = 10pm.
GAT1 wild-type construct was transfected into HEK293 cells and intracellularly 
stained. As can be seen from figure 5.32, the GAT1 wild-type protein is expressed 
intracellularly. This image also demonstrates that the three missense variants 
( G A T lpMITOV, G A T lpU151 and G A T lpM555V) and the deletion variant ( G A T lpS594Afs22X) 
proteins are also expressed intracellularly. The images show that there is high 
expression levels surrounding the nucleus and lower expression levels in the extremities 
of the cells.
The confocal microscopy images of GAT3 wild-type and variants show that the GAT3 
protein is expressed intracellularly and the expression level is unaffected by any of the 
variants that have been inserted. As with GAT1 variants expression seems to be most 
prominent surrounding the nucleus of the cell and is less concentrated in the extremities 
(Figure 5.33).
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Figure 5.33 GAT3 wild-type and variant e x p r e ss io n  in HEK293 ce lls .  HEK293 cells were 
transfected with the GAT3 wild-type and the six GAT3 variants identified in this s tudy (p.H142Y, 
p.N160K, p.V256L, p.D295N, p.R436Q and p.R597W). The cells were intracellularly stained for 
the GAT3 protein and expression levels were exam ined  under confocal microscope. GAT3 wild- 
type and variants were se e n  to be ex p re ssed  intracellularly. Bar = 10pm.
To ensure the GAD65 variants identified were expressed intracellularly, GAD65 wild- 
type as well as the six GAD65 variant constructs (p.C45F, p.D102N, p.P153Q, 
p.G232E, p.S527L and p.I575T) were transfected into HEK293 cells. Following 
intracellular staining, the cells containing variant proteins were visualised via confocal 
microscopy and compared to wild-type. Figure 5.34 shows that all GAD65 variants 
were expressed and as with the wild-type, a predominant amount of expression occurred 
perinuclearly whilst some expression was witnessed in the extremities of the cell.
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Figure 5.34 GAD65 wild-type and variant ex p ress io n  in HEK293 cells .  HEK293 cells were 
transfected and stained for the GAD65 wild-type protein a s  well all the six GAD65 variants 
identified in the study. It can  be se e n  that GAD65 wild-type is ex p re ssed  throughout the cells 
predominantly around the nucleus. The variants also exp ress  GAD65 and this can be seen  
surrounding the nucleus and less concentra ted  in the extremities of the cell. Bar = 10pm.
Images were created for GAD67 wild-type and the GAD67 variants (p.R89G, p.R89W  
and p.Y127F) in the same way as for the other three genes. Intracellular staining 
revealed that GAD67 wild-type , G A D 67pR89°, G A D 67pR89W and G A D 67P YI27F were 
expressed intracellularly. As seen with the other genes, the majority of expression 
occurs surrounding the nucleus whilst some expression can also be observed in the 
extremities (Figure 5.35).
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Figure 5.35 GAD67 wild-type and variant e x p r e ss io n  in HEK293 ce lls .  Following 
transfection of GAD67 wild-type and variant constructs into HEK293 cells, the cells were stained 
and imaged via confocal microscopy. The figure dem onstra te s  that GAD67 wild-type is 
ex p ressed  intracellularly a s  are  the variant proteins. Bar = 10pm.
5.7 Utilising genetic constructs
Figures 5.32 to 5.35 demonstrate that the selected proteins are expressed following 
transfection into HEK293 cells. This information provides a firm platform for the use o f  
the constructs in further analysis, to assess the pathological consequences o f  the variants 
identified in the GABA transporters and enzymes.
The GABA transporter constructs could be further examined via their transfection and 
extracellular staining o f  cells, to determine the success o f  transport o f  the protein. If 
proteins do reach the cell membrane, electrophysiology analysis could be carried out to 
determine the efficiency o f  the protein and determine whether the variant causes a 
pathological state in this way. Transfection o f  both G A BA  transporters and enzymes 
into cells provides useful information on variant consequence; transfection o f  constructs 
into animal models however would also provide a valuable insight into the 
pathophysiology o f  variants.
I6l
Quantitative enzymatic assays would be a valuable tool for measuring the efficiency of 
GABAergic enzymes. This assay would determine the activity levels of the enzyme and 
identify whether the variants cause a decrease in function as predicted. A splicing assay 
would be an accurate method for determining whether the splice site variant preceding 
exon three in the GAT1 gene causes changes to splicing. A splice construct would need 
to be created using an exon trap vector as opposed to the entry vector used for missense 
variants.
5.8 Summary of protein analysis of GABAergic variants
Exon mapping shows that in all, the variants identified in this study occur in highly- 
conserved amino acid residues, which occur in crucial domains of the protein. These 
domains are believed to be involved in the normal function of the protein. In silico 
analysis demonstrated that variants caused changes at a protein level by causing 
structural changes which in some cases had knock on effects to upcoming amino acids, 
such as GATlpM179V, which causes alteration to glycosylation sites of the protein 
upstream. Variants also cause alteration in side chain size, protrusion, direction and 
polarity, which could have detrimental effects on protein function. Gene constructs were 
created for GABAergic variants for immunocytochemisty analysis. 
Immunocytochemistry results show that the missense variants identified in this study in 
all four genes were expressed intracellularly.
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Chapter Six
Discussion
The GABAergic system has been studied extensively over the last few decades 
combining genetics, biomarker, molecular animal models, and imaging datasets. No 
gene variations, however, have been identified in GABA transporters GAT1 and GAT3 
nor the GABA synthesising enzymes GAD65 and GAD67 in relation to epilepsy. 
Animal models of GAT1 and GAD65 show evidence of epileptogenesis and a 
susceptibility to seizure, which gives reason to believe that variants in these genes and 
their closely-related genes GAT3 and GAD67 are potential targets as valid candidates in 
human epilepsy (Conti et al., 2004, Asada et al., 1996). This is supported by the 
importance of GABAergic inhibition in the human brain and clear evidence relating to 
mediators of regulatory cycles of sleep, consciousness, and neural networks e.g. 
thalamo-cortical networks.
Given the evidence outlined in Chapter One the screening of these four GABAergic 
genes in genetic generalised epilepsy patient samples is justified as a start point to test 
the hypothesis. This chapter will aim to analyse and interpret the outcomes of the 
previous results as well as to indicate any further work that could be carried out to 
identify the pathogenic functional consequences of the identified GABAergic variants. 
Any limitations that were encountered in the study have been highlighted given the 
revolution in genetics/genomics.
6.1 Variant detection rate in GGE
The genetic screening of GAT1, GAT3, GAD65 and GAD67 resulted in the 
identification of 20 variants, which were identified in 48 of the 707 epilepsy patient 
samples screened; representing a patient detection rate of 6.8%. Eighteen patients had 
variants that were identified in GABA transporters representing a detection rate of 
2.5%, whilst 30 gene variants were identified in GABAergic enzymes representing a 
detection rate of 4.24%. All variants identified in this study were found in patients that 
have a diagnosis of GGE with a high incidence of absence seizures and is the subject of
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another clinical PhD. The GABAergic variants were generally not present in control 
populations (novel) with some having a rare population frequency (rare variant), which 
were supported by phylogenetic conservation alignments. On-line mutation predictive 
tools were used to predict damaging consequences of variants using principles of 
conservation, structure, composition or polarity.
In addition to the in silico methods to assess gene-variants, structural modelling was 
used as another predictive source of pathogenicity evidence and has been integrated into 
the arguments below. Furthermore, expression mutant constructs were prepared from 
wild-type GAT1, GAT3 GAD65, and GAD67 clones. The validation of expression in 
Chapter Five was demonstrated by immunocytochemistry in transiently transfected 
HEK293 cells and provides the springboard to in vitro functional analysis as outlined in 
Further Work (Section 6.8).
6.2 Putative consequences of GAT1 and GAT3 variants
6.2.1 Variants in pincer formation of transporters
Heterozygous variants GATlpL4151, GAT3p V256Land GAT3pR436Q were identified as part 
of this thesis, in the pincer like formation of the transporters, which corresponds to 
transmembrane domains 4, 5, 9 and 10. This region is responsible for protein stability 
and holding the substrate and ion binding regions in position (Yamashita et al., 2005). 
Previous studies of other disease-causing SLC6 family transporters show that variants 
in this region cause decreased transporter activity due to trafficking defects (Hahn and 
Blakely, 2007, Hahn et al., 2003).
The first disease-associated variant identified in the transporter family SLC6, was 
p.A457P in the Norepinephrine transporter (NET) gene SLC6A2; which was identified 
by Hahn et al., (2003). This amino acid change caused increased levels of plasma NE 
due to decreased transporter activity believed to result in elevations in standing-induced 
heart rate. Multiple cell lines showed that there was a decrease in human NET at the cell 
membrane compared to wild-type as a result of diminished protein created by p.A457P; 
which was confirmed by western blot analysis of COS-7 cells. As well as decreased
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levels of the variant protein, a dominant negative effect was also exhibited on wild-type 
transporters (Hahn et al., 2003).
Hahn et al., (2003) identified that the co-transfection of the wild-type protein and 
p.A457P in COS-7 cells showed a decreased uptake of 60.9% of NE levels compared to 
when only wild-type was transfected. Western blot analysis showed that there was a 
50% decrease in wild-type expression at the cell membrane when co-expressed with the 
variant protein compared to wild-type only transfection. This suggests that the abnormal 
trafficking of p. A457P influences the trafficking of human NET wild-type to the plasma 
membrane (Hahn and Blakely, 2007, Hahn et al., 2003).
Animal models support this theory and show that the heterozygous variant p.A457P 
causes significant decreases in transport activity in the atria and ventricles of the heart, 
as well as a 60% decrease in transport levels in the cortex and hippocampus compared 
to NET wild-type mice (Shirey-Rice et al., 2013). Compared to NET knock-out mice, 
p.A457P mice maintain high levels of expression of non functioning protein which 
influences the function of normal transporters; knock-out mice do not express 
significant changes in NE transport (Shirey-Rice et al., 2013).
It can be hypothesised therefore from previous analysis of NETs, that the variants 
identified in this thesis, in the pincer like formations of GABA transporters, could cause 
a decreased uptake of GABA due to trafficking defects which cause a dominant 
negative effect on wild-type transporters. Decreased GABA uptake into the pre-synapse 
would result in increased GABA levels in the synaptic cleft.
6.2.2 Variants in the substrate binding domain of transporter
Missense variants GATlpM179V, GAT3pH142Y and GAT3pNI60K as well as the GAT1 
splice variant IVS3+1 were identified in the substrate binding region (transmembrane 
domains 3 and 8) of their corresponding transporters (Bismuth et al., 1997, Tamura et 
al., 1995). Other disease-associated SLC6 family transporters suggest that variants in 
this region cause changes in levels of substrate binding, resulting in altered transport 
levels (Kilic et al., 2003). It has also been identified that glycosylation sites are retained
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in this region and alteration to this site can cause trafficking defects, again resulting in 
changes in membrane transport (Cai et al., 2005) (Hahn et al., 2005).
Variants have been identified in the serotonin transporter SLC6A4 (SERT), which cause 
psychiatric disorders such as OCD, anorexia nervosa and Asperger’s syndrome, due to 
enhanced transporter activity (Kilic et al., 2003). This enhancement occurred in a study 
by Kilic et al., (2003) as a result of the variant p.I425V and was identified via western 
blot analysis. It was demonstrated that this increased activity was due to enhanced 
binding as a result of up to a 40% increase in maximum binding sites, and along with a 
large decrease in dissociation constant, a higher binding affinity for the mutant was 
created compared to wild-type (Kilic et al., 2003).
If this increase in transporter activity causes such effects due to a single point mutation, 
it gives reason to believe that the variants of similar regions identified in the research 
carried out for this thesis could have the same effects. This would result in decreased 
GABA levels in the synaptic cleft and a subsequent reduction in inhibition. This 
inability to inhibit the excitation of the post-synaptic nerve terminal could result in 
excessive excitation and ability to seizure.
6.2.3 Variants affecting glycosylation of transporters
Variant GATlp M179v, as mentioned previously, occurs in the substrate binding domain 
of the protein. The variant also occurs amongst the three glycosylation sites Asnl76, 
Asnl81 and Asnl84 (Bismuth et al., 1997). The glycosylation sites are involved in the 
management of the physicochemical and biological properties of the protein which 
include protein folding, stability, targeting and ligand binding. The transport activity 
and surface expression of neurotransmitters is controlled by glycosylation (Bismuth et 
al., 1997). As demonstrated by figure 6.2, GATlpM179v appears to cause significant 
changes to the glycosylation site positioning, as well as the whole extracellular loop, 
following the variant amino acid.
166
Figure 6.2 3D structure of GAT1pM179V. Chimera analysis crea ted  the predicted protein 
c o n seq u en ces  of an amino acid change  from methionine to valine at amino acid position 179. 
The variant has  knock on effects that change  the s h a p e  and overall positioning of glycosylation 
sites of the protein.
Interruption of glycosylation via genetic variation has been studied by Cai et al., (2005), 
who identified via GABA uptake assays that GABA uptake in mutant proteins was 
significantly reduced by GAT1. Kinetical analysis of GAT1 wild-type and variant 
transporter showed that changes to glycosylation sites cause trafficking defects, 
preventing GAT1 from reaching the cell surface (Cai et al., 2005).
Other variants identified in SLC6A2, have been associated with disruption of the 
glycosylation of the transporter, which has had a knock on effect and interfered with the 
surface trafficking of the protein (Hahn et ah, 2005). Variant p.A369P of extracellular 
loop six and p.N292T of transmembrane domain five of NET have been identified via 
sequencing analysis (Hahn et al.. 2005). Human NET wild-type and variant constructs 
were transfected into COS-7 cells to assess the influence o f  the variants identified on 
transporter expression, which was measured by immunoblotting. p.A369P transporters 
were unable to carry out any transport activity of both NE and dopamine (DA), whilst 
N292T showed a decrease in transport activity. Biotinylation and western blot analysis 
showed an intense decrease in human NET wild-type at the surface and in total for both 
variants, suggesting a dominant negative effect by the variants. The NE transporter 
variants mentioned, cause decreased transporter activity resulting in diseases associated 
with pathogenic heart rates, such as long QT syndrome (Hahn et al., 2005).
It could therefore be hypothesised that the variant p .M179V identified in GAT1 as part 
of this thesis, will cause the protein to have trafficking defects resulting in a lack of
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transporters reaching the cell membrane. The level of decreased activity seems to vary 
amongst amino acid changes so it would be difficult to speculate whether a complete 
loss of function or reduced levels would be witnessed. However it is likely that 
p.M179V will cause a decrease in GAT1 wild-type at the cell membrane due to a 
dominant negative effect, resulting in reduced GAB A uptake from the synapse.
6.2.4 Variants in Ion binding region of transporters
GAT3p'D295N resides in the extracellular loop preceding transmembrane domain six 
which along with transmembrane domain one, forms the ion binding site of the protein 
(Hansra et al., 2004). The ion binding site along with the substrate binding site 
(transmembrane domains three and eight) form the central pore of the protein (Bismuth 
et al., 1997). GAT1 variants in the ion binding domain have been previously identified 
and have resulted in malfunctioning transporters and therefore a decreased level of 
GAB A uptake was witnessed (Mager et al., 1996).
Mager et al. (1996) demonstrated via concentration and voltage-jump experiments that 
the variant p.W68L of GAT1, which resides in the central ring of the protein, causes a 
decrease in GABA uptake from the synapse (<5% compared to wild-type). Charge 
movements show that GAT1 wild-type binds two sodium ions followed by GABA, 
before releasing GABA intracellularly. Mutant transporter W68L and W68S causes 
sodium ions to bind tighter and at a faster rate whilst GABA is bound much looser 
compared to wild-type. As GABA is so poorly bound, the sodium ions remain bound 
for long periods of time, seized in the transporter resulting in slow release into the cell 
(Mager et al., 1996).
Although both the variant proteins and wild-type produce charge movements due to 
conformational changes, the final stage of GABA uptake which is carried out via a 
currently unknown mechanism is prevented, which would under normal circumstances 
release GABA into the pre-synaptic cleft. Immunocytochemistry results of the GABA 
analogue tiagabine binding to GAT1 in HeLa cells, support charge jump results and 
show that the variant protein W68L was expressed at approximately equal levels to 
wild-type, however, was functionally faulted (Mager et al., 1996).
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It could be hypothesised that GAT3pD295N could cause alteration in sodium binding, 
which would lead to the loose binding and lack of GABA uptake from the synapse. 
Slowed GABA uptake due to variant transporters would result in a build up of GABA 
in the synapse and decreased GABAergic inhibition.
6.2.5 C-terminal domain of transporters
Deletion variant GATlp S594Afs22x was identified in the C-terminal domain of GAT1 of 
this thesis. The C-terminus is responsible for trafficking, stability and degradation of the 
protein (de Juan-Sanz et al., 2013). Large alterations in the C-terminal domain 
sequence, such as the amino acid changes caused by GATlp'S594Afs22x have been 
identified to cause disease. Variants of the creatine transporter SLC6A8 have also been 
associated with diseases such as X-linked mental retardation (Rosenberg et al., 2004).
Rosenberg et al, (2004) reported by DNA sequence analysis on a panel of 290 unrelated 
families with X-mental retardation, the insertion Y1378X in SLC6A8. This variant 
affects transmembrane domains 7-12, causes a premature stop codon and changes the 
length of the C-terminus. It is suggested that this premature stop codon causes unstable 
or inappropriate folding, resulting in the protein becoming inactive (Rosenberg et al., 
2004). GATlp'S594Afs22X identified in this thesis causes the removal of the stop codon and 
the addition of 22 amino acids, to the final exon of the protein causing changes to the 
length of the C-terminal. Comparison with the results from the creatine transporter gives 
reason to suspect that the additional amino acids will cause changes to the folding of the 
protein as well as the stability, resulting in the protein becoming inactive (Rosenberg et 
al., 2004).
GATlpM555V and GAT3pR597W were also identified as part of this thesis in the C- 
terminal domain. Limited research has been carried out in other membrane transporters, 
which directly correspond to theses amino acid regions. As these variants are novel in 
this population it could be predicted from chimera analysis as well other predictive tools 
that the amino acid changes would have an effect on the protein trafficking, stability and
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degradation. This could result in alterations in transporter activity and cause changes in 
GABA levels in the synaptic cleft.
6.3 Putative consequences of GAD65 and GAD67 variants
6.3.1 N-terminal domain of GAD65 and GAD67
GAD65pC45F, GAD65pD102N, GAD65pP153Q, GAD67pR89G, GAD67pR89w and 
GAD67p Y127F, identified in this thesis, all occur in their respective N-terminal domains. 
The N-terminal domain is essential for the dimerisation of two monomers to create a 
functional protein (Fenalti et al., 2007). Human genetic screening by Lin et al., (2007), 
identified variant S41Y, in the N-terminal of tryptophan hydroxylase 2 in a highly 
conserved residue. Recombinant construct analysis demonstrates that there was a 
decrease in enzymatic activity when the amino acid change was introduced, compared 
to wild-type. This change in activity was suggested to occur as a result of alterations in 
regulatory level due to modifications in 3D structure (Lin et al., 2007).
The decrease in active tryptophan hydroxylase causes a reduced level of serotonin 
production. Abnormally low levels of serotonin synthesis by the enzyme tryptophan 
hydroxylase, is believed to be associated with ADHD. Sheehan et al., (2005) identified 
that the removal of the first 156 amino acids of the enzyme caused a decrease in the 
level of serotonin synthesis correlating to ADHD. It is possible therefore that this region 
could be equally as crucial in increasing enzymes synthesis of other neurotransmitters 
such as GAD65 and GAD67. This region corresponds to amino acid residues 185-190 
and 199-203 of GAD65 and GAD67 respectively, when aligned (Sheehan et al., 2005). 
GAD65p P153Q occurs before this region and could have an effect on the site as a proline 
change has such significant effects on the protein structure. As proline ordinarily causes 
a large fold in a protein, the removal of the amino acid would severely alter the shape of 
the protein, causing knock-on effects structurally downstream (Fu et al., 2003). If this 
variant causes changes to the structure at amino acid position 185, this could cause a 
reduction in the level of GABA production from glutamate. Decreased GABA
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production could result in diminished inhibition at the post-synaptic nerve terminal 
causing excessive excitation and seizure.
Proline residues act to slow down the process of folding especially if the proline caps an 
a-helix. This was witnessed by Fu et al. (2003), using FRET traces to show the 
refolding of proline mutants in serine hydroxymethyltransferase. G A D 65pP153Q 
identified in this thesis, also caps an a-helix (as shown in figure 6.3), and the amino acid 
change from proline to glutamine therefore is predicted to interfere with the rate of 
folding. This interference could result in insufficient folding and could render the 
protein inactive (Fu et al., 2003)
Figure 6.3 3D structure of wild-type and variant GAD65 protein p.P153Q. The 3D structure 
diagram of GAD65 wild-type show s that the proline residue a p p ea rs  before the a-helix. Clear 
differences can be seen  between the proline side chain which h as  num erous bends  and 
eventually turns back on itself and the glutamine side chain.
6.3.2 Variants of the C-terminal domain of GABAergic enzymes
This thesis identified variants G A D 65P S;>27L and G A D 65p I575T in the C-terminal domain 
of  the protein. Fenalti et al., (2007) identified via crystal structure analysis that the 
highly mobile GAD65 C-terminal is likely to contribute to the dynamic role of the 
catalytic loop in enzyme autoinactivation. They also derived that both the sequence of 
the catalytic loop and the C-terminal, to which it is packed against, is highly crucial for 
the modulation of the enzyme autoinactivation. The variant Tyr425 of  the catalytic loop 
of GAD65 was identified to completely eliminate G A BA production. Mice models 
support this and show that variants in the C-terminal domain of neurotransmitter
synthesiser tryptophan hydroxylase can result in a 50-70% reduction of serotonin 
synthesis compared to wild-type (Posner and Petersen, 1990, Aston-Jones et al., 1999, 
Fenalti et al., 2007).
Genetic screening of human tryptophan hydroxylase-2 in 300 individuals in a 
psychosocial group identified the novel SNP, p.R441H (Zhang et al., 2005). This highly 
conserved variant protein was transfected into pheochromocytoma cells (PC 12) and 
serotonin levels produced were calculated. It was identified that there was an 
approximately 80% reduction in serotonin levels produced compared to wild-type, 
demonstrating that the variant causes loss of function (Zhang et al., 2005).
Variants identified in this thesis in the C-terminal domain occur in highly conserved 
residues. With a current lack of such mouse models for GAD65 and GAD67, it is viable 
to suggest that the variants could cause a substantial reduction in the level of GABA 
synthesis. Fenalti et al., (2007) suggest that a single point variant in the C-terminal 
domain could result in alterations in GABA production. Decreased GABA production 
could result in decreased GABAergic inhibition at the post-synapse.
6.4 The GABAergic system and absence seizures
The patients with variants identified in this study in GAT1, GAT3, GAD65 and GAD67 
had several forms of GGE phenotypes, however all 48 patients had a significant 
component of absence seizure presentation. Absence seizures are thought to be a 
genetically determined electro-clinical marker of GGE and are specifically detected by 
spike and wave electrical activity, primarily in the thalamo-cortical network. In turn, the 
specific cellular network between the thalamus and the pyramidal cells of the cortex are 
connected by excitatory (primarily glutamatergic) connections. GABAergic neurons are 
positioned evenly throughout the cortex and thalamus forming a network of inhibitory 
influence on excitatory networks and controlling rhythmic oscillations maintaining 
sleep and consciousness (Figure 6.3).
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The impairment, potentially caused by the variants identified in this study, would result 
in changes in GABA levels and a decrease in the inhibition signal of GABAergic 
neurons. Excessive GABA levels in the synaptic cleft due to a decreased uptake by 
G A BA transporters cause a pathological state by activating not only G A B A a receptors 
but also by activating G A B A b receptors, causing slow activating IPSP which would 
prevent the neuron from creating an action potential, therefore causing a decrease in 
oscillation frequency (Blumenfeld, 2003). This mechanism could cause the absence 
seizures experienced by the patients of this study which have variants in the GABA 
transporters by causing the transporter to become inactive, through an inability to reach 
the membrane or via a reversal of the transporter activity (Blumenfeld, 2003).
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Figure 6.3 Formation of the thalamo-cortical network. Pyramidal cells of the cortex are 
connected  to tha lam us by excitatory thalamo-cortical and cortico-thalamic axons. Collaterals 
from the axons connect with GABAergic neurons and upon excitation, c a u se  GABA re lease  and 
signal inhibition. Excessive inhibition is reduced by connections betw een GABAergic neurons. 
(Adapted from model by Steinlein, 2004).
A decrease in GA BA levels in the synapse due to a lack in production by GADs or 
excessive removal by GABA transporters due to the variants identified in this thesis,
Cortex
Thalamus
GABAergic
neurons
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would cause a decrease in inhibitory projections from GABAergic cells to the thalamus. 
A decrease or elimination of inhibitory projections would not allow intrathalamic 
oscillations due to a lack of hyperpolarisation of the thalamo-cortical neurons and post- 
inhibitory rebound action potentials exciting TRN neurons. This decrease in projections 
causes the absence seizure phenotype whereby the normal synchronous oscillation 
frequency of approximately 15Hz transforms to a spike wave discharge at 
approximately 3Hz (Kostopoulos, 2000). We predict that the variants identified in this 
study cause absence seizures via these mechanisms. For example, GAT1 and GAT3 
mutations may result in excess GABA being perpetuated in the synapse leading to over­
stimulation of GAB Aa and GABAb receptors, which in turn over-inhibits the balance of 
bi-directional excitatory tone, leading to cortical deactivation and absence blackouts. 
Alternatively, the excess GABA may lead to GABA receptor attenuation and under­
inhibition of thalamo-cortical networks leading to over-excitation of oscillations and 
rhythm re-boot phenotypically expressed as cortical deactivation and absence blackouts. 
If functional analysis proves that GAD65 and GAD67 enzyme activity is compromised 
then a decreased GABA production is created. Null GABA production would be 
regarded as a lethal event and explains why this is not observed. A shortage of GABA 
agonist will result in quantal loss of ligand and under-potentiation of GABAa receptors 
and so the lack of inhibition model is more likely here. As with the GABA transporters 
this may affect the thalamo-cortical network by over-excitation and neuronal re­
synchronisation through cortical deactivation, causing a circuit overload.
6.5 GABAergic animal models and absence seizures
Numerous animal models support the genetic link between the GABAergic neurons and 
absence seizures, including rat models such as GAERS and Wistar Albino Glaxo from 
Rijswijk (WAG/Rjj) rats. Cope et al, (2009) identified that adult GAERS had elevated 
GABA levels in the ventral thalamus compared to the non epileptic controls, which is 
likely to be due to a lack of uptake by GABA transporters.
To test this theory Cope et al, (2009) blocked both GAT1 and GAT3 independently 
using respective transporter blocking drugs and identified that there was a significant
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increase in GABA levels in the thalamus, especially from the blockage of GAT3 which 
is believed to be most abundant in the thalamus. When both GAT1 and GAT3 were 
blocked simultaneously, a greater increase in GABA levels in GAERS than non­
epileptic animals suggested a compensatory mechanism when only one of the 
transporters are inhibit; a mechanism wiped out in epileptic strains (Cope et al., 2009). 
Currently, no GAD animal models of absence seizures are available. GAT animal 
models, such as those described above, support and strengthen the link between the 
variants identified in the GGE patient samples of this study and absence seizures. 
Similar principles can be applied to the GAD variants as they are part of the 
GABAergic system and can cause the same pathogenic effects.
Animal models of GAERS and WAG/Rjj models show that tiagabine prevents the 
reuptake of GABA by acting on GABA transporters, enhancing the number and 
duration of spike wave discharges, which cause an increase in absence seizure 
(Marescaux et al., 1992) (Coenen et al., 1995). Carbazepine and oxcarbazypine are 
believed to aggravate absence seizure by their activation on the GABA receptors at a 
thalamo-cortical level in GAERS and similar animal models. Vigabatrin is a 
transaminase inhibitor that acts by prevents the breakdown of GABA and its reuptake 
into the Kreb cycle, therefore causing an increase in whole brain GABA levels. 
Vigabatrin and tiagabine can aggravate absence seizures or create de novo absences 
(Vrielynck, 2013). Gabapentin acts in a similar way, but causes the reversal of GABA 
transporters therefore increasing the GABA levels in the synaptic cleft. As described 
previously, this increase in GABA levels would cause the activation of the GABAb 
receptors resulting in slowed IPSP production. These results support the hypothesis that 
the GABAergic system is involved in the pathology of absence seizures.
It has been identified that up until postnatal day 16 in GAERS, the tonic current in 
ventrobasal nuclei of the somatosensory thalamus equals that of the non-epileptic 
control mouse. This changes suddenly between day 16 and 17, with an increase of 
almost two-fold in the tonic current in the epileptic rat, which remained elevated 
following seizure onset, until day 30. This data suggests that the enhancement of tonic 
GABA inhibition during development in GAERS is pathogenic and likely pro-epileptic. 
This is supported by work carried out by Russo et al (2010), which suggests that early 
long-term AED treatment that begins before the onset of seizure, which is
175
approximately two months in WAG/Rjj, can modify the development of absence 
seizures (Russo et al., 2010). Further studies by Russo et al (2010) suggest that 
treatment using ethosuximide and levetiracetam from six weeks old reduces the 
frequency of spike wave discharges witnessed at six months (Russo et al., 2010). Early 
long-term treatment with zonisamide could cause a reduction in absence seizure 
generation and synchronisation by altering the development of the pathological state 
(Russo et al., 2011).
The importance of early detection of absence seizures is emphasised in these studies. 
This can be achieved by identifying the variants causing the disease, such as those 
variants identified in this study. Functional analysis of the variants, which we identified, 
needs to be carried out to determine whether the amino acid changes are pathological. 
However, predictive 3D modelling, alignment analysis, previous study data and animal 
models support our hypothesis that the GABAergic variants identified in this study 
result in changes in GABA levels that, via susceptible neuronal networks, cause absence 
seizures.
6.6 Conclusion
1. Twenty novel/rare variants have been identified in 48 patient samples in the 
GABAergic genes GAT1, GAT3, GAD65 and GAD67 representing a detection 
rate of 6.8% of the analysed GGE cohort.
2. All 48 patients have a confirmed diagnosis of GGE with a significant component 
of absence seizure presentation.
3. In GABA transporters, 11 variants were found including one novel splice 
variant, one deletion variant, two novel missense mutations and seven rare 
missense variants.
4. In biosynthetic GADs, four novel missense variants and five rare missense 
mutations were found in GAD65 and GAD67.
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5. In silico predictive analysis indicates the majority of variants have pathogenic 
outcomes on protein structure and function and are typically highly conserved in 
phylogenetic alignment.
6. Structural modelling using the pdb database also provided higher-level 
prediction of structural changes that would compromise transporter and GAD 
enzyme activity.
7. Mutation constructs for all missense, splice and deletion variations have been 
prepared for functional platforms.
8. Immunocytochemistry demonstrates that each variant has intracellular 
expression, indicating the validation of construct integrity.
9. The core mechanisms of dysfunction remain to be desiphered, although it is 
suspected that compromised GABA transporter activity and GAD-induced 
GABA deficiency would produce a GGE phenotype with 3Hz absence features.
10. The evidence for GABAergic pathology in epilepsy is taken from 
pharmacological studies, animal models, GABA receptor mutations in humans, 
and knowledge of electrophysiological circuitry in thalamo-cortical networks.
11. Proving the pathogenicity of the GABAergic variants will aid in the early 
diagnosis of absence seizures and will allow for accurate and timely dispensing 
of effective medication.
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6.7 Limitations of the study
Although every effort was made to identify and solve any issues raised by the study, it 
was not possible in every case. As a genetic study we took a candidate gene approach, 
due to the technical limitations at the start of the project (2008). At the time, 
Lightscanner technology was the fastest way to screen large number of samples in a 
small laboratory setting. It has only been in the past 2 years that exome sequencing has 
become affordable and if the project started now it would be likely that 300-400 exomes 
(or genomes) would have been commissioned. This has resulted in a dataset established 
around a specific hypothesis with exon and flanking intronic data in targeted genes. Any 
intronic variants with a regulatory function were therefore missed. Although a limited 
number of variants have been identified in the intronic regions of genes which have 
been linked to disease, such as in the ErbB4 gene and schizophrenia (Law et al., 2007), 
SLC6A3 and ADHD (Greenwood and Kelsoe, 2003), the majority of disease associated 
mutations identified to date occur in protein coding regions.
Due to costs, not all exons were sequenced for each sample. Instead, all exons for each 
sample underwent PCR and the lightscanner was used to detect variations in the sample 
sequence; desired samples would then be selected for sequencing. Although deemed 
highly-sensitive and every effort was made to select any deviation in melt curve, there is 
a small chance that a variant was missed by the lightscanner, resulting in the sample not 
being sequenced for that exon. Also, due to some borderline quality/age issues with 
some samples it was impossible to get all samples to PCR within normal standards and 
quality. Many of these samples were third-party cohorts where quality issues were not 
determined in this laboratory.
Another limitation to the study involved the commercially available unaffected control 
population samples. Due to the nature of absence seizures, the condition was 
historically often missed in childhood and patients were not correctly diagnosed but 
instead categorised as day-dreamers, as having anxiety tics or behavioural problems. If 
subjects who were overlooked as children then unknowingly become one of the 
unaffected control samples, this could have implications on our results. This may be one
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of the reasons why some variants in the study were identified in the control population 
and may only be partially informative.
Due to time constraints created by large scale screening and mutation construct creation, 
we were unable to progress onto various functional studies. However, the project did 
create the basis for function work, which is now part of a separate study (see section 
6.8). One further limitation is the lack of familial samples. This would have helped us 
understand whether variants were inherited or whether they were de novo or mosaic, 
which would be highly beneficial in assessing the true pathological consequences of 
each variant.
The immunocytochemistry work carried out in this study was on the HEK293 cell line. 
This was due to the fact that they have the biochemical capability to carry out the post- 
translational changes required for this study without interference from endogenous 
proteins. HEK293 cells do not provide the same level of biochemistry and cell 
architecture as neuronal preparations, however this methodology has been identified as 
an invaluable means in faithful reconstruction of numerous neuronal proteins, 
eliminating the topographical and biochemical complexities of the central nervous 
system (Thomas and Smart, 2005).
6.8 Further work
This study focused on identifying novel and rare SNPs in epilepsy patient samples. A 
follow on study would be highly beneficial in determining the functional significance of 
these variants. For example, extracellular staining of the GABA transporters would be 
constructive in determining whether the transporters successfully transport to their 
desired location on the cell membrane. If the transporters traffic to the membrane then 
the question remains whether they will work effectively or whether they are trafficking 
mutants that deplete the number of transporters at the cell surface. If they do reach the 
cell membrane then electrophysiology analysis could be carried out to determine the 
efficiency of the transporters and to identify whether the variant has a dominant 
negative or haploinsuffiency effect on the wild-type transporters. Lastly, transporter 
activity can be assessed by using either a radiolabeled transfection study or a mass
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spectrometry approach that can more safely mimic the sensitivity and specificity of the 
radiolabelled methods.
Some of the mutations will need more specific experimentation. In particular 
GAT1IVS3+1 which is likely to be pathogenic based on the hundreds of genetic disorders 
that have splice mutations at +1 and +2. A proof of principle splice site assay should be 
commissioned to show exonic deletion or retention as a direct results of the mutation. 
GAD65 and GAD67 are not expressed on the cell surface but are intracellular 
biosynthetic enzymes creating GABA. An appropriate experiment, therefore, is a 
sensitive and quantitative enzymatic assay which could determine the activity levels of 
the GAD enzyme by measuring activity metabolites e.g. GABA deficiency or an 
accumulation of glutamate.
To determine whether the genetic variants identified in the patient samples are inherited 
or de novo, close family members such as parents, grandparent and siblings could be 
recruited to distinguish whether or not they have the variant. The prevalence of the 
disease can be determined which would help further aid validation to determine whether 
the variant identified is pathological and whether it does cause absence seizures. Once 
the functional consequence of mutations are finalised it would then be possible to 
source the gene carrier patients and consent them for skin biopsies to create patient 
specific fibroblast cell-lines which could be used to create pluripotent stem cells to 
attain genomic context and ex-vivo electrophysiological recordings or transcriptome 
profiling.
Transgenic animal models would be highly useful in determining the pathogenic effects 
of the variants as in vivo events could be recorded on euthanized brain tissue with no 
post-mortem delay (as seen in human studies). Live models expressing mutant GAT’s 
and GAD’s could be used in seizure termination experiments and profile new and old 
anti-seizure treatments.
Four genes of the GABAergic system were selected for screening in GGE patient 
samples. As all the variants identified in the study were present in absence seizure 
patients, it could be feasible to select other genes from system and screen for these 
genes in the 707 GGE samples. This could help highlight the GABAergic system
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further as a primary cause of absence seizures. Viable options for the candidate gene 
selection include the genes responsible for GABA breakdown (GABAT) and SSA 
oxidation (SSADH). Various animal models of GABAT have been identified and 
demonstrate an increase in synaptic GABA due to reduced GABAT activity (Wu et al., 
2001). SSADH knock out models show an extreme increase in GABA levels resulting 
in absence seizures and eventually tonic-clonic seizures (Akaboshi et al., 2003).
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